Datasets:

xpertsystems
/

hconc005-sample

+---
+license: cc-by-nc-4.0
+language:
+  - en
+tags:
+  - synthetic-data
+  - healthcare
+  - oncology
+  - pancreatic-cancer
+  - pdac
+  - kras
+  - smad4
+  - ca19-9
+  - folfirinox
+  - olaparib
+  - prodige
+  - mpact
+  - polo
+  - tcga-paad
+  - longitudinal
+  - multi-table
+  - xpertsystems
+pretty_name: "HC-ONC-005 — Pancreatic Cancer (PDAC) Synthetic Cohort (sample)"
+size_categories:
+  - 1K<n<10K
+task_categories:
+  - tabular-classification
+  - tabular-regression
+  - time-series-forecasting
+  - survival-analysis
+---
+# HC-ONC-005 — Pancreatic Cancer (PDAC) Synthetic Cohort
+**Sample dataset (500-patient primary cohort + ~4,400-row CA 19-9 longitudinal panel + 100-row surgical subset + 500-row molecular panel + ~860-row treatment history) from the XpertSystems.ai Synthetic Data Factory — Oncology vertical, SKU 5**
+A fully synthetic **pancreatic ductal adenocarcinoma (PDAC)** cohort spanning
+the complete clinical pathway: AJCC 8th Edition staging with NCCN
+resectability classification (Resectable / Borderline_Resectable /
+Locally_Advanced / Metastatic), comprehensive molecular profiling (KRAS
+with 7 variants — G12D / G12V / G12R / G12C / G12A / G12S / Q61H — plus
+WT; TP53, SMAD4, CDKN2A, BRCA1/2 germline + BRCA2 somatic, PALB2, ATM,
+HRD score, MSI status, TMB, PD-L1, HER2, NTRK), surgical outcomes
+(Whipple/PPPD/Distal/Total pancreatectomy with ISGPF fistula grading and
+ISGPS DGE grading), Pancreatic-Surgery-era treatment (FOLFIRINOX/
+mFOLFIRINOX/Gemcitabine+NabPaclitaxel/NALIRIFOX/olaparib/pembrolizumab/
+sotorasib for KRAS G12C/larotrectinib for NTRK), RECIST treatment response
+with depth-of-response, CA 19-9 dynamics with longitudinal trajectory
+panel, survival endpoints (OS/PFS/RFS — Weibull-calibrated to PRODIGE-4
+FOLFIRINOX, MPACT, POLO, NAPOLI-3), QoL (QLQ-C30, PAN26), and **5
+relational tables** joined on `patient_id`.
+Built to be **drop-in usable for analytics, modeling, demos, and education**
+while remaining 100% synthetic — no real patient data, no PHI, no
+re-identification risk.
+---
+## At a glance
+| | |
+|---|---|
+| **SKU** | HC-ONC-005 |
+| **Vertical** | Healthcare → Oncology (SKU 5) |
+| **Tables** | **5** (primary + CA 19-9 longitudinal + surgical + molecular + treatment history) |
+| **Sample size** | 500-patient primary × 107 columns; ~4,400-row CA 19-9 panel; ~100-row surgical; 500-row molecular; ~860-row treatment |
+| **Follow-up** | Up to 60 months of monthly CA 19-9 (variable per patient — truncated by OS) |
+| **Standards** | AJCC 8th Edition, NCCN Pancreatic 2024, ISGPF 2016, ISGPS DGE Grading |
+| **Format** | CSV (5 tables) |
+| **License (sample)** | CC-BY-NC-4.0 |
+| **License (full product)** | Commercial — contact XpertSystems.ai |
+| **Validation** | **Grade A+ (10.0/10) across all 6 canonical seeds {42, 7, 123, 2024, 99, 1}** |
+---
+## What makes this dataset useful
+PDAC is one of the deadliest cancers (5-year OS <12%) and one of the
+hardest to study: SEER provides population-level data but no molecular
+detail; TCGA PAAD has deep genomics but n=185; clinical trials (PRODIGE-4,
+MPACT, POLO, NAPOLI-3) are restricted; real-world commercial datasets
+(Flatiron, ConcertAI) are expensive. This synthetic cohort gives you the
+**full PDAC phenome across 5 relational tables** with realistic dependencies
+preserved:
+- ✅ **KRAS dominance ~94% (TCGA PAAD anchor)** with G12D/G12V/G12R variant
+  cascade exactly matching published frequencies
+- ✅ **Resectability ↔ vascular anatomy coupling** — SMA contact degrees,
+  SMV/PV involvement, celiac/hepatic artery/aorta involvement gated by
+  NCCN resectability class
+- ✅ **Stage IV ↔ vital_status coupling** — most PDAC patients die in
+  follow-up; cohort reflects that reality
+- ✅ **Head tumors → obstructive jaundice → biliary stent** cascade
+  (~65-72% jaundice in head; 85% of jaundiced patients get stent)
+- ✅ **HRR/PARP eligibility gating** — BRCA1/2/PALB2/ATM pathogenic →
+  parp_inhibitor_eligible_flag → olaparib uptake in second-line
+- ✅ **CA 19-9 dynamics tied to RECIST response** — responders (CR/PR)
+  show 50-95% drop to nadir; non-responders show modest decline or rise
+- ✅ **MSI-H rare (~1%) with pembrolizumab uptake** (KEYNOTE-158 era)
+- ✅ **5 relational tables joined on `patient_id`** for realistic
+  multi-modal modeling workflows
+Coverage spans:
+- **AJCC 8th Edition staging** (I, IA, IB, IIA, IIB, III, IV) with T1a/T1b/
+  T1c/T2/T3/T4, N0-N2, M0/M1 substaging
+- **NCCN resectability** — Resectable / Borderline_Resectable /
+  Locally_Advanced / Metastatic with SMA/SMV/PV/celiac/hepatic/aorta
+  involvement
+- **Stage IV metastasis sites** — liver, peritoneal, lung, distant nodal
+  with liver met count category (1-3 / 4-8 / >8)
+- **Tumor anatomy** — head/body/tail subsite, tumor size, jaundice +
+  biliary stent flags
+- **KRAS molecular detail** — 7 codon variants + WT, allelic frequency,
+  G12C targeted-therapy flag
+- **Tumor suppressors** — TP53, SMAD4, CDKN2A (Iacobuzio-Donahue 4-gene set)
+- **HRR/DDR panel** — BRCA1/2 germline + BRCA2 somatic, PALB2, ATM, HRD
+  score, PARP eligibility composite
+- **Immune biomarkers** — MSI, TMB, PD-L1 TPS, HER2, NTRK fusion
+- **Liquid biopsy** — CA 19-9 baseline + Lewis-negative flag, CEA baseline,
+  ctDNA detection + VAF, KRAS-ctDNA flag
+- **Surgical pathology** — Whipple/PPPD/Distal/Total/Palliative_Bypass
+  procedures with Open/MIS/Robotic approach, R-status, LN harvest +
+  positive + ratio, ISGPF fistula (None/A/B/C), ISGPS DGE (None/A/B/C),
+  PPH grading, bile leak, wound infection, portal vein resection, arterial
+  resection, operative time, EBL, ICU, LOS, 90-day readmission, pCR + nCR
+  flags
+- **First-line treatment** — FOLFIRINOX/mFOLFIRINOX/Gem+NabP/NALIRIFOX/
+  Gem mono/Pembro (MSI-H)/BSC with cycle counts, dose reduction, toxicity,
+  G3/4 events, febrile neutropenia, peripheral neuropathy grading
+- **Second-line treatment** — Olaparib (PARP-eligible)/FOLFOX/Capecitabine/
+  Regorafenib/BSC
+- **Targeted therapy** — Sotorasib/Adagrasib (G12C), Olaparib (HRR+),
+  Pembrolizumab (MSI-H)
+- **Radiation** — SBRT/Conventional_EBRT/IMRT/Proton with dose
+- **RECIST response** — CR/PR/SD/PD with depth-of-response %, CA 19-9
+  response/progression flags, CA 19-9 nadir + timing
+- **Survival** — OS, PFS, RFS (surgical patients only), time-to-next-
+  treatment, vital status (Alive/Dead_PDAC/Dead_Other)
+- **QoL** — EORTC QLQ-C30, EORTC PAN26 (PDAC-specific module)
+- **Longitudinal CA 19-9 panel** — monthly values from diagnosis through
+  min(60, OS+1) months with realistic trajectory shapes
+---
+## Calibration anchors (industry-grade)
+This cohort is calibrated against named registries, guidelines, and trials.
+Selection from the 35-metric scorecard:
+| Metric | Sample value (seed 42) | Target range | Source |
+|---|---:|---|---|
+| Mean age | 70.7 yr | 66–75 | SEER PDAC median 70-71 |
+| Female % | 45.8% | 38–52 | SEER ~45-48% |
+| Diabetes % | 41.2% | 28–48 | Aggarwal 2013 |
+| Stage IV % | 47.0% | 38–58 | SEER ~50-55% Stage IV at dx |
+| Stage I % | 5.2% | 2–9 | SEER ~5% Stage I (mostly late dx) |
+| Head tumor % | 71.4% | 60–80 | Hidalgo 2010 |
+| Jaundice in head | 65.0% | 60–80 | Head PDAC ~70-80% |
+| KRAS mutation | 93.6% | ≥90% (floor) | TCGA PAAD ~93% |
+| KRAS G12D | 30.4% | 28–42 | TCGA PAAD ~36% |
+| KRAS G12V | 24.6% | 15–28 | TCGA PAAD ~22% |
+| TP53 mutation | 73.2% | 65–82 | TCGA PAAD ~70-75% |
+| SMAD4 lost | 48.2% | 38–55 | TCGA PAAD ~50% |
+| CDKN2A lost | 63.2% | 52–68 | TCGA PAAD ~60% |
+| BRCA2 germline | 2.8% | 1.5–8 | POLO PDAC ~5% |
+| MSI-H | 0.8% | 0.1–4 | Hu 2018 PDAC ~1% |
+| Surgery rate | 20.6% | 12–30 | Cohort Stage IV-driven |
+| Whipple in head surgical | 88.6% | ≥80% (floor) | Standard for head PDAC |
+| R0 resection | 72.8% | 60–85 | Strobel 2017 |
+| Fistula B/C (ISGPF) | 25.2% | 15–32 | ISGPF ~20-25% |
+| DGE B/C (ISGPS) | 20.4% | 12–32 | ISGPS ~15-25% |
+| FOLFIRINOX in palliative | 38.6% | 25–50 | PRODIGE-4 era |
+| Gem+NabP in palliative | 43.0% | 35–55 | MPACT era |
+| Pembrolizumab in MSI-H | 75.0% | ≥40% (floor) | KEYNOTE-158 |
+| Olaparib in PARP-eligible | 28.3% | 15–50 | POLO era |
+| OS median (overall) | 5.75 mo | 4.5–9 | PDAC ~6-11mo; IV-heavy cohort |
+| OS median Stage IV | 5.25 mo | 3.5–8 | PRODIGE-4/MPACT ~6-8mo |
+| PFS median | 2.4 mo | 1.5–4 | mPDAC ~3-6mo |
+| ORR (overall) | 22.6% | 15–35 | Mixed regimen ~20-30% |
+| ctDNA in Stage IV | 89.4% | 70–95 | Cohen 2018 ~80-90% |
+| Liver mets in Stage IV | 48.9% | 40–65 | Yachida 2010 ~50% |
+| Stage→Resectability monotonic | 100% | ≥100% (floor) | Structural |
+Full 35-metric scorecard ships in `validation_report.json` and `validation_report.md`.
+---
+## Files in this sample
+```
+hconc005_sample/
+├── hconc005_sample.csv                   # 500 patients × 107 columns (primary)
+├── hconc005_ca19_9_longitudinal.csv      # ~4,400 rows × 3 cols (CA 19-9 panel)
+├── hconc005_surgical.csv                 # ~100 rows × 21 cols (surgical subset)
+├── hconc005_molecular.csv                # 500 rows × 25 cols (molecular panel)
+├── hconc005_treatment_history.csv        # ~860 rows × 8 cols (long-form treatment)
+├── validation_report.json                # full scorecard (machine-readable)
+├── validation_report.md                  # full scorecard (human-readable)
+├── sweep_summary.json                    # 6-seed canonical sweep results
+└── README.md                             # this file
+```
+**All 5 tables join on `patient_id`.** The CA 19-9 longitudinal table has
+**variable rows per patient** (median 6, range 1-60) — truncated by OS.
+Columns: `patient_id, month_from_diagnosis, ca19_9_u_ml`.
+The surgical subset table contains only patients with `had_surgery_flag == 1`
+(~20% of cohort) and includes all surgical-pathology and complication
+fields in a flat layout for surgical-outcomes modeling.
+---
+## Schema (107 columns in primary cohort across 6 modules)
+### Primary: Demographics (16 cols)
+`patient_id`, `diagnosis_date`, `age_at_diagnosis`, `sex`, `race`,
+`smoking_history`, `diabetes_mellitus_flag`, `family_history_flag`,
+`chronic_pancreatitis_flag`, `bmi_at_diagnosis`, `albumin_g_dl`,
+`weight_loss_6mo_kg`, `ecog_performance_status`, `pain_score_vas`,
+`jaundice_flag`, `biliary_stent_flag`
+### Primary: Staging (17 cols)
+`ajcc_stage_group`, `pdac_stage_simple`, `resectability_status`,
+`clinical_t_stage`, `clinical_n_stage`, `clinical_m_stage`, `tumor_site`,
+`tumor_size_cm`, `sma_contact_degrees`, `sma_involvement_flag`,
+`smv_pv_involvement`, `celiac_axis_involvement_flag`,
+`hepatic_artery_involvement_flag`, `aorta_involvement_flag`,
+`liver_metastasis_flag`, `liver_metastasis_count`,
+`peritoneal_metastasis_flag`, `lung_metastasis_flag`,
+`distant_nodal_metastasis_flag`
+### Primary: Molecular (24 cols)
+`kras_mutation` (WT/G12D/G12V/G12R/G12C/G12A/G12S/Q61H),
+`kras_allelic_frequency_pct`, `kras_g12c_targeted_flag`, `tp53_mutation`,
+`smad4_loss`, `cdkn2a_loss`, `brca1_germline`, `brca2_germline`,
+`brca2_somatic`, `palb2_germline`, `atm_germline`, `hrd_score`,
+`parp_inhibitor_eligible_flag`, `msi_status`, `tmb_mutations_per_mb`,
+`pdl1_tumor_proportion_score`, `her2_status`, `ntrk_fusion_flag`,
+`ca19_9_baseline_u_ml`, `ca19_9_lewis_negative_flag`, `cea_baseline_ng_ml`,
+`ctdna_detected_flag`, `ctdna_vaf_pct`, `kras_ctdna_detected_flag`
+### Primary: Surgery (22 cols)
+`had_surgery_flag`, `neoadjuvant_therapy_flag`, `surgery_procedure`,
+`surgical_approach`, `r_status`, `lymph_nodes_harvested`,
+`lymph_nodes_positive`, `lymph_node_ratio`, `pancreatic_fistula_isgpf`,
+`delayed_gastric_emptying_isgps`, `post_pancreatectomy_hemorrhage`,
+`bile_leak_flag`, `wound_infection_flag`, `portal_vein_resection_flag`,
+`arterial_resection_flag`, `operative_time_minutes`,
+`estimated_blood_loss_ml`, `icu_admission_flag`, `hospital_los_days`,
+`readmission_90d_flag`, `pathologic_complete_response_flag`,
+`near_complete_response_flag`
+### Primary: Treatment (17 cols)
+`first_line_regimen`, `second_line_regimen`, `targeted_agent`,
+`recist_response`, `recist_depth_of_response_pct`, `ca19_9_response_flag`,
+`ca19_9_progression_flag`, `ca19_9_nadir_u_ml`, `ca19_9_nadir_timing_weeks`,
+`cycles_completed`, `dose_reduction_flag`,
+`treatment_discontinuation_reason`, `grade3_4_toxicity_flag`,
+`febrile_neutropenia_flag`, `peripheral_neuropathy_grade`,
+`parp_response_flag`, `radiation_flag`, `radiation_type`,
+`radiation_dose_gy`
+### Primary: Outcomes (7 cols)
+`overall_survival_months`, `progression_free_survival_months`,
+`recurrence_free_survival_months`, `time_to_next_treatment_months`,
+`vital_status`, `quality_of_life_qlq_c30`, `quality_of_life_pan26`
+### CA 19-9 Longitudinal Panel (3 cols × ~4,400 rows)
+`patient_id`, `month_from_diagnosis` (0, 1, 2, ..., min(60, OS+1)),
+`ca19_9_u_ml`
+### Surgical Subset (21 cols × ~100 rows)
+Joins all surgical-pathology and complication fields for the ~20% of
+patients who had surgery; flat layout for surgical modeling.
+### Molecular Panel (25 cols × 500 rows)
+Flat molecular profile for the full cohort.
+### Treatment History (8 cols × ~860 rows)
+Long-form: one row per (`patient_id`, `treatment_line`) where
+`treatment_line ∈ {First, Second}`. Includes regimen, targeted_agent,
+RECIST response, cycles completed, PFS months, discontinuation reason.
+---
+## Use cases
+1. **PDAC molecular subtyping** — KRAS variant classification, HRD-high vs
+   -low stratification, MSI-H detection workflows.
+2. **Resectability prediction** — features → NCCN resectability
+   classification.
+3. **NCCN guideline-concordance audit** — FOLFIRINOX vs Gem+NabP in fit
+   patients, olaparib uptake in HRR+, pembro in MSI-H.
+4. **Survival modeling** — Cox PH on OS/PFS with KRAS variants, HRD score,
+   resectability, treatment as covariates.
+5. **CA 19-9 longitudinal modeling** — mixed-effects models on the CA 19-9
+   panel; predict response from kinetics.
+6. **Whipple complications** — predict ISGPF fistula grade B/C from
+   patient + tumor features.
+7. **HRR-targeted therapy benefit** — quasi-experimental olaparib uptake
+   in HRR+ vs HRR- mPDAC.
+8. **Multi-table joins for ML** — combine primary + CA 19-9 + surgical +
+   molecular + treatment for complex ML pipelines.
+9. **Liquid biopsy modeling** — ctDNA detection probability by stage,
+   KRAS-ctDNA detection in KRAS+ patients.
+10. **Teaching & training** — oncology fellows, HPB surgery residents,
+    ML-for-healthcare bootcamps focused on rare-but-deadly diseases.
+---
+## Loading examples
+### pandas (all 5 tables)
+```python
+import pandas as pd
+df      = pd.read_csv("hconc005_sample.csv")
+ca_long = pd.read_csv("hconc005_ca19_9_longitudinal.csv")
+surg    = pd.read_csv("hconc005_surgical.csv")
+mol     = pd.read_csv("hconc005_molecular.csv")
+tx      = pd.read_csv("hconc005_treatment_history.csv")
+print(df.shape)        # (500, 107)
+print(ca_long.shape)   # (~4,400, 3)
+print(surg.shape)      # (~100, 21)
+print(df["kras_mutation"].value_counts())
+```
+### Hugging Face `datasets`
+```python
+from datasets import load_dataset
+ds = load_dataset("xpertsystems/hconc005-sample")
+df = ds["train"].to_pandas()
+```
+### KRAS variant survival analysis
+```python
+from lifelines import KaplanMeierFitter
+import matplotlib.pyplot as plt
+df["dead"] = (df["vital_status"] != "Alive").astype(int)
+kmf = KaplanMeierFitter()
+for variant in ["G12D", "G12V", "G12R", "G12C", "WT"]:
+    sub = df[df["kras_mutation"] == variant]
+    if len(sub) < 5: continue
+    kmf.fit(sub["overall_survival_months"], event_observed=sub["dead"], label=variant)
+    kmf.plot_survival_function()
+plt.title("OS by KRAS Variant in PDAC")
+plt.show()
+```
+### CA 19-9 trajectory by RECIST response
+```python
+import matplotlib.pyplot as plt
+import numpy as np
+merged = ca_long.merge(df[["patient_id", "recist_response"]], on="patient_id")
+for resp in ["CR", "PR", "SD", "PD"]:
+    sub = merged[merged["recist_response"] == resp]
+    if len(sub) == 0: continue
+    avg = sub.groupby("month_from_diagnosis")["ca19_9_u_ml"].median()
+    plt.plot(avg.index, avg.values, label=resp, marker='o', markersize=3)
+plt.yscale("log")
+plt.xlabel("Months from diagnosis"); plt.ylabel("CA 19-9 (U/mL, log scale)")
+plt.legend(); plt.title("Median CA 19-9 Trajectory by RECIST Response")
+plt.show()
+```
+### HRR-stratified olaparib uptake audit
+```python
+hrr_pos = df[df["parp_inhibitor_eligible_flag"] == 1]
+ola_uptake = (hrr_pos["second_line_regimen"] == "Olaparib").mean()
+print(f"Olaparib in PARP-eligible second-line: {ola_uptake:.1%}")
+# Expected ~25-40% (POLO era)
+```
+### Whipple complications by approach
+```python
+whipple = surg[surg["surgery_procedure"].isin(
+    ["Pancreaticoduodenectomy_Whipple", "PPPD"])]
+fistula_rate = whipple["pancreatic_fistula_isgpf"].isin(
+    ["Grade_B", "Grade_C"]).mean()
+print(f"Whipple ISGPF Grade B/C fistula: {fistula_rate:.1%}")
+```
+---
+## Honest limitations & generator quirks
+This is a **commercial synthetic dataset** — not a research-grade simulation
+study. We disclose all known generator quirks below so users can decide whether
+the artifact fits their use case.
+1. **🚨 Generator required a wrapper patch to run at all.** The original
+   generator had a fatal `ValueError` at line 60:
+   ```python
+   patient_ids = [str(uuid.UUID(int=rng.integers(0, 2**128))) for _ in range(N)]
+   ```
+   Numpy's `rng.integers()` returns int64 values, which max out at ~`2^63`.
+   Passing `2**128` as `high` raises `ValueError: high is out of bounds for int64`.
+   The wrapper applies a minimal in-place patch that composes a 128-bit
+   UUID from four 32-bit integer draws (deterministic-seeded):
+   ```python
+   _uuid_parts = rng.integers(0, 2**32, (N, 4), dtype=np.int64)
+   patient_ids = [str(uuid.UUID(int=int(p[0]) | (int(p[1]) << 32) |
+                  (int(p[2]) << 64) | (int(p[3]) << 96))) for p in _uuid_parts]
+   ```
+   The patch is applied in `/home/claude/hconc005_work/hc_onc_005_simulation_engine.py`;
+   the original is preserved at `hc_onc_005_simulation_engine_original.py.bak`.
+   **The full commercial product fixes this in the source.**
+2. **Module-level script architecture.** Unlike other SKUs in the catalog,
+   this generator has **no function or class wrapper** — all generation
+   runs at import time. `parser.parse_args()` executes at module level,
+   reading from `sys.argv`. The wrapper patches `sys.argv` before each
+   `import` / `importlib.reload()` cycle. For sweeps, this is slightly
+   more fragile than a kwargs-API generator but works reliably.
+3. **OS median heavily Stage IV-weighted.** Cohort is ~47% Stage IV at dx
+   (matches SEER ~50-55%), so overall median OS ~5.7mo trends toward the
+   PDAC mortality reality. For Stage I/II-only analyses, filter on
+   `pdac_stage_simple` before computing summary stats — Stage I OS observed
+   ~6-8mo is biologically low for resected Stage I PDAC (literature ~24-36mo
+   for resected R0). The generator's Stage I subset is small (~5%) and OS
+   distributions are dominated by Stage IV physics. **The generator's
+   Weibull formula is mathematically correct** (unlike HCONC004), but the
+   `os_scale_map` lookup falls back to default 9.0 months for many Stage I
+   combinations not explicitly mapped.
+4. **Stage I cohort is small (~3-5% of 500 patients = 15-25 patients).**
+   Survival estimates and molecular subset metrics for Stage I have wide
+   sampling variance. **For Stage-I-focused modeling, request a larger
+   cohort in the full commercial product.**
+5. **MSI-H is rare (~1%) so pembrolizumab uptake metric has wide variance
+   across seeds** (50-100% in MSI-H subset depending on n=2-10 MSI-H
+   patients). The structural floor is set at ≥40% to accommodate this.
+6. **`recist_response` for second-line treatment is drawn independently
+   from `rng.choice(["PR","SD","PD"], p=[0.15, 0.35, 0.50])`** in the
+   treatment-history table (line 480) — not coupled to first-line response
+   or molecular features. This is realistic for "next-line outcome roughly
+   matches biology" but not causally derived.
+7. **CA 19-9 longitudinal panel has VARIABLE rows per patient** (3-60,
+   median 6) — truncated at `min(int(osm), 60)+1` (line 430). Shorter
+   survivors have fewer CA 19-9 visits. **Cannot use this panel for
+   fixed-N visit analyses without filtering.** Join on `patient_id` and
+   `groupby` is safe.
+8. **`time_to_next_treatment_months`** is drawn from an exponential with
+   rate 0.15 independently of treatment regimen or response — not coupled
+   to PFS or progression. For treatment-pathway modeling, prefer the
+   `treatment_history` table's `pfs_months`.
+9. **`recurrence_free_survival_months` is only present for surgical patients**
+   (`had_surgery_flag == 1`). For non-surgical patients, this column is
+   `NaN` by design.
+10. **Lewis-negative patients (~10%) have low CA 19-9 even with disease**
+    (line 171: `np.where(lneg_fl==1, rng.uniform(0.1, 5.0, N), ...)`).
+    This is clinically accurate (Lewis-negative individuals don't secrete
+    CA 19-9), so filter on `ca19_9_lewis_negative_flag` for CA 19-9 model
+    training to avoid spurious correlations.
+11. **No CEA longitudinal panel** — only CA 19-9 has the longitudinal
+    table. CEA is captured as `cea_baseline_ng_ml` only in the primary
+    cohort.
+12. **Race/ethnicity not coupled to outcomes.** Real PDAC epidemiology
+    shows Black patients have higher PDAC incidence and worse survival
+    (Singal 2012). Cohort is intentionally race-blinded in outcomes to
+    avoid encoding disparity bias.
+13. **`dx_year` uniform 2015-2026.** Recent dx years have less follow-up
+    in real data but the synthetic OS distribution doesn't account for
+    administrative censoring by dx year. For temporal trend analyses, use
+    only `dx_yr <= 2021` patients.
+These quirks are documented in the validation scorecard footnotes, not buried
+— we believe honest disclosure makes the dataset more useful, not less.
+---
+## What you get in the full commercial product
+| | Sample (this dataset) | Full product |
+|---|---|---|
+| Cohort patients | 500 | 20,000+ (configurable) |
+| CA 19-9 panel | ~4,400 rows (variable) | Configurable cadence |
+| Int64 UUID bug | Wrapper-patched (disclosed) | **FIXED** in source |
+| Module-level CLI | Yes (script-style) | Function-API option |
+| Stage I cohort size | ~5% (small subset) | Configurable enrichment |
+| Race-outcome coupling | None (race-blinded) | Configurable disparity profiles |
+| CEA longitudinal | Baseline only | Full longitudinal panel option |
+| Validation report | Yes (35 metrics) | Yes + custom scorecard |
+| Format | CSV | CSV, Parquet, JSON |
+| License | CC-BY-NC-4.0 (non-commercial) | Commercial use license |
+| Schema mapping | — | SEER / NCCN / NCDB / TCGA-PAAD |
+| Multi-line treatment | First + Second | Multi-line cascade |
+| Support | Community | Email / SLA |
+---
+## Citation
+```bibtex
+@dataset{xpertsystems_hconc005_2026,
+  title  = {HC-ONC-005: Pancreatic Cancer (PDAC) Synthetic Cohort with CA 19-9 Longitudinal Panel and Five Relational Tables},
+  author = {{XpertSystems.ai}},
+  year   = {2026},
+  version= {1.0.0},
+  url    = {https://huggingface.co/datasets/xpertsystems/hconc005-sample},
+  license= {CC-BY-NC-4.0 (sample); Commercial (full product)},
+  note   = {Calibrated against SEER PDAC 2017-2021, TCGA PAAD molecular frequencies (Waddell 2015, Bailey 2016), NCCN Pancreatic Adenocarcinoma Guidelines 2024, AJCC 8th Edition, ISGPF 2016 fistula grading, ISGPS DGE grading, PRODIGE-4 / ACCORD-11 (Conroy 2011 FOLFIRINOX), MPACT (Von Hoff 2013 Gem+NabP), POLO (Golan 2019 olaparib maintenance), NAPOLI-3 (Wainberg 2023 NALIRIFOX), KEYNOTE-158 (Marabelle 2020 pembrolizumab MSI-H), KRYSTAL-1 (Skoulidis 2021 sotorasib G12C), Pritchard 2016 (BRCA2 prevalence), Iacobuzio-Donahue 2009 (SMAD4), Yachida 2010 (metastasis patterns), Hidalgo 2010 (head tumor proportion), Cohen 2018 (PDAC ctDNA).}
+}
+```
+---
+## Contact
+- **Email:** [pradeep@xpertsystems.ai](mailto:pradeep@xpertsystems.ai)
+- **Web:** [https://xpertsystems.ai](https://xpertsystems.ai)
+- **Vertical:** Healthcare / Oncology
+- **SKU catalog:** SKU 5 of the Oncology vertical (15 SKUs total across Cardiology + Oncology); ~80 SKUs across 8 verticals
+XpertSystems.ai — synthetic data, calibrated to real-world registries.

hconc005_ca19_9_longitudinal.csv ADDED Viewed

The diff for this file is too large to render. See raw diff

hconc005_molecular.csv ADDED Viewed

	@@ -0,0 +1,501 @@

+patient_id,kras_mutation,kras_allelic_frequency_pct,kras_g12c_targeted_flag,tp53_mutation,smad4_loss,cdkn2a_loss,brca1_germline,brca2_germline,brca2_somatic,palb2_germline,atm_germline,hrd_score,parp_inhibitor_eligible_flag,msi_status,tmb_mutations_per_mb,pdl1_tumor_proportion_score,her2_status,ntrk_fusion_flag,ca19_9_baseline_u_ml,ca19_9_lewis_negative_flag,cea_baseline_ng_ml,ctdna_detected_flag,ctdna_vaf_pct,kras_ctdna_detected_flag
+705a5661-a791-ffc1-c621-fbcd16d92688,G12D,23.89,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,38.6,0,MSS,2.86,0.2,Negative,0,106.01,0,3.51,0,0.0,0
+b286b60e-1600-888d-dbcd-12c26eda1624,G12A,15.96,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,21.8,0,MSS,5.61,16.7,Negative,0,591.46,0,2.4,1,16.33,1
+f9c262ed-86c7-538c-181c-01b5339381eb,G12R,26.83,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,12.5,0,MSS,8.0,2.5,Negative,0,2412.47,0,7.11,1,9.83,0
+c93b82a3-b7ac-9740-c2da-0d2fbc5a4471,G12D,24.05,0,WT,Lost,Intact,WT,WT,WT,WT,WT,16.5,0,MSS,7.24,24.0,Negative,0,1504.14,0,0.67,0,0.0,0
+734c7e29-d6f9-bd6e-20cc-0e168362d113,G12V,42.81,0,WT,Lost,Lost,Pathogenic,WT,WT,WT,WT,52.8,1,MSS,6.66,6.2,Amplified_3+,0,1993.44,0,18.85,1,10.19,0
+ed407866-2ebb-92af-5eec-9e8b80171029,G12A,10.98,0,WT,Lost,Intact,WT,WT,WT,WT,WT,24.8,0,MSS,6.03,9.2,Negative,0,0.8,1,7.64,1,9.64,0
+d2a0814d-6704-a0b6-a4d4-5831c814ce06,Q61H,15.13,0,Mutant,Lost,Lost,WT,WT,Mutant,Pathogenic,WT,40.7,1,MSS,6.85,13.8,Negative,0,69.45,0,8.08,1,2.36,1
+3a2c511e-7351-513a-7183-97ca8ba13e23,G12D,37.91,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,7.9,0,MSS,4.06,12.6,Negative,0,101.59,0,0.5,1,2.98,1
+105653e3-e34c-bfaf-8df9-44c317963822,Q61H,16.71,0,WT,Lost,Intact,WT,WT,Mutant,WT,WT,19.8,0,MSS,8.0,16.4,Negative,0,933.09,0,1.58,1,4.22,1
+a1b4c210-46d9-b92c-d3df-a2f0dbb8fa6e,WT,0.0,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,25.8,0,MSS,8.0,19.6,Negative,0,181.9,0,19.9,0,0.0,0
+5ac236be-b355-791f-c212-09c32a4c73f5,G12R,17.22,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,32.7,0,MSS,5.25,18.9,Negative,0,403.39,0,3.75,1,1.37,1
+e4a395f7-7218-933c-f87f-aa6d11633489,G12A,23.09,0,WT,Intact,Lost,WT,WT,WT,WT,WT,23.7,0,MSS,7.21,22.7,Negative,0,202.47,0,0.8,1,1.64,1
+31d3d7a4-c288-c510-c744-240fad8c19b0,G12V,23.14,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,27.7,0,MSS,3.04,11.7,Negative,0,1761.68,0,5.59,1,7.29,1
+0b36b93d-7f6f-4439-777b-07175d28f217,WT,0.0,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,19.4,0,MSS,6.5,13.4,Negative,0,109.72,0,8.84,0,0.0,0
+aedc4bd3-be4d-e22b-277f-84228bebfaa0,G12R,13.23,0,WT,Intact,Lost,WT,WT,WT,WT,WT,22.7,0,MSS,5.74,21.9,Negative,0,10565.62,0,7.63,0,0.0,0
+f7aeb7c3-5ddc-4b0b-bea8-bb8eec2ac8d4,G12D,39.01,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,25.4,0,MSS,8.0,7.1,Negative,0,1022.22,0,3.86,1,2.63,1
+5ed67281-e7d1-3122-5369-4a69692d7d22,G12D,54.37,0,WT,Intact,Intact,WT,WT,WT,WT,WT,9.5,0,MSS,5.59,6.1,Negative,0,63.16,0,13.95,0,0.0,0
+308131ea-cbb1-aed0-7834-cf45138b3a1f,G12D,7.8,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,37.4,0,MSS,8.0,0.2,Negative,0,208.67,0,2.22,1,5.68,1
+79c7cc4c-afbd-0939-2142-8928768345f6,G12R,9.66,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,13.8,0,MSS,5.17,18.5,Negative,0,1222.15,0,7.69,1,9.07,1
+ab78ee11-9083-10a7-3a16-bb295487bf35,G12D,44.78,0,Mutant,Intact,Lost,WT,WT,Mutant,WT,WT,24.2,0,MSS,2.42,17.2,Negative,0,450.4,0,5.13,1,6.19,0
+d52a65f4-2922-dc01-6fe9-302af0b7e67a,G12V,62.92,0,Mutant,Lost,Intact,WT,WT,Mutant,WT,WT,22.4,0,MSS,5.53,6.9,Negative,0,45657.76,0,3.92,1,3.03,1
+4ff7429d-18e3-d83f-b344-92dfa1383bb7,Q61H,6.84,0,WT,Lost,Lost,WT,WT,WT,WT,WT,34.1,0,MSS,6.55,3.2,Negative,0,1263.85,0,3.07,1,13.96,1
+ce050974-6f6a-5c0a-d50e-fa74c4916b35,G12R,40.02,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,4.5,0,MSS,6.43,1.1,Negative,0,4187.91,0,3.18,1,19.88,0
+49cfdee0-e5e9-1216-6331-c875d7791e4a,G12V,65.54,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,35.4,0,MSS,6.46,12.2,Negative,0,2625.51,0,4.63,1,3.44,1
+23c6d19a-a302-d2b1-aeb8-067d3d53a8b1,G12V,14.62,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,5.5,0,MSS,4.94,4.8,Negative,0,0.43,1,3.34,1,10.14,1
+01e27e63-ce0d-de47-332d-2f17d52e3c45,G12D,63.29,0,Mutant,Intact,Lost,Pathogenic,WT,WT,WT,WT,35.8,1,MSS,5.31,19.8,Negative,0,18.3,0,9.33,1,3.45,1
+aa33aa6d-c7c5-f4bb-c973-e041cbfde031,G12V,22.05,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,34.5,0,MSS,3.86,23.8,Negative,0,297.41,0,2.62,0,0.0,0
+c7dddb97-46f1-715d-b485-b7df78b89fd7,G12D,29.63,0,WT,Intact,Lost,WT,WT,WT,WT,WT,10.3,0,MSS,2.72,19.4,Negative,0,8528.83,0,21.51,1,3.67,1
+919905e4-816f-6949-757b-81178e3ee115,G12D,15.93,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,24.5,0,MSS,5.8,21.3,Negative,0,3.38,1,2.51,1,9.0,0
+1d51d7c8-3ed7-da8e-23c9-bc6f098a05db,G12D,44.73,0,Mutant,Intact,Lost,WT,Pathogenic,Germline,WT,WT,58.5,1,MSS,4.49,24.8,Negative,0,283.46,0,11.25,1,19.22,1
+7899c2ce-a788-a657-ab1c-74dd708a83e6,G12V,40.47,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,37.4,0,MSS,8.0,18.5,Negative,0,43.47,0,11.74,0,0.0,0
+c3d6f712-1446-47f3-90b3-503fdae685fc,G12D,69.05,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,31.3,0,MSS,2.53,14.2,Negative,0,2324.55,0,5.29,1,7.8,1
+8db7612d-90bc-4e67-a27c-e65a931906c7,G12D,58.23,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,13.4,0,MSS,6.8,20.3,Negative,0,3744.78,0,4.84,1,19.55,0
+4dcfac72-cb7f-64aa-8f28-3353172f5c7b,G12S,24.4,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,32.5,0,MSS,8.0,14.1,Negative,0,2255.38,0,2.16,0,0.0,0
+6fccb5f8-58f5-b52c-07e3-ad779a539b6e,G12D,80.0,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,9.0,0,MSS,5.62,10.8,Negative,0,1653.35,0,2.67,1,4.33,1
+6895554c-46cb-df16-36ef-0567fb94be4e,G12R,55.17,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,24.6,0,MSS,6.04,0.8,Negative,0,112.42,0,5.58,1,12.55,1
+3be37549-08e1-a35d-da78-9fb1fe1f5581,G12V,33.93,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,30.1,0,MSS,7.17,16.1,Negative,0,1030.18,0,4.28,1,6.5,1
+4808c655-db0d-3ebb-0eec-edb0d25941ba,G12V,13.49,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,28.1,0,MSS,7.4,22.4,Negative,0,174.36,0,14.63,0,0.0,0
+a9735c57-6f2f-62dc-4b28-f5e3eaeb4005,WT,0.0,0,WT,Lost,Lost,WT,WT,WT,WT,WT,26.3,0,MSS,5.14,17.3,Negative,0,292.26,0,2.84,0,0.0,0
+c8ad8d93-8148-b20d-8e99-a8bd2053ef2c,WT,0.0,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,33.2,0,MSS,4.04,10.1,Negative,0,37.41,0,3.02,1,18.12,0
+6808f827-68c0-7153-aa10-73c1ff00dcbc,G12A,14.01,0,WT,Lost,Lost,WT,WT,Mutant,WT,WT,22.2,0,MSS,7.85,15.4,Negative,0,216.39,0,0.85,1,23.34,1
+2abebcbe-523b-31ba-d063-a3d26aff5827,G12V,56.06,0,Mutant,Intact,Intact,WT,Pathogenic,Germline,Pathogenic,WT,100.0,1,MSS,2.82,20.3,Negative,0,6625.25,0,8.53,1,4.44,1
+170d6069-1b2c-290a-05d0-755b55941fbd,G12D,32.86,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,5.8,0,MSS,8.0,19.1,Negative,0,548.96,0,7.79,1,3.56,1
+763d960e-b25f-9215-b8ec-8adac5847580,G12D,16.98,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,14.2,0,MSS,5.17,12.3,Negative,0,503.23,0,11.91,1,3.11,1
+8044786a-e68f-247a-2949-1b78b791258c,G12V,22.61,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,31.3,0,MSS,6.06,9.0,Negative,0,315.65,0,12.6,1,18.94,1
+b2420d56-7f51-061c-26fd-ed0bf02422d1,G12D,21.02,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,12.3,0,MSS,4.9,9.9,Negative,0,870.63,0,9.86,1,14.49,0
+618a9b69-2a8d-01c2-7237-4c347ee1564a,G12V,39.65,0,WT,Intact,Intact,WT,WT,WT,WT,WT,17.7,0,MSS,8.0,22.7,Negative,0,1393.74,0,10.29,1,14.46,1
+a15a3334-af07-01b0-4d2f-e5723d1fc937,G12V,14.48,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,30.9,0,MSS,6.68,4.2,Negative,0,3928.36,0,8.25,0,0.0,0
+167039a0-f5ae-69c4-5c9f-c0519b7139b0,G12V,30.26,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,21.5,0,MSS,5.32,21.6,Negative,0,9064.83,0,9.62,1,2.57,1
+f63eece3-56c5-0571-1e35-a28257b4076c,G12A,29.37,0,WT,Intact,Lost,WT,WT,WT,WT,WT,7.5,0,MSS,5.26,4.9,Negative,0,4.05,1,0.71,1,2.1,1
+b32001b8-7ebc-9f7d-e898-be805dc37279,G12V,14.74,0,WT,Lost,Lost,WT,WT,WT,WT,WT,7.0,0,MSS,5.7,24.5,Negative,0,4.8,1,1.49,0,0.0,0
+f81bf16c-c3a4-8a9b-4410-0dc575194ff8,Q61H,63.61,0,Mutant,Lost,Lost,WT,WT,Mutant,WT,WT,12.0,0,MSS,8.0,11.2,Negative,0,47247.58,0,1.27,1,2.95,1
+b7861d8d-42da-1234-c75c-382043765d82,G12V,20.55,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,12.1,0,MSS,3.57,18.3,Negative,0,2502.21,0,15.96,0,0.0,0
+45b19f7c-bca6-c348-7309-5afbc9fc5585,G12V,13.52,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,5.5,0,MSS,8.0,18.2,Negative,0,247.84,0,2.05,0,0.0,0
+e710f35e-7270-2580-18ad-13fe1449f553,G12R,40.92,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,33.4,0,MSS,7.59,19.3,Negative,0,0.27,1,2.4,0,0.0,0
+33ce15e1-b43b-71f3-74ad-c14320a8e05d,G12V,25.35,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,11.3,0,MSS,8.0,19.7,Negative,0,12.44,0,4.51,0,0.0,0
+9447bbd1-cf04-6404-4e53-2c5eb8bbda30,WT,0.0,0,WT,Intact,Lost,WT,WT,WT,WT,WT,32.1,0,MSS,7.78,1.0,Negative,0,692.9,0,1.29,0,0.0,0
+db4b12df-7694-a997-2d40-fb298c021d71,Q61H,12.05,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,38.9,0,MSS,6.06,6.8,Negative,0,3012.55,0,6.56,1,5.48,1
+b82eb96a-7e25-ad15-c22e-55fe04ff863b,Q61H,39.94,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,13.3,0,MSS,8.0,5.7,Negative,0,117237.46,0,0.53,1,4.3,1
+a0974feb-4f04-d04c-6e9d-a642a9cde609,G12D,80.0,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,38.8,0,MSS,6.63,17.5,Negative,0,203.99,0,1.38,0,0.0,0
+a65c58cd-183d-e94f-9587-71ca23e5bcdf,G12V,11.5,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,7.6,0,MSS,8.0,17.1,Negative,0,2987.89,0,5.47,1,2.21,1
+6a725a99-c1ea-ba0b-159e-249da0f5737d,G12C,30.34,1,WT,Lost,Lost,WT,WT,WT,WT,WT,25.9,0,MSS,8.0,7.4,Negative,0,606.66,0,1.29,1,0.71,1
+7e762ead-2df0-dc70-0aa7-39fbc9716412,Q61H,15.31,0,WT,Intact,Intact,WT,WT,WT,WT,WT,39.6,0,MSS,6.28,19.8,Negative,0,4767.4,0,16.43,1,7.5,1
+24ff8988-a91d-04d8-5471-c8cf302f865e,G12V,80.0,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,32.3,0,MSS,5.11,7.8,Negative,0,20.61,0,4.69,0,0.0,0
+966fdfeb-2cd8-ef97-1a78-9decad7df0a1,WT,0.0,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,9.2,0,MSS,4.68,8.6,Negative,0,97077.95,0,13.9,1,7.83,0
+ecd4ac0d-4ccc-53da-2bab-fb14cb21b79f,G12R,29.06,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,10.3,0,MSS,7.24,10.0,Amplified_3+,0,413.39,0,6.41,1,3.28,0
+58cc75a2-7271-17a2-94c0-6c3ffd5be90e,G12D,11.74,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,10.5,0,MSS,4.26,18.6,Negative,0,114.98,0,4.43,0,0.0,0
+05d67978-4b74-ef51-9746-3cd69cc9a625,G12R,13.58,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,37.7,0,MSS,5.26,0.3,Negative,0,152.49,0,1.65,0,0.0,0
+7b783cf0-6b0c-334c-f564-22f826c897d1,G12V,38.39,0,Mutant,Intact,Lost,WT,WT,WT,Pathogenic,WT,39.8,1,MSS,4.11,22.7,Negative,0,536.78,0,11.35,1,10.96,1
+152dcb14-10a0-fe58-c861-55fa77945c4e,G12R,10.83,0,WT,Intact,Intact,WT,WT,WT,WT,WT,20.4,0,MSS,7.41,17.3,Negative,0,458.92,0,6.97,1,5.66,1
+7d9ef93c-abce-c8fb-7c95-a3ef469decd4,G12D,11.04,0,WT,Intact,Lost,Pathogenic,Pathogenic,Germline,WT,WT,84.0,1,MSS,4.48,14.7,Negative,0,55.78,0,36.04,0,0.0,0
+925cc507-2938-899b-f015-650170f06420,G12V,24.66,0,Mutant,Intact,Lost,WT,WT,Mutant,WT,WT,14.5,0,MSS,3.62,5.9,Negative,0,2236.04,0,10.26,1,5.08,1
+4458845d-cebe-b4ba-7936-99f48ad08bf0,G12V,26.58,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,16.3,0,MSS,3.88,19.6,Negative,0,662.46,0,3.01,0,0.0,0
+854ac95c-8b85-69e7-54e1-b4aff42a7555,G12D,30.82,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,13.8,0,MSS,4.81,21.8,Negative,0,6150.27,0,5.99,1,5.49,1
+05885e88-48d8-db1f-705c-805fd98b0b4e,G12D,18.85,0,WT,Intact,Lost,WT,WT,WT,WT,WT,24.0,0,MSS,4.99,12.5,Negative,0,5018.61,0,6.84,1,4.8,1
+e56acad7-0289-de2b-d387-de175d1a049e,G12D,42.61,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,17.0,0,MSS,6.69,7.3,Negative,0,5607.79,0,14.34,1,3.19,1
+8dd5500d-4d5b-9fe0-23e7-5d428af6b75d,G12S,14.63,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,17.6,0,MSS,5.67,9.5,Negative,0,36.29,0,16.81,1,17.71,0
+ac17ed3e-aa7e-3f5b-1bcb-9ea950d133b5,G12V,35.73,0,WT,Lost,Lost,Pathogenic,WT,WT,WT,Pathogenic,70.2,1,MSS,7.02,10.4,Negative,0,1201.45,0,3.81,1,4.31,0
+a8cfebfa-3e6e-7a36-47fe-eff01e6e8b01,G12R,27.9,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,14.2,0,MSS,7.24,7.6,Negative,0,3.18,0,1.33,0,0.0,0
+c4c614ff-f052-a825-ba1c-51acbaf4a6ce,G12V,35.18,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,30.2,0,MSS,8.0,17.8,Negative,0,2.83,1,0.7,0,0.0,0
+ea7fc095-9d59-3b7e-1b94-e91f52180c46,G12S,49.86,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,20.1,0,MSS,2.82,8.6,Amplified_2+,0,3229.64,0,1.43,1,3.32,1
+0993de89-3c88-57fc-3aef-4dd9f9a3c76d,G12V,18.67,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,20.4,0,MSS,3.85,20.5,Negative,0,3699.11,0,2.48,1,6.61,1
+5ef4c346-8bfb-4cd1-8e0a-cfba2429c191,G12D,16.5,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,8.4,0,MSS,7.55,11.6,Negative,1,23.08,0,20.17,1,1.43,0
+cee99187-75c4-c8a5-d46d-19c14f593d5b,G12D,8.91,0,Mutant,Intact,Lost,WT,WT,WT,WT,Pathogenic,21.2,1,MSS,6.58,15.7,Negative,0,0.78,1,20.48,1,10.45,1
+f3f136fa-33e6-a87a-5130-03b4f6950d95,WT,0.0,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,32.4,0,MSS,8.0,23.7,Negative,0,1241.23,0,11.71,1,5.83,0
+83dac8b5-9f32-375d-4a79-9768a2844a4b,G12S,22.07,0,WT,Intact,Intact,WT,WT,WT,WT,WT,34.2,0,MSS,3.26,11.2,Negative,0,128.56,0,15.34,0,0.0,0
+efa08d28-fdcb-4363-4186-ed9ce7d0f523,G12R,23.0,0,Mutant,Intact,Lost,WT,WT,WT,Pathogenic,WT,39.6,1,MSS,5.0,4.3,Negative,0,5364.23,0,2.21,1,8.33,1
+0b7f4329-887c-f758-2a23-bce92e427c6d,G12R,12.79,0,Mutant,Intact,Lost,WT,WT,Mutant,WT,WT,14.4,0,MSS,5.37,13.7,Negative,0,1306.05,0,0.98,1,6.95,0
+fe0c5330-f828-d966-6f62-855b4c7e05e9,G12R,14.55,0,WT,Intact,Lost,WT,WT,WT,WT,WT,14.3,0,MSS,6.47,12.4,Negative,0,2098.53,0,1.64,1,6.63,1
+bfa4c671-1747-1c89-e444-f61926cb525c,G12A,61.2,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,27.4,0,MSS,6.14,19.6,Negative,0,319.12,0,0.59,1,3.75,1
+e4b8eb42-3931-eb1e-e40a-fa07d87c0a58,Q61H,41.49,0,WT,Lost,Intact,WT,WT,WT,WT,WT,7.5,0,MSS,7.3,21.5,Negative,0,1208.62,0,1.47,0,0.0,0
+50e0b9f1-7834-1ee5-84d3-e6c91db0ecb1,G12R,11.51,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,39.1,0,MSS,5.78,17.8,Negative,0,9985.12,0,2.7,1,9.72,1
+a962a1ee-55e8-cf6c-c5a2-9b5405a94655,G12D,18.81,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,2.5,0,MSS,8.0,24.3,Negative,0,1138.52,0,5.29,1,8.8,1
+182ef7b1-e2e4-4a0c-5fa8-086d69042c43,G12D,31.3,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,39.0,0,MSS,8.0,6.7,Negative,0,47852.75,0,5.13,1,11.04,1
+43309cc4-6147-1eaa-bf2d-9a9dbc92f486,G12V,16.85,0,WT,Intact,Lost,WT,WT,WT,WT,WT,2.8,0,MSS,3.87,6.0,Negative,0,3.25,1,2.25,0,0.0,0
+3db03f62-f29e-8777-efd2-fc94015bcde5,G12C,15.1,1,WT,Lost,Intact,WT,WT,WT,WT,WT,12.7,0,MSS,6.16,7.3,Negative,0,8191.03,0,7.92,1,8.94,1
+d4c3ccd2-1151-0aee-1f6d-1059082b5295,G12V,20.03,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,10.0,0,MSS,8.0,16.8,Negative,0,58.76,0,2.29,1,31.72,1
+2de48720-bf2a-5126-273d-a416e4544f1d,G12D,47.2,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,10.4,0,MSS,7.65,5.8,Negative,0,2120.77,0,4.53,0,0.0,0
+dfe34c43-b84d-1f42-9971-268f5e0168aa,G12R,49.84,0,Mutant,Intact,Intact,WT,WT,WT,WT,Pathogenic,59.8,1,MSS,5.14,2.2,Negative,0,5128.18,0,1.48,1,7.38,1
+4f715f4a-47cf-69ac-3249-8ad10b7704e4,G12V,15.78,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,18.3,0,MSS,6.7,24.4,Negative,0,53.65,0,13.31,1,1.63,1
+f8c99ddd-5206-dd09-c704-00e3ff7ec0f7,G12D,32.34,0,WT,Lost,Lost,WT,WT,WT,WT,WT,4.8,0,MSS,3.21,7.9,Negative,0,201.16,0,4.58,1,2.53,1
+24d6777b-6f06-e33e-8030-930a7fd29524,G12S,24.44,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,39.3,0,MSS,6.0,5.6,Negative,0,1482.68,0,8.84,0,0.0,0
+3acabcd2-2c9d-8495-0391-541bef3308f9,G12V,13.4,0,WT,Lost,Intact,WT,WT,Mutant,WT,WT,9.7,0,MSS,3.37,9.0,Negative,0,533.01,0,1.33,1,11.32,1
+ad7b09f1-0499-1e7f-21bf-19d247800a92,G12D,20.53,0,Mutant,Intact,Lost,WT,Pathogenic,Germline,WT,WT,42.9,1,MSS,7.41,4.0,Amplified_2+,0,1215.36,0,5.34,1,7.53,1
+819ed6a1-4be9-bb2f-1f30-6a3ef824b1c8,G12D,11.49,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,1.0,0,MSS,3.87,0.9,Negative,0,2990.59,0,7.94,1,9.59,1
+94c40edf-c424-e7af-b1bb-2ed7ed70cb7e,G12V,49.3,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,18.5,0,MSS,6.46,7.6,Negative,0,1696.93,0,0.58,1,14.06,1
+cddb1add-dd43-b51b-3324-7f426ac2db76,G12V,62.27,0,Mutant,Intact,Intact,WT,WT,WT,Pathogenic,WT,66.7,1,MSS,6.87,8.4,Negative,0,134.73,0,14.41,1,3.32,1
+bd2e0e41-159a-7574-b724-ebf1066d0a58,G12D,19.18,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,0.7,0,MSS,6.24,20.3,Negative,0,2305.23,0,1.28,1,6.63,0
+1fae544b-6f0f-de03-218d-0034d371b610,G12V,16.62,0,WT,Lost,Lost,WT,WT,WT,WT,WT,29.0,0,MSS,4.7,10.9,Negative,0,676.83,0,5.53,0,0.0,0
+65c7af3c-14b3-ddef-ed74-bd4591396849,G12R,46.19,0,WT,Intact,Lost,WT,WT,WT,WT,WT,10.4,0,MSS,5.56,18.4,Negative,0,2.99,1,26.78,1,4.95,0
+7d13d810-21d8-f441-4d0a-f934f91e6d1e,WT,0.0,0,WT,Lost,Lost,WT,WT,WT,WT,WT,8.8,0,MSS,8.0,18.4,Negative,0,2559.68,0,11.65,1,5.53,0
+f4a3b9cc-5051-1ac5-a9b1-78138224b4a2,G12V,12.57,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,28.2,0,MSS,5.1,19.7,Negative,0,1991.62,0,1.01,1,3.45,0
+ecc03ec6-f5d5-339e-4954-8a388561bf0a,G12V,22.45,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,29.9,0,MSS,6.1,23.0,Negative,0,3161.53,0,3.75,1,2.8,0
+8e21757a-98d0-ce0b-065d-310e7fc94344,G12D,23.68,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,22.4,0,MSS,4.84,12.5,Negative,0,151.22,0,15.39,1,5.79,0
+1b1c179d-d73e-3f5a-a24c-316325f0fce4,G12D,15.45,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,8.1,0,MSS,8.0,2.6,Negative,0,6885.41,0,1.98,0,0.0,0
+6b4b1376-bfb3-1411-23ed-4bbbb92bac18,G12D,30.93,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,0.3,0,MSS,6.24,1.0,Negative,0,1029.55,0,3.13,1,6.66,1
+98963ea9-2a7d-08e3-f75a-f97f01aab4fe,G12V,16.12,0,WT,Lost,Lost,WT,WT,WT,WT,WT,29.5,0,MSS,4.46,4.7,Negative,0,142.05,0,3.04,0,0.0,0
+cdea98d2-bd02-e712-eeda-9c1f2e74b3aa,G12A,17.74,0,WT,Intact,Lost,WT,WT,Mutant,WT,WT,24.0,0,MSS,6.07,20.7,Negative,0,12562.16,0,7.93,1,4.15,1
+c8e641e5-a261-8fca-77a6-52156e9cc9bb,G12V,23.09,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,16.9,0,MSS,5.49,14.4,Negative,0,963.92,0,0.96,0,0.0,0
+1bf0dc68-a9df-2869-0490-f393d8d3a6d2,Q61H,10.04,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,8.5,0,MSS,8.0,3.5,Negative,0,1268.16,0,8.38,1,7.76,0
+cbfc3467-4021-a19e-d455-6f0749b5e547,G12D,7.14,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,30.5,0,MSS,5.94,3.3,Negative,0,3363.48,0,2.4,1,5.52,1
+87e08411-5591-0712-3b8e-57fa7687ade6,G12R,42.56,0,WT,Intact,Intact,WT,WT,WT,WT,WT,2.8,0,MSS,3.48,22.3,Negative,0,1701.01,0,4.43,1,8.96,1
+de2423db-eee7-c203-9b23-da52c3e0af56,G12V,15.73,0,Mutant,Intact,Intact,WT,WT,WT,WT,Pathogenic,45.7,1,MSS,7.39,13.0,Negative,0,204.89,0,3.58,0,0.0,0
+699e4a55-4a33-fda0-9a65-3b0cc0dbc6ef,G12R,80.0,0,WT,Intact,Intact,WT,WT,WT,WT,WT,27.5,0,MSS,8.0,4.3,Negative,0,7211.95,0,8.16,1,2.16,1
+6d069bc0-ed2d-48f2-5fca-86851e6fdb26,Q61H,80.0,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,8.9,0,MSS,8.0,22.4,Amplified_2+,0,98.91,0,4.39,1,4.66,0
+de13ddb4-f66d-edae-a6e4-f3a21d1d5506,G12V,18.1,0,WT,Intact,Lost,WT,Pathogenic,Germline,WT,WT,59.3,1,MSS,3.89,18.0,Negative,0,985.07,0,18.92,0,0.0,0
+3f7269e1-87f0-b2ce-7432-96084629dfdb,G12V,80.0,0,WT,Intact,Lost,WT,WT,WT,WT,WT,20.8,0,MSS,5.43,11.9,Negative,0,2209.24,0,12.05,1,5.01,1
+befacab7-fe9c-e145-3c95-e79544c8ff72,Q61H,43.06,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,23.7,0,MSS,5.98,11.6,Negative,0,1690.35,0,2.02,1,0.36,1
+1af38115-f58a-6cfe-d10a-a685d7425cfe,Q61H,16.66,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,36.0,0,MSS,6.0,16.8,Negative,0,62.7,0,17.55,1,8.65,0
+982ccdf9-79b5-3108-110a-0051e1b2a9d1,Q61H,5.21,0,Mutant,Intact,Intact,Pathogenic,WT,WT,WT,WT,51.9,1,MSS,7.05,8.5,Negative,0,202.37,0,6.17,0,0.0,0
+d31d3140-313a-a8f6-256b-9c175b9cc8bf,G12D,37.07,0,WT,Intact,Lost,WT,WT,WT,WT,WT,2.7,0,MSS,5.27,25.0,Negative,0,107.66,0,5.31,1,4.1,0
+24d4ca7e-ec61-718d-4f72-17db5197e3c2,WT,0.0,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,13.8,0,MSS,4.19,19.6,Negative,0,12439.82,0,10.47,1,2.91,0
+2a604977-993b-3463-ebc4-b88bea4eeec9,G12V,31.78,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,25.1,0,MSI-High,50.0,10.9,Negative,0,50.1,0,1.58,0,0.0,0
+2753351c-93d1-830d-48e3-6a5227e67f65,G12R,21.39,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,13.3,0,MSS,3.86,17.2,Negative,0,3874.05,0,1.13,1,11.3,1
+0569f4d6-8a50-0f6d-1d90-c1be74a5ff79,G12D,12.35,0,WT,Lost,Intact,WT,WT,WT,WT,WT,30.7,0,MSS,4.39,24.9,Negative,0,291.32,0,4.59,1,4.83,1
+2cb54dae-31df-d80d-0e2e-64beb583650e,G12D,18.99,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,7.6,0,MSS,3.85,0.3,Negative,0,3248.55,0,2.44,1,6.0,1
+9755337d-6de3-f611-0daa-7036d4bc075d,G12V,37.49,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,5.7,0,MSS,7.73,0.6,Negative,0,1829.71,0,35.65,1,1.51,1
+64c4f732-cd98-0c39-ae43-4ea6841848d7,G12D,19.83,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,9.2,0,MSS,6.31,19.6,Negative,0,3.09,1,2.09,1,10.79,1
+8128a1a7-fc03-2076-5167-dd51d4061611,G12R,19.76,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,35.0,0,MSS,8.0,5.2,Negative,0,1432.09,0,4.67,1,1.5,1
+d9e3c325-caeb-3127-e000-52eabc6b5ecb,G12D,9.86,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,27.2,0,MSS,4.42,17.1,Negative,0,3536.27,0,5.43,1,7.64,0
+2e76ae05-7e3a-b901-0b21-2e818958f429,G12S,25.91,0,WT,Lost,Lost,WT,WT,WT,WT,WT,20.8,0,MSS,3.66,12.6,Negative,0,37862.32,0,15.35,1,16.79,1
+3fd7dd3a-3a62-c8c8-3c9b-4fd6e39d24fb,G12D,12.59,0,WT,Intact,Lost,WT,WT,WT,WT,WT,12.0,0,MSS,5.07,8.0,Negative,0,2767.37,0,1.66,0,0.0,0
+6a902ca0-f2e7-3c4a-923c-4d95a47f38f2,G12V,42.57,0,WT,Lost,Intact,WT,WT,WT,WT,WT,36.7,0,MSS,5.62,5.8,Negative,0,1557.35,0,0.89,1,3.15,1
+5fa52d1a-01cf-ba0a-0c9b-eb02484361b6,G12V,15.79,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,35.6,0,MSS,6.58,19.4,Negative,0,482.85,0,18.07,1,12.17,1
+1a072b79-e4bf-8967-8614-ac59ed025e68,G12D,20.54,0,Mutant,Intact,Lost,WT,Pathogenic,Germline,WT,WT,56.0,1,MSS,3.09,4.3,Negative,0,1.92,1,4.86,1,4.49,1
+0d4d5f75-1b53-7210-d55d-8a2f17e3e2a3,G12V,80.0,0,WT,Lost,Lost,WT,WT,WT,WT,WT,30.1,0,MSS,7.33,4.0,Negative,0,3.84,0,10.07,1,4.83,0
+195f7a95-b07b-6dd1-ecc2-6fcd67729e4f,G12S,20.41,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,36.5,0,MSS,4.23,11.0,Negative,0,1814.36,0,10.56,0,0.0,0
+e71446c4-ccfa-72c3-d7f4-872cd64e3854,G12V,18.83,0,WT,Lost,Intact,WT,WT,Mutant,WT,WT,12.5,0,MSS,4.67,3.0,Negative,0,2540.68,0,12.55,1,8.62,0
+cd51916e-5219-2745-fac5-24e53d68a561,G12D,34.86,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,13.1,0,MSS,8.0,16.0,Negative,0,1.0,1,3.07,1,3.81,0
+a479c8b2-a0b8-c604-c78b-d71194513c43,G12R,8.41,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,21.8,0,MSS,2.53,24.8,Negative,0,66.93,0,2.34,1,1.55,1
+22720376-bd31-eb65-c76c-4e1a9dc4cb57,G12D,51.96,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,16.3,0,MSS,6.88,18.7,Negative,0,531.26,0,0.61,0,0.0,0
+83a41c2a-52b5-9863-893b-c13ad3785525,G12V,44.54,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,30.5,0,MSS,6.87,15.1,Negative,0,24.52,0,1.66,0,0.0,0
+767a04eb-d56d-43ff-db89-d918f78c3a99,G12V,33.6,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,21.5,0,MSS,4.36,9.9,Negative,0,25864.76,0,4.77,1,16.69,1
+a3ba6b25-afa8-8a7d-6295-39a7c8bd41f7,G12V,5.0,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,8.5,0,MSS,5.06,24.7,Negative,0,1229.02,0,2.22,1,14.81,1
+23c7dcd2-0fa6-6bfb-4436-f0a23ff2ced5,WT,0.0,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,14.3,0,MSS,8.0,22.0,Negative,0,11.09,0,1.43,0,0.0,0
+6ab942fc-2a45-5a31-7a56-2a3f6f01a1cb,G12D,11.43,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,26.8,0,MSS,8.0,20.5,Negative,0,1326.41,0,4.71,1,3.2,1
+5e154105-5696-b18e-3b89-b4209aab60be,G12D,48.16,0,WT,Lost,Intact,WT,WT,WT,WT,WT,2.1,0,MSS,8.0,5.8,Negative,0,2.73,1,17.17,1,3.17,1
+53d6bfd2-bca8-670a-5dcb-e545814b362b,G12V,46.13,0,Mutant,Lost,Intact,WT,WT,Mutant,WT,WT,13.7,0,MSS,8.0,3.1,Negative,0,318.66,0,4.24,1,3.22,1
+af8ce03a-2ed3-91ce-6124-8ed46f13db9a,G12V,30.96,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,0.6,0,MSS,4.59,4.4,Negative,0,168.88,0,1.44,1,5.69,1
+f2e85a63-caf1-cad1-4c00-18bd3c463327,G12R,11.92,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,32.8,0,MSS,3.22,6.5,Negative,0,240.48,0,16.0,1,3.55,1
+7b1cf221-daac-3cc2-ea95-c8a7abbc60a0,G12D,60.13,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,4.7,0,MSS,5.92,2.0,Negative,0,159.13,0,2.07,0,0.0,0
+8912411f-75e3-2282-540f-7adcc531bcaf,G12D,20.96,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,3.1,0,MSS,8.0,22.2,Negative,0,343.95,0,19.68,1,4.5,1
+a70ff6c5-7d3f-aebc-d93b-429bf5e2ded2,G12R,72.47,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,31.5,0,MSS,2.88,4.6,Negative,0,273.32,0,3.44,1,6.85,1
+88607cb1-8d93-e545-cdec-9f7233cda2b2,G12V,28.77,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,3.6,0,MSS,4.18,5.7,Negative,0,221.1,0,4.97,1,8.79,1
+49c490fb-128d-33d8-a206-e3c6c42b283a,G12S,33.25,0,WT,Lost,Intact,WT,WT,WT,WT,WT,27.4,0,MSS,4.37,22.2,Negative,0,33.1,0,21.35,0,0.0,0
+33d0c994-08ff-67b2-bc21-f5522d3d7444,G12D,18.61,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,15.2,0,MSS,6.98,24.0,Negative,0,7506.82,0,1.16,0,0.0,0
+dc5815b9-80d8-9701-b1de-4a4898f2286c,G12D,57.06,0,WT,Intact,Lost,WT,WT,WT,WT,WT,32.9,0,MSS,6.63,5.5,Negative,0,3316.48,0,1.57,0,0.0,0
+9d47fd9c-f3d7-c45a-21d1-7dd5eb3fa854,G12D,35.34,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,7.3,0,MSS,4.44,7.4,Amplified_2+,0,401.5,0,3.23,1,26.19,1
+b9c87fd9-9f32-fed6-1858-31e8a2df4232,G12R,58.31,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,3.4,0,MSS,6.5,20.0,Negative,0,617.1,0,3.9,1,7.56,1
+ef99c091-85f2-3bfc-15a1-58fb94aeba3e,G12V,27.29,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,9.1,0,MSS,3.83,24.3,Negative,0,958.62,0,62.93,1,16.27,1
+f5792d00-f5be-879e-232d-2a85b931d313,G12D,23.85,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,37.3,0,MSS,5.1,16.2,Negative,0,1724.55,0,1.84,1,4.93,0
+97fb8b39-681e-9cbf-cd06-bed02b5d8159,G12D,35.06,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,33.2,0,MSS,3.65,11.1,Negative,0,2657.85,0,1.22,0,0.0,0
+cb8ca565-ff25-19b6-c85a-0da671f7bae3,G12R,58.3,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,11.4,0,MSS,5.7,16.9,Negative,0,3621.27,0,1.76,1,4.07,1
+40ddbb42-1711-2650-f22e-d45fee6e5ba3,G12D,45.15,0,WT,Intact,Lost,WT,WT,WT,WT,WT,8.2,0,MSS,4.39,19.5,Negative,0,1286.37,0,5.65,1,3.68,1
+185524eb-0cd6-6126-970f-36c0b8cb9796,G12R,26.65,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,6.3,0,MSS,7.97,2.8,Negative,0,6841.75,0,7.33,1,3.7,0
+2bd9bf35-2aef-a7a0-9dbd-090a85429803,G12D,8.05,0,WT,Lost,Lost,WT,WT,WT,WT,WT,8.8,0,MSS,5.99,10.9,Negative,0,4.83,1,2.21,1,6.56,1
+928ace61-0202-b23a-90a0-9a70211c70d3,G12D,39.89,0,WT,Lost,Intact,WT,WT,WT,WT,WT,8.2,0,MSS,5.53,21.4,Negative,0,0.83,1,4.58,1,2.32,1
+85cb322f-ade5-0c95-774a-cd9079d675fb,G12D,10.35,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,35.5,0,MSS,8.0,17.6,Negative,0,21.89,0,31.35,1,1.39,0
+cc9b4d3e-eb8c-d63a-c390-7bb8ba4dbe11,Q61H,25.05,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,0.8,0,MSS,7.05,3.8,Amplified_2+,0,7736.31,0,4.64,0,0.0,0
+997ef4ae-3c57-65eb-7dfd-c0cd8488649b,WT,0.0,0,Mutant,Intact,Intact,WT,WT,Mutant,WT,WT,35.2,0,MSS,5.22,18.9,Negative,0,1428.65,0,6.18,1,6.33,0
+1ea6dc46-d854-d20f-ee65-7f79239e615f,G12D,10.48,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,1.7,0,MSS,4.79,16.7,Amplified_2+,0,122.69,0,29.64,0,0.0,0
+16741909-b8a2-36c8-1dfa-7fd1c9346796,G12S,30.68,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,33.1,0,MSS,3.77,6.6,Negative,0,1304.42,0,2.23,0,0.0,0
+6b29e9e1-ba93-58e2-a869-ba6e7cfa3e6c,G12D,80.0,0,WT,Lost,Lost,WT,WT,WT,WT,WT,17.0,0,MSS,5.89,8.6,Negative,0,2299.4,0,2.09,1,6.28,1
+abd5d268-3550-d6d1-c639-eda6ebef83f7,G12D,20.34,0,WT,Intact,Intact,WT,Pathogenic,Germline,WT,WT,43.1,1,MSS,6.84,7.9,Negative,0,3462.63,0,2.8,1,9.25,1
+e5fb599c-bcfc-ba55-5569-48bcbb045089,G12D,38.84,0,WT,Intact,Lost,WT,WT,WT,WT,WT,32.0,0,MSS,2.81,24.8,Negative,0,1033.92,0,2.64,0,0.0,0
+4541c723-a26e-6c90-c335-4e89d12e66dc,G12R,80.0,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,10.3,0,MSS,3.51,4.6,Negative,0,0.12,1,0.73,1,3.64,1
+507f2377-883e-0d02-5d3b-b025cb93bb2d,G12V,41.16,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,35.1,0,MSS,4.92,20.7,Negative,0,822.79,0,5.14,1,9.7,1
+25d5218f-f617-9ac8-2859-3cac5021e30d,G12S,16.66,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,30.1,0,MSS,3.9,13.3,Negative,0,466.41,0,5.57,1,45.3,1
+701a7a9e-8e15-57c8-efa6-0ca816150ec2,G12R,28.28,0,WT,Lost,Lost,WT,WT,Mutant,WT,WT,39.3,0,MSS,6.16,22.0,Negative,0,19.37,0,3.72,1,8.12,1
+baccaebf-20bf-78a1-6221-3f76bccc3baf,G12V,32.74,0,Mutant,Lost,Lost,WT,WT,Mutant,WT,WT,33.3,0,MSS,6.51,24.5,Negative,0,1265.74,0,5.74,1,11.46,1
+efa6dec3-f2f5-ff95-8d90-f41a2d0e4d9f,G12D,57.99,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,9.6,0,MSS,5.76,24.0,Negative,0,602.6,0,5.8,1,8.32,1
+7ab7f6b8-9cd8-5235-c7c1-d6b55c5c4621,G12A,50.83,0,WT,Lost,Lost,WT,WT,WT,WT,WT,16.4,0,MSS,7.54,21.4,Negative,0,910.48,0,1.2,0,0.0,0
+fc93e28a-a6e4-1a79-6059-182e23d2543a,G12S,5.0,0,Mutant,Intact,Intact,WT,WT,WT,Pathogenic,WT,57.9,1,MSS,4.79,10.3,Negative,0,4.48,1,5.98,1,9.54,1
+f3817e44-d8a9-8869-b7bf-228401408248,G12S,14.68,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,12.6,0,MSS,5.94,6.8,Negative,0,1019.68,0,7.83,1,9.28,1
+d9bc9340-455e-1af6-1e54-9cae6c7e660d,G12D,23.52,0,Mutant,Lost,Intact,WT,WT,Mutant,WT,WT,21.9,0,MSS,4.05,8.0,Negative,0,680.89,0,0.91,1,7.91,1
+1f364255-1f6b-ebc3-a317-4628e0c057ca,G12R,13.34,0,WT,Intact,Lost,WT,WT,WT,WT,WT,9.5,0,MSS,6.78,16.3,Negative,0,6784.53,0,19.36,1,4.33,1
+afa402ea-0849-f72c-9698-13877a697cd7,G12R,5.0,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,26.5,0,MSS,6.24,8.5,Negative,0,1226.47,0,1.3,1,2.11,1
+744e2e94-187e-52c4-0326-44d18b650240,Q61H,15.87,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,13.7,0,MSI-High,36.91,93.9,Negative,0,13.38,0,1.44,0,0.0,0
+4b9ca62a-6e69-c7fe-d34d-61e2b8fb5bee,G12D,24.48,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,2.2,0,MSS,5.69,2.0,Negative,0,188.51,0,5.48,1,2.3,1
+713b7fa6-50bd-6177-7563-6836f7e32fe0,G12A,17.9,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,38.7,0,MSS,5.96,19.3,Negative,0,78.81,0,7.65,1,9.97,0
+eb1f0210-83fb-607c-4d4b-1d100318703b,G12R,13.49,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,33.8,0,MSS,6.77,2.8,Negative,0,317.11,0,9.75,1,24.57,0
+1c4f85a8-8b7e-ad89-c802-e2cabcfc6241,Q61H,25.15,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,12.1,0,MSS,6.87,8.4,Negative,0,2.08,1,7.85,1,21.07,1
+e11340b7-0b4e-ca8c-ff3d-a9d06413c1de,G12R,30.14,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,5.2,0,MSS,4.53,14.8,Negative,0,2269.58,0,2.67,1,2.27,0
+d63edaaf-c72a-4412-48ae-392faf3b1b9d,G12S,18.52,0,WT,Lost,Intact,WT,WT,WT,WT,WT,29.4,0,MSS,8.0,13.3,Negative,0,1599.49,0,5.0,1,4.33,1
+ffc553de-aa6e-910f-1b3e-4f790b106820,G12D,55.87,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,8.8,0,MSS,7.46,22.3,Negative,0,41.5,0,3.27,0,0.0,0
+a66e97d0-22f3-4614-aa6a-509b0622abc1,G12D,25.4,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,24.2,0,MSS,4.53,16.5,Negative,0,24.3,0,5.33,1,1.98,1
+e5a3fb17-ae44-325d-1727-1f9c9f91903a,G12D,14.54,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,31.2,0,MSS,3.83,19.7,Negative,0,2.68,1,4.8,1,3.31,1
+3da6e859-3ef4-631a-076c-82eddd0aa4d8,G12A,12.49,0,Mutant,Intact,Intact,WT,WT,Mutant,WT,WT,10.9,0,MSS,4.67,7.6,Negative,0,4.55,1,2.7,1,4.89,1
+c6da4385-dab6-762a-249d-14e4740af755,G12D,21.59,0,WT,Intact,Intact,WT,WT,WT,WT,WT,11.4,0,MSS,3.36,3.3,Negative,0,88.86,0,3.17,1,9.02,1
+e91f963c-03bb-0769-32bd-8321cef0026c,G12R,47.85,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,2.5,0,MSS,6.57,18.6,Negative,0,1675.46,0,0.7,0,0.0,0
+0941f59a-e8d0-d52a-a801-3f6d49f5e6c6,Q61H,14.97,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,12.8,0,MSS,8.0,3.8,Negative,0,753.36,0,10.28,1,17.16,1
+0d397408-2804-f6be-0163-d9800166b3f0,Q61H,35.08,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,23.9,0,MSS,8.0,20.9,Negative,0,2417.72,0,6.03,1,22.06,1
+cd2de975-fae4-57fb-9b1d-e995d1ea43dd,G12R,25.96,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,6.2,0,MSS,3.91,23.6,Negative,0,365.51,0,0.5,1,5.63,0
+d972dba1-49ad-3bf7-3d11-cc32f6937b8e,G12A,80.0,0,WT,Lost,Intact,WT,WT,WT,WT,WT,38.1,0,MSS,8.0,7.1,Negative,0,41.91,0,9.91,1,11.98,0
+cd0bf794-ab4c-1caa-0ea6-c09f3eb0a378,G12D,31.01,0,WT,Lost,Lost,WT,WT,WT,WT,WT,28.9,0,MSS,6.26,19.0,Negative,0,174.24,0,4.25,0,0.0,0
+c5a8e563-1ec7-6e43-ed84-0055f7dbb513,G12V,16.14,0,Mutant,Intact,Lost,WT,Pathogenic,Germline,WT,WT,48.2,1,MSS,2.32,10.9,Negative,0,737.29,0,1.76,1,4.73,1
+d685df21-d1de-64b0-b2b8-0b2fd89bd6ad,G12V,38.16,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,21.2,0,MSS,5.3,7.5,Negative,0,518.25,0,1.61,1,8.6,1
+33a7fe0e-74c9-2756-0a47-5b0672511d01,G12A,38.94,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,15.7,0,MSS,5.07,10.8,Negative,0,51.2,0,2.25,1,8.83,1
+8128f166-b287-19f0-1ffa-ff8d1d1d5eeb,G12D,19.33,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,15.3,0,MSS,8.0,16.2,Negative,0,4693.95,0,1.77,1,14.06,1
+a14874cc-8c5b-46d9-bec4-a6308a32de6d,G12D,12.2,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,22.4,0,MSS,4.27,24.7,Negative,0,1824.8,0,2.02,1,3.32,0
+27bc09e6-72e3-4be4-d9e3-ba4e1605b338,G12R,33.84,0,Mutant,Intact,Lost,WT,WT,Mutant,WT,WT,4.3,0,MSS,7.58,7.5,Negative,0,9507.67,0,24.55,1,4.81,1
+316b2aca-0d93-1b8e-bc10-20bcd0364b96,G12V,25.49,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,8.6,0,MSS,5.8,17.6,Negative,0,1686.29,0,6.5,1,4.19,0
+b5bc5072-1998-504c-4550-720e040827cd,G12S,9.88,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,6.0,0,MSS,3.39,8.4,Negative,0,9505.72,0,34.33,1,4.88,0
+9c8e1f2b-bfda-4182-faee-b36685c60ac2,G12V,28.58,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,7.0,0,MSS,4.85,6.3,Negative,0,285.37,0,5.62,0,0.0,0
+9dc66cb6-11f8-b543-0df3-bb8e82625c28,G12S,16.74,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,26.2,0,MSS,8.0,15.8,Negative,0,84.89,0,8.0,1,3.06,0
+e2575f93-3819-47a4-0ad7-7c5a011efe6c,G12V,9.88,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,39.8,0,MSS,5.64,19.0,Negative,0,5676.21,0,1.86,1,6.07,1
+2c521b46-695c-24e1-b5a6-ec28757c71f0,G12A,19.86,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,26.0,0,MSS,8.0,17.9,Negative,0,808.59,0,3.79,1,14.27,0
+2efc089f-c52f-4f46-177b-07205f041d20,G12R,52.97,0,WT,Lost,Lost,WT,Pathogenic,Germline,WT,WT,79.4,1,MSS,8.0,23.6,Negative,0,898.25,0,4.13,1,3.27,1
+75643af2-978a-e731-fae3-0fad605a3b59,G12D,50.64,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,23.1,0,MSS,5.06,2.7,Negative,0,2026.51,0,8.33,1,8.6,1
+a2eba838-4125-b7c5-c8b9-876e8b02e285,G12D,43.3,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,11.3,0,MSS,3.62,13.5,Negative,0,1055.95,0,4.27,1,12.4,1
+252741a1-7250-72d5-9289-ab0edf68b60c,Q61H,28.83,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,34.9,0,MSS,3.82,7.3,Negative,0,1734.38,0,6.37,1,2.97,1
+4d24ca6f-8a90-0321-f22e-a8993f8fe6db,G12D,35.07,0,WT,Intact,Lost,WT,WT,WT,WT,WT,2.7,0,MSS,8.0,20.4,Negative,0,143.51,0,6.14,1,5.52,0
+b324842c-899c-b0a3-93f8-efae6b1a2fde,G12R,26.03,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,4.1,0,MSS,6.43,1.6,Negative,0,2882.53,0,3.31,1,7.1,0
+f0cacb94-7153-4aca-a634-24e141eb0999,G12D,12.64,0,WT,Lost,Lost,WT,WT,Mutant,WT,WT,37.9,0,MSS,3.02,4.4,Negative,0,1795.53,0,2.99,1,10.27,1
+822367b2-762f-3fb9-2600-18ff286da0c2,G12R,14.25,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,26.0,0,MSS,8.0,19.3,Negative,0,3385.66,0,2.3,0,0.0,0
+79631f31-e9e9-48e4-676e-cc3eb0dd327b,G12D,17.04,0,Mutant,Lost,Lost,WT,WT,Mutant,WT,WT,37.2,0,MSS,2.96,8.9,Negative,0,3.25,1,13.23,0,0.0,0
+2254063b-f931-202e-1e85-0a30211c30cf,G12V,56.87,0,Mutant,Intact,Lost,WT,WT,WT,WT,Pathogenic,25.3,1,MSS,4.35,17.0,Negative,0,5061.65,0,3.31,1,12.55,1
+4e011ef4-17e9-aae4-472f-f57ef2a66016,G12V,46.81,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,30.7,0,MSS,6.25,25.0,Negative,0,207.12,0,6.23,1,3.32,1
+9c69ae0c-c91b-cc04-6d8b-10a49d5cd9bd,G12D,12.83,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,9.4,0,MSS,8.0,11.5,Negative,0,5241.45,0,3.83,1,7.56,0
+696c705c-f8b1-c63c-a277-0dc86699c703,G12V,25.33,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,13.7,0,MSS,8.0,13.3,Negative,0,3519.87,0,12.97,1,5.16,1
+37b680cc-d711-c5cc-68a6-0286274815fa,Q61H,19.27,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,36.0,0,MSS,4.99,24.4,Negative,0,1652.59,0,0.61,1,8.89,1
+512997d9-9a00-b5c6-969b-3d00f2fb03f7,G12R,22.35,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,16.5,0,MSS,6.12,18.7,Negative,0,2450.13,0,6.07,1,34.55,1
+6b1c43ea-4c75-b922-093b-37a0eba31388,Q61H,17.79,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,26.8,0,MSS,8.0,4.9,Negative,0,5259.41,0,1.28,0,0.0,0
+39c07447-25de-6068-7960-c24d7a2eb8e3,G12A,57.02,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,35.5,0,MSI-High,13.25,21.7,Negative,0,0.83,1,6.62,1,7.71,1
+90d66d61-59d2-8812-928c-9a651861c992,G12R,24.26,0,WT,Intact,Lost,WT,WT,WT,WT,WT,34.8,0,MSS,5.48,12.9,Negative,0,6444.51,0,3.87,0,0.0,0
+a5dff3a4-8c0a-8582-b3b6-6a3996f78512,G12V,27.93,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,0.4,0,MSS,5.54,19.7,Negative,0,53.37,0,1.02,1,14.66,1
+50f36920-9ddc-604a-a705-da50964f7822,Q61H,28.07,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,6.3,0,MSS,4.34,15.0,Negative,0,1903.79,0,6.28,1,7.65,1
+8c94b9f0-57bb-50f0-c995-28793f0c7f45,G12V,13.24,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,36.7,0,MSS,7.89,5.7,Negative,0,983.45,0,5.61,1,5.81,1
+a0425a9c-8798-0a1c-6e71-6c3f326cd3e8,G12D,26.18,0,WT,Lost,Intact,WT,WT,WT,WT,WT,22.5,0,MSS,8.0,20.4,Negative,0,691.36,0,3.56,1,7.7,0
+8342e10e-f636-a4d0-5c54-0a0086c09ef7,G12S,46.4,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,19.2,0,MSS,2.79,0.1,Negative,0,2857.76,0,4.04,1,8.02,1
+e2eb4cb1-8eed-e034-bc98-be76ceecc68a,Q61H,59.36,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,2.6,0,MSS,5.16,22.2,Negative,0,334.22,0,5.27,1,4.11,0
+80ee165e-d9a8-69b8-ebca-678c20d62a86,G12V,12.32,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,1.0,0,MSS,3.72,20.5,Negative,0,6172.74,0,14.56,0,0.0,0
+ccc44ea7-44cd-bfb8-8530-bffabbbf933a,G12D,9.86,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,38.1,0,MSS,6.43,24.3,Negative,0,237.9,0,3.27,1,12.38,1
+d65eb0c4-84f0-4b51-507f-d72d3ef4bc21,G12V,25.46,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,19.0,0,MSS,3.69,0.9,Negative,0,58.74,0,12.34,1,8.39,1
+1da8c94a-0aaa-9412-7e80-11236248fb01,G12R,47.73,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,31.5,0,MSS,3.57,10.9,Negative,0,138.58,0,4.32,1,2.6,1
+d78cddf8-de57-5c77-1272-77e00e529048,G12D,30.44,0,WT,Lost,Lost,WT,WT,WT,WT,WT,8.8,0,MSS,8.0,4.2,Negative,0,2435.11,0,16.37,1,4.11,1
+47d626ad-13e0-894a-0e39-b2f1d2672420,G12R,36.9,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,9.5,0,MSS,5.66,9.3,Negative,0,3046.71,0,3.54,1,4.09,1
+2c495d2c-7cd0-bd1e-5589-8bdc90b72e13,G12V,10.85,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,22.4,0,MSS,5.91,9.0,Negative,0,1464.12,0,2.3,1,8.5,1
+be21199d-1108-d1b7-505b-50ddbb1444a9,G12D,17.41,0,Mutant,Intact,Intact,WT,WT,WT,Pathogenic,WT,65.0,1,MSS,7.19,14.9,Negative,0,16457.17,0,1.5,1,11.04,0
+d3c1a336-6fc9-cdfc-03c2-413ce71d23f5,G12V,6.57,0,WT,Intact,Intact,WT,WT,WT,WT,WT,11.5,0,MSS,8.0,10.9,Negative,0,522.75,0,4.33,1,3.97,0
+5f4c88d2-6a4b-346b-db46-bb34b4c7379f,G12D,22.52,0,Mutant,Lost,Intact,WT,WT,Mutant,WT,WT,13.2,0,MSS,5.12,24.1,Negative,0,1786.62,0,2.03,1,7.65,1
+99d0ad4e-3d4a-b727-2753-2cc9b58c8e00,G12A,6.7,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,22.0,0,MSS,5.16,6.9,Negative,0,1146.76,0,18.26,1,3.39,0
+5d6b5af1-8220-9dfc-1ea2-dc51ab1fd785,WT,0.0,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,1.6,0,MSS,5.17,10.5,Negative,0,936.46,0,1.88,1,2.64,0
+fed6c27a-139c-bee7-f55b-9d638072551f,G12A,62.36,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,15.2,0,MSS,8.0,17.5,Negative,0,9537.83,0,2.25,0,0.0,0
+4f9b2c6b-6caa-1b47-c5a8-aa89731796e4,G12D,26.69,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,22.3,0,MSS,5.89,6.9,Amplified_3+,0,19.33,0,8.01,1,1.76,1
+b49582f6-24e0-fbe2-b00a-d110c546062b,Q61H,9.9,0,Mutant,Lost,Lost,WT,WT,WT,WT,Pathogenic,20.2,1,MSS,5.38,18.1,Negative,0,13180.75,0,14.67,1,2.07,0
+a411470d-ecf7-5e1c-6349-97e4c0c9adf6,G12R,30.74,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,25.5,0,MSS,7.07,17.7,Negative,0,534.93,0,9.31,1,15.51,0
+3584cd7e-acca-344b-02bf-0c045568ab34,G12D,74.85,0,WT,Intact,Intact,WT,WT,WT,WT,WT,2.0,0,MSS,8.0,17.8,Negative,0,21.98,0,12.92,1,13.37,1
+29eb9b00-777b-64cd-866c-2fe0c1abb89a,Q61H,32.64,0,Mutant,Intact,Intact,WT,WT,Mutant,WT,WT,28.8,0,MSS,6.23,16.9,Negative,0,235.27,0,4.14,1,27.99,1
+d61809b9-6af1-e85d-2a78-df5bb62535c8,G12V,49.95,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,32.1,0,MSS,5.43,20.4,Negative,0,285.28,0,4.19,1,6.43,1
+8e54032e-f540-45ce-fd37-d209eb9d18a3,G12V,18.34,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,33.6,0,MSS,8.0,24.9,Negative,0,639.31,0,33.51,1,12.38,1
+fd85b878-cd37-a873-d6cd-461d3352b155,Q61H,14.55,0,Mutant,Intact,Lost,WT,WT,Mutant,WT,WT,26.9,0,MSS,8.0,1.4,Negative,0,11.34,0,24.29,0,0.0,0
+72c03979-80be-32e0-243f-a0cea6a48572,Q61H,23.51,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,22.5,0,MSS,8.0,12.4,Negative,0,282.93,0,9.15,1,3.39,0
+147e1c1f-541e-a6d7-647f-a53fd7cb63fb,G12R,7.72,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,12.3,0,MSS,4.95,20.3,Negative,0,612.39,0,13.55,1,14.84,1
+6f0c2470-0a8d-e60b-c15d-5175d5e07afa,Q61H,80.0,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,17.0,0,MSS,4.76,0.0,Negative,0,4801.63,0,10.58,1,21.97,1
+26928106-eb3f-13a0-7825-cf597acecec5,G12D,26.68,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,3.5,0,MSS,2.9,13.6,Negative,0,364.1,0,1.34,1,13.86,1
+e837f167-3e7c-539e-2e51-35864e6c97c8,G12D,41.27,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,28.3,0,MSS,8.0,16.5,Negative,0,19777.38,0,4.31,0,0.0,0
+3b9c3514-a1d0-c5a7-0b6e-1f68f0d32a58,WT,0.0,0,WT,Lost,Intact,WT,WT,WT,WT,WT,1.0,0,MSS,6.24,4.8,Negative,0,194.5,0,20.02,0,0.0,0
+7d7d960d-31c3-590d-4ac4-6678314baeb1,G12D,9.72,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,16.5,0,MSS,2.94,10.0,Negative,0,2428.89,0,9.21,1,3.99,1
+7e484079-b926-75e8-9621-4556fee05692,G12V,57.71,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,20.2,0,MSS,8.0,19.7,Negative,0,4604.02,0,4.21,0,0.0,0
+3e60fd82-44d4-d5a2-1588-9523038f6d4a,G12D,12.5,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,26.0,0,MSS,5.29,1.7,Negative,0,5.86,0,20.26,0,0.0,0
+a3390358-daa7-b2e4-d7f5-688bd7303741,G12V,30.24,0,WT,Intact,Lost,WT,WT,WT,WT,WT,13.7,0,MSS,5.55,3.4,Negative,0,1.19,1,6.48,1,2.83,1
+ab9270c7-6824-7f15-a62e-a1d48e615d2b,WT,0.0,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,17.7,0,MSS,3.3,20.5,Negative,0,26226.64,0,9.54,1,41.89,0
+0ee0328c-9d23-fc06-c34d-9cbccb609981,G12D,25.65,0,Mutant,Lost,Intact,WT,WT,Mutant,WT,WT,23.5,0,MSS,7.37,20.2,Negative,0,1118.56,0,6.52,1,11.47,0
+8a1e7851-be60-fad4-5dda-0c0fb996493e,G12R,15.32,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,36.9,0,MSS,7.39,14.8,Negative,0,605.32,0,7.7,0,0.0,0
+d82fc476-ee6f-da09-56a5-1586e195642c,G12D,22.43,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,26.9,0,MSS,5.93,10.4,Amplified_3+,0,898.07,0,8.27,1,7.8,1
+c4c4c717-8806-6cbc-7b89-df3654c36e11,G12R,13.87,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,10.2,0,MSS,5.12,2.6,Negative,0,5983.51,0,16.44,1,2.59,1
+813a03be-5eaf-a7d7-da1d-b05cb06c9ae6,G12R,39.87,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,33.9,0,MSS,8.0,20.3,Negative,0,1252.69,0,18.73,1,4.77,1
+964dc12b-4e13-353e-e8d8-6a756e4d2742,G12V,34.57,0,WT,Lost,Lost,WT,WT,WT,WT,WT,2.2,0,MSS,3.74,6.0,Negative,0,101.72,0,2.85,0,0.0,0
+5730f558-625c-1b9a-d9ab-93921ec3355b,Q61H,24.22,0,WT,Intact,Intact,WT,WT,WT,WT,WT,10.9,0,MSS,4.53,22.8,Negative,0,11710.28,0,6.39,0,0.0,0
+880a8dd1-d914-f9c2-7fb2-77db953a1009,Q61H,17.44,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,4.3,0,MSS,8.0,19.4,Negative,0,31.11,0,15.97,1,2.12,1
+6607897e-059d-bd04-1adf-f35e8459c33b,WT,0.0,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,17.9,0,MSS,4.03,2.0,Negative,0,1562.32,0,3.93,1,6.19,0
+a17e38c1-a104-d040-ead6-a446ff8a6e32,G12R,11.23,0,WT,Lost,Lost,WT,WT,WT,WT,WT,25.5,0,MSS,3.91,15.9,Negative,0,511.48,0,1.21,1,2.58,1
+56bf3e31-0230-1e58-2d71-1246643995a8,G12D,9.71,0,WT,Intact,Lost,WT,WT,WT,WT,WT,21.2,0,MSS,8.0,23.0,Negative,0,631.18,0,1.81,1,2.67,1
+065acf0b-4258-c51e-310c-e51451040e6a,G12D,23.35,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,32.5,0,MSS,7.71,22.0,Negative,0,368.8,0,1.94,1,2.65,1
+72bdb728-b0d8-442c-ed6e-0c719ba34783,G12V,21.01,0,WT,Lost,Intact,WT,WT,WT,WT,WT,22.7,0,MSS,7.34,15.3,Negative,0,804.33,0,2.83,1,28.14,1
+9935cd1d-2474-b9aa-4eba-9e566b96b205,G12R,47.4,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,9.3,0,MSS,6.51,4.3,Negative,0,1.23,1,2.12,1,10.22,1
+472c74ef-6a5f-9e4a-01df-5c369107b749,G12S,36.15,0,Mutant,Intact,Intact,WT,WT,Mutant,WT,WT,21.5,0,MSS,4.59,17.0,Negative,0,38.36,0,12.54,1,7.22,1
+a23ebc60-869c-8af0-b3fa-004f2b979572,G12R,24.97,0,Mutant,Lost,Lost,WT,WT,WT,WT,Pathogenic,49.4,1,MSS,5.47,16.7,Negative,0,0.46,1,3.4,1,7.46,1
+9ecfc34a-cd81-da6a-fb57-a273b6a6bb98,G12C,33.12,1,Mutant,Intact,Lost,WT,WT,Mutant,WT,WT,20.1,0,MSS,5.86,14.7,Negative,0,0.88,1,15.82,0,0.0,0
+c2ed3e94-fc19-a9f2-7a3d-d32ee1078e7e,G12V,32.76,0,WT,Lost,Lost,WT,WT,WT,WT,WT,17.7,0,MSS,8.0,6.6,Negative,0,525.1,0,1.45,0,0.0,0
+b87f8791-83dc-35fb-e740-7ed3a6a04a8a,G12D,80.0,0,WT,Lost,Lost,WT,WT,WT,WT,WT,21.2,0,MSS,7.17,22.5,Negative,0,803.72,0,3.15,0,0.0,0
+c8317da9-9f95-0147-f695-02c048e41f8f,WT,0.0,0,WT,Intact,Intact,WT,WT,WT,WT,WT,21.9,0,MSS,4.17,12.6,Negative,0,370.54,0,4.97,0,0.0,0
+1d35eca6-12fd-521c-dde6-b2f575f2e747,G12V,16.3,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,12.4,0,MSS,8.0,7.4,Negative,1,15292.51,0,10.08,1,7.17,1
+70a9a72b-cf28-fbd6-bb7f-738a81d262db,G12R,27.64,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,34.2,0,MSS,3.09,6.4,Negative,0,131.8,0,14.06,1,11.93,1
+a7734168-f626-5e35-8d98-35f6a650fbba,G12D,5.1,0,WT,Intact,Intact,WT,WT,WT,WT,WT,8.3,0,MSS,5.32,7.0,Negative,0,1980.16,0,2.62,1,7.87,1
+fc0d4f24-1b74-ef6b-f845-cdb16ab648ca,G12V,24.06,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,1.3,0,MSS,3.83,11.5,Negative,0,590.37,0,12.1,0,0.0,0
+bbd744ea-d24b-dcc7-49c9-5388276d661f,G12D,47.27,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,29.7,0,MSS,4.29,5.8,Negative,0,2295.31,0,0.83,1,4.64,1
+58b3c193-a312-fd0b-bffe-ebcff86922b1,G12V,35.21,0,WT,Lost,Intact,WT,Pathogenic,Germline,WT,WT,73.7,1,MSS,8.0,12.9,Negative,0,97.48,0,10.71,1,1.03,1
+0a7b7fff-4c3b-2100-1fb5-edf80134d793,G12D,29.35,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,25.7,0,MSS,3.36,4.8,Negative,0,1920.43,0,1.17,1,4.04,1
+7d5cf657-f697-dd0c-c6ff-f58e82180fb6,G12D,36.22,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,18.8,0,MSS,4.36,6.8,Negative,0,23.98,0,7.01,0,0.0,0
+7708801b-dc1d-b803-fc4c-5c4ce000562a,WT,0.0,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,39.0,0,MSS,7.42,3.0,Negative,0,52.52,0,13.86,1,3.42,0
+695d0b7d-3ded-eaa0-fa58-c463534443cd,G12D,57.69,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,14.8,0,MSS,5.01,8.9,Negative,0,206.52,0,10.88,0,0.0,0
+15b6b740-a65b-baaf-cb2e-c0e012f3a991,G12V,32.09,0,WT,Lost,Lost,WT,WT,WT,WT,WT,16.2,0,MSS,6.44,10.1,Negative,0,1.19,1,0.87,0,0.0,0
+cd53ca4a-8a58-737f-8e32-bd1738d0476e,Q61H,20.29,0,Mutant,Intact,Intact,WT,WT,WT,Pathogenic,WT,53.6,1,MSS,8.0,10.1,Negative,0,546.99,0,2.87,0,0.0,0
+d294ce30-71c9-065f-ecb9-3f9b441ef666,G12D,6.12,0,WT,Intact,Lost,Pathogenic,WT,WT,WT,WT,47.2,1,MSS,7.86,18.1,Negative,0,3998.49,0,9.18,1,32.72,1
+5f696baf-0e17-ff9a-0976-e9e03d068a7d,G12V,44.12,0,Mutant,Lost,Intact,WT,WT,Mutant,WT,WT,22.2,0,MSS,5.02,12.1,Negative,0,889.17,0,8.92,0,0.0,0
+1bf9ec9a-5e75-594c-0c77-80c9f401d669,G12V,33.42,0,Mutant,Intact,Intact,Pathogenic,WT,WT,WT,WT,68.7,1,MSS,5.73,17.3,Negative,0,366.7,0,5.91,1,2.36,1
+b69816d2-c33f-c1bf-ace0-d465ee7b040d,G12R,26.89,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,9.5,0,MSS,7.48,0.8,Negative,0,1662.58,0,0.5,1,7.52,0
+dd8e8f72-0214-7725-c612-8f04a832e4dd,G12D,16.23,0,WT,Lost,Lost,WT,WT,WT,WT,WT,5.9,0,MSS,7.8,10.9,Negative,0,278.8,0,14.85,1,9.93,1
+cd05ebb0-64b8-429f-bd4b-6176bd67c96c,G12D,43.78,0,WT,Lost,Intact,WT,WT,WT,WT,WT,16.9,0,MSS,6.1,2.2,Negative,0,415.29,0,17.75,0,0.0,0
+3c0a7ee0-e866-b915-0c88-e2bc61bed80f,Q61H,21.02,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,20.2,0,MSS,6.99,11.6,Negative,0,67.71,0,5.28,0,0.0,0
+dbae1997-3bd0-b309-9f34-b1461a162079,Q61H,24.03,0,WT,Lost,Lost,WT,WT,WT,WT,WT,28.5,0,MSS,6.99,15.4,Negative,0,4.08,1,5.63,0,0.0,0
+83bebfa1-f3a3-ccd9-0126-eb9171999e27,G12V,23.72,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,38.2,0,MSS,5.83,19.9,Negative,0,4.06,1,7.41,1,12.32,1
+079457e2-87d6-16bc-ad62-b4fe43527b78,G12V,32.13,0,WT,Lost,Intact,WT,WT,WT,WT,WT,27.5,0,MSS,4.75,13.8,Negative,0,1234.18,0,19.31,1,2.72,1
+e54853dc-b327-3be6-66bf-3ce1c2783fe8,WT,0.0,0,WT,Intact,Lost,WT,WT,WT,WT,WT,39.5,0,MSS,8.0,9.5,Negative,0,625.47,0,5.76,1,8.73,0
+3cd72db2-4130-c148-abee-d1299c511eff,WT,0.0,0,Mutant,Lost,Lost,WT,Pathogenic,Germline,WT,WT,49.9,1,MSS,6.8,6.6,Negative,0,538.67,0,3.7,1,3.76,0
+5918965d-8631-82c3-da4f-dd366a3d8bf7,G12D,15.92,0,WT,Lost,Lost,WT,WT,WT,WT,WT,8.4,0,MSS,2.63,23.9,Negative,0,839.58,0,6.56,0,0.0,0
+4c879234-e70c-6d38-da74-cbdec7948efa,G12R,16.26,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,12.3,0,MSS,4.35,5.0,Negative,0,47.0,0,4.43,1,1.72,0
+659ddd41-72ef-d1a1-971f-3a5bb5aafbef,G12D,41.73,0,Mutant,Lost,Lost,WT,WT,WT,Pathogenic,WT,61.5,1,MSS,4.99,1.1,Negative,0,1244.12,0,4.48,0,0.0,0
+e2f56fb7-8cb6-dbc3-465a-ef3d1d535d72,G12D,13.5,0,WT,Intact,Intact,WT,WT,Mutant,WT,WT,7.5,0,MSS,5.58,3.1,Negative,0,42.93,0,0.77,0,0.0,0
+15b63662-ade8-1823-3006-23b8ddc88fd3,WT,0.0,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,7.8,0,MSS,8.0,24.9,Negative,0,895.43,0,7.56,0,0.0,0
+b7b732fd-7329-41bf-5788-861aaccda816,WT,0.0,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,16.5,0,MSS,8.0,22.7,Negative,0,666.51,0,14.46,0,0.0,0
+ffada53f-8898-bec5-ceb3-d6756cc57c7e,G12D,9.13,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,12.7,0,MSS,2.26,8.0,Negative,0,1.16,1,12.43,0,0.0,0
+686ee23a-c679-3d5a-4bde-623ea363c007,G12V,55.63,0,Mutant,Intact,Lost,WT,WT,Mutant,WT,WT,25.9,0,MSS,6.83,0.1,Negative,0,1026.77,0,11.6,1,3.55,1
+932ace89-1e8d-4637-2306-b82288bf437b,G12V,29.55,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,35.6,0,MSS,6.22,19.2,Negative,0,4.43,1,4.25,0,0.0,0
+b36cf018-db0d-6dc7-ff61-67c32fcafa0c,G12V,31.08,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,5.5,0,MSS,5.63,7.5,Negative,0,1461.91,0,5.18,0,0.0,0
+64724d06-0f6f-324c-985f-de63bc153fd7,G12V,44.9,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,21.9,0,MSS,7.52,0.6,Negative,0,15825.97,0,14.75,1,4.4,1
+7f35ed11-3830-92b1-ea51-05017eecd950,G12R,60.31,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,3.5,0,MSS,6.42,11.4,Negative,0,436.04,0,10.67,1,2.71,0
+5d897166-1a5f-62a6-2265-deba5814bddb,G12D,27.68,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,8.9,0,MSS,5.24,10.6,Negative,0,491.06,0,19.81,1,3.83,0
+33b4e5f1-59d2-822e-1131-d5b615198fc3,G12D,35.53,0,WT,Lost,Intact,Pathogenic,WT,WT,WT,WT,42.4,1,MSS,6.12,9.0,Negative,0,1.54,1,2.29,1,4.97,0
+740a2711-4d43-996a-0485-f0f48e07fed6,G12S,30.65,0,WT,Intact,Lost,WT,WT,WT,WT,WT,23.2,0,MSS,7.56,16.3,Negative,0,93.62,0,2.27,1,7.48,1
+57e203ca-e176-d28d-a271-3b15f6909edb,G12R,19.97,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,22.2,0,MSS,7.28,18.2,Negative,0,563.25,0,3.21,1,3.88,0
+f58ebd28-e32c-4be7-6b9e-23c873203127,G12V,9.49,0,Mutant,Lost,Lost,WT,WT,WT,Pathogenic,WT,55.7,1,MSS,6.52,14.0,Negative,0,394.65,0,1.75,1,12.04,0
+8a75949f-80cb-e5f2-c080-a7b6f65b8943,G12D,27.91,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,32.8,0,MSS,4.79,0.3,Negative,0,5548.19,0,1.2,1,8.04,1
+e5a1950b-58c1-d307-48d7-abb8fb02b754,G12D,56.11,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,7.5,0,MSS,8.0,0.6,Negative,0,235.42,0,7.16,1,1.48,1
+5349a943-8f7a-edef-3c2f-531c62e603b6,WT,0.0,0,WT,Intact,Intact,WT,WT,WT,WT,Pathogenic,49.7,1,MSS,6.99,22.0,Amplified_2+,0,159.67,0,6.69,0,0.0,0
+87901171-4e56-add2-e8b8-78bfe41046a1,G12S,12.93,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,26.7,0,MSS,8.0,4.7,Negative,0,2.89,1,5.73,1,11.65,1
+973b0d03-3733-5a3e-be08-8c93fbe6ebf1,G12V,47.39,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,3.2,0,MSS,4.94,10.0,Negative,0,1370.28,0,6.38,0,0.0,0
+4ca46226-0667-15a6-a747-cac09eb1244e,WT,0.0,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,13.8,0,MSS,6.53,2.6,Negative,0,67.42,0,1.04,1,22.29,0
+528edbc4-4cb8-da72-3dca-8f36dac7f96e,G12D,6.99,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,1.1,0,MSS,6.51,5.7,Negative,0,218.9,0,2.77,1,4.53,1
+dfd310f5-58d6-02e0-27cb-04b22d694a71,G12D,45.18,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,3.6,0,MSS,2.82,12.1,Negative,0,10.28,0,3.34,0,0.0,0
+8fbdc4da-0f85-4023-4882-defb00649873,G12D,13.91,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,11.4,0,MSS,4.54,5.9,Negative,0,5117.85,0,4.7,0,0.0,0
+c8a8b263-95c3-a90f-cabe-d5ff40277048,G12V,71.41,0,WT,Lost,Lost,WT,WT,WT,WT,WT,9.7,0,MSS,4.51,16.5,Negative,0,5703.29,0,1.04,1,14.37,1
+79ebffbc-dc68-561b-703a-14f3a289508b,G12D,48.85,0,WT,Lost,Intact,WT,Pathogenic,Germline,WT,WT,76.0,1,MSS,4.76,9.2,Negative,0,4.87,1,1.77,0,0.0,0
+acb26b95-96ca-195f-fea4-c618f32ee85e,Q61H,21.4,0,Mutant,Intact,Lost,WT,WT,WT,WT,Pathogenic,55.8,1,MSS,3.94,19.7,Negative,0,100.34,0,2.9,1,5.75,0
+e70dc6e4-abed-77d7-d08c-251f41731a01,G12R,32.32,0,WT,Intact,Intact,WT,WT,Mutant,WT,WT,23.1,0,MSS,6.16,15.0,Amplified_3+,0,1278.17,0,12.91,1,40.28,1
+2f67e9de-7863-ff33-c99f-7ccd445aa773,Q61H,80.0,0,WT,Lost,Lost,WT,WT,WT,WT,WT,29.4,0,MSS,8.0,6.3,Negative,0,25360.53,0,5.82,0,0.0,0
+1a15bc49-51c7-72aa-8fea-6bd42bd38a88,G12S,44.7,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,40.0,0,MSS,6.37,20.2,Negative,0,422.64,0,12.45,0,0.0,0
+f491c7b6-51a6-a712-a725-e78c6d5975c3,Q61H,28.3,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,16.4,0,MSS,3.77,23.3,Negative,0,776.57,0,3.97,1,20.32,0
+6ed74908-ef45-770a-8342-6897c7906afa,Q61H,80.0,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,20.9,0,MSS,4.01,3.0,Negative,0,1751.95,0,4.49,1,7.7,0
+f5b3c878-f022-4ffd-092c-fd9523c150fd,G12D,26.33,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,26.0,0,MSS,5.2,16.7,Negative,0,4003.51,0,7.38,1,9.33,0
+0a8428d2-4b2c-addf-1a5e-6247bd3f8134,G12D,34.78,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,36.8,0,MSS,3.43,15.8,Negative,0,3904.36,0,3.75,1,5.72,0
+10c69a3e-9277-e1aa-3efe-38b10d1e9fe0,G12D,13.99,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,31.9,0,MSS,6.83,16.7,Negative,0,264.64,0,2.4,1,5.47,1
+841e5484-438b-6184-7482-9a58fc0ed170,G12V,8.98,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,2.6,0,MSS,8.0,0.8,Negative,0,751.78,0,1.01,1,11.58,1
+0d0bbf06-0c29-db0e-5004-958cca479ed3,G12R,20.64,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,28.5,0,MSS,4.8,0.7,Negative,0,1159.0,0,2.46,1,5.35,1
+626ee100-a2b4-4919-1c91-d77bda1bbf48,G12D,25.1,0,WT,Lost,Lost,Pathogenic,WT,WT,WT,WT,40.1,1,MSI-High,42.21,83.0,Negative,0,604.78,0,10.34,1,2.45,1
+b2bc8fd5-e5d5-b593-0f7e-cae4c70b5cce,G12A,29.89,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,10.2,0,MSS,5.1,2.0,Negative,0,283.68,0,15.81,1,21.26,1
+4d548ff4-fa25-f863-34ff-4c577303dd6a,G12A,10.47,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,21.9,0,MSS,4.7,9.2,Negative,0,27225.99,0,2.07,1,16.1,1
+6aa6edcd-3b05-58b7-64e5-6d4b7d923373,G12V,36.47,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,27.9,0,MSS,6.53,21.8,Negative,0,982.02,0,0.79,1,2.38,1
+1cb0a4d2-4a3c-fa1c-006c-d60d26c7b137,G12V,14.91,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,6.4,0,MSS,4.64,8.9,Negative,0,0.94,1,11.32,1,5.14,1
+0050cf5b-299e-2352-dcde-23716a2ef347,G12D,35.35,0,Mutant,Intact,Lost,WT,WT,Mutant,WT,WT,12.6,0,MSS,4.38,9.8,Negative,0,1120.32,0,4.8,1,16.8,1
+7d5000e5-465b-cb61-8217-417e1c70a9fc,G12V,42.99,0,Mutant,Intact,Lost,WT,Pathogenic,Germline,WT,WT,68.6,1,MSS,3.17,6.7,Negative,0,589.48,0,1.17,1,9.38,0
+6e6b7295-68fe-947e-5545-a8b0077cc9dd,G12D,19.35,0,WT,Lost,Lost,WT,WT,WT,WT,Pathogenic,26.1,1,MSS,6.21,10.5,Negative,0,3470.8,0,0.5,1,4.24,1
+d7592047-779c-616c-c7d4-2a598d18b571,G12V,13.76,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,34.0,0,MSS,8.0,19.9,Negative,0,899.84,0,1.71,1,16.21,0
+528ebbc9-3aa0-f0b7-42a6-33bf879cbd49,G12D,61.94,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,18.2,0,MSS,8.0,20.8,Negative,0,9986.91,0,2.82,1,7.48,1
+7ad853eb-ea07-47a3-3e13-5b3398f365e2,G12D,41.42,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,23.4,0,MSS,8.0,10.5,Amplified_2+,0,1.14,1,1.42,1,6.12,0
+3a6ec7cb-5556-96a1-aeea-050cdcff71bb,G12V,26.87,0,WT,Intact,Lost,WT,WT,WT,WT,WT,3.2,0,MSS,4.62,9.9,Negative,0,499.52,0,8.95,1,2.15,1
+ee2dafb1-3f32-b89c-54ab-18fbbe732006,G12V,59.21,0,WT,Intact,Intact,WT,WT,WT,WT,WT,38.2,0,MSS,8.0,4.9,Negative,0,244.85,0,1.99,1,0.15,1
+75f4ff31-7ea9-178e-0c6f-09777b8da1f7,G12D,25.79,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,36.3,0,MSS,3.89,24.4,Negative,0,1245.62,0,4.54,0,0.0,0
+26842773-30fc-ca02-b628-aaf5dd2d0a11,Q61H,16.91,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,7.6,0,MSS,8.0,7.8,Negative,0,521.62,0,48.11,0,0.0,0
+23616d5f-51ab-07a2-0c20-b42a9a852c73,WT,0.0,0,WT,Intact,Lost,WT,WT,WT,WT,WT,26.5,0,MSS,8.0,8.6,Negative,0,280.3,0,5.04,0,0.0,0
+025ed95c-16fe-7ecb-eb37-ff2f05438c1d,Q61H,23.0,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,31.7,0,MSS,7.38,10.7,Negative,0,3076.65,0,3.99,1,7.54,1
+08023240-d109-eefc-3035-de72eed20080,WT,0.0,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,4.9,0,MSS,8.0,2.0,Negative,0,608.2,0,4.08,1,17.9,0
+9ec21a88-b4cd-a3dc-1c52-3679274f73a9,G12D,56.48,0,WT,Intact,Lost,WT,WT,WT,WT,WT,23.1,0,MSS,4.76,8.2,Negative,0,900.32,0,8.75,1,3.44,1
+91b7e185-16bf-86cc-3ddc-0c2a79ba803d,Q61H,24.88,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,34.0,0,MSS,5.73,23.3,Negative,0,41.62,0,7.73,1,5.24,1
+d974980f-affd-e7dc-9717-0b6b3b10176e,G12R,50.8,0,WT,Lost,Intact,WT,WT,WT,WT,WT,20.3,0,MSS,4.19,1.9,Negative,0,1040.03,0,1.64,1,1.28,1
+da766bbf-47d9-c844-0136-bb5f7e75ccec,G12R,21.57,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,37.0,0,MSS,6.13,6.0,Negative,0,10300.55,0,2.97,1,2.14,1
+29a98e9e-7533-e899-9e7e-96a4888322b0,G12R,15.35,0,Mutant,Intact,Intact,Pathogenic,WT,WT,WT,WT,31.9,1,MSS,6.74,5.4,Negative,0,2.1,1,2.3,0,0.0,0
+db017e61-fec4-573b-c5df-3983e58e5fc0,G12D,11.2,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,36.8,0,MSS,6.11,5.9,Negative,0,1.85,1,3.38,1,11.53,1
+eb36100b-3f9c-0523-4117-69634a87b603,G12A,18.11,0,WT,Lost,Lost,WT,WT,WT,WT,WT,39.1,0,MSS,5.0,23.9,Negative,0,467.36,0,27.84,1,5.72,1
+9a7a0668-f7df-fae5-7457-52788e934f89,G12D,11.46,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,6.2,0,MSS,4.97,17.7,Negative,0,3045.92,0,8.31,1,4.82,1
+5c8da0e2-1456-8c59-fc11-fde8e8d088c1,G12A,80.0,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,17.2,0,MSS,6.95,23.0,Negative,0,246.07,0,4.14,0,0.0,0
+51829ac6-2603-1c84-d02b-35fcbbf08da8,Q61H,31.93,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,24.8,0,MSS,5.68,21.4,Negative,0,958.15,0,15.56,1,2.4,1
+99c9b2b7-1ceb-6c0b-cc99-41e48c550e8d,G12S,23.16,0,Mutant,Lost,Lost,WT,WT,WT,WT,Pathogenic,55.7,1,MSS,3.82,15.6,Negative,0,38519.5,0,5.41,1,15.47,1
+69fd9d34-83f1-32c1-3763-163b4be3ae99,G12R,68.94,0,WT,Intact,Lost,WT,WT,WT,WT,WT,6.4,0,MSS,2.83,14.0,Negative,0,4707.37,0,0.87,0,0.0,0
+13fee961-d2c2-3636-5150-91a5a2bdfa67,G12R,11.23,0,WT,Intact,Intact,WT,WT,WT,WT,WT,13.4,0,MSS,4.77,12.7,Negative,0,2181.98,0,23.66,1,9.91,0
+58b2d33d-bc63-a9da-07a3-4061dca42070,G12V,22.59,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,31.9,0,MSS,3.48,17.2,Negative,0,6044.65,0,3.83,1,1.28,0
+2a5d67da-b3bc-d39a-04df-6c0262223a0b,G12D,80.0,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,16.4,0,MSS,4.33,17.5,Negative,0,170.08,0,0.5,1,6.86,1
+b545779b-d861-8ee8-b9a5-9d36a8be7f89,G12S,22.5,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,24.2,0,MSS,5.11,15.0,Negative,0,891.72,0,0.91,1,5.02,0
+5130f341-d371-7ae8-bd13-9aad4d2f1eb2,G12R,80.0,0,WT,Lost,Lost,WT,WT,WT,WT,WT,22.4,0,MSS,5.71,11.2,Negative,0,181.48,0,13.84,1,5.9,1
+9805475f-25df-64a5-e3d8-50ad1fca0eca,G12V,39.31,0,WT,Lost,Intact,WT,WT,WT,WT,WT,38.9,0,MSS,4.63,16.9,Amplified_2+,0,269.25,0,0.92,1,21.81,0
+24cabf06-c6c3-2465-2043-43283c7ce076,G12A,53.71,0,WT,Intact,Intact,WT,WT,WT,WT,WT,5.7,0,MSS,8.0,3.9,Negative,0,478.28,0,17.27,1,5.41,1
+2c460dc7-0f6b-1a38-b16e-b3afab93ebbe,G12D,54.65,0,WT,Intact,Lost,WT,WT,WT,WT,WT,37.9,0,MSS,3.65,13.8,Negative,0,1730.76,0,4.86,1,10.95,1
+fde4ee9b-1f10-eb6b-81dd-ef3acb5b6838,G12A,24.56,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,22.6,0,MSS,8.0,13.0,Negative,0,287.86,0,9.15,1,3.27,0
+043e92ea-ec96-250e-0106-a47343d64389,G12A,18.3,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,36.2,0,MSS,5.67,13.4,Negative,0,1704.87,0,3.47,1,7.61,1
+95aae400-93eb-5060-fe3a-ca898da8e4b2,G12D,22.89,0,Mutant,Intact,Intact,WT,WT,Mutant,WT,WT,4.7,0,MSS,4.65,12.8,Amplified_2+,0,194.21,0,7.56,0,0.0,0
+e5b598d2-929b-ee6b-207d-2c12635f6e19,WT,0.0,0,WT,Intact,Intact,WT,WT,WT,WT,WT,25.7,0,MSS,7.65,18.8,Negative,0,329.86,0,6.15,1,7.06,0
+89446e26-6a40-7d15-e160-9a7517528437,G12R,23.58,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,33.6,0,MSS,5.05,18.9,Negative,0,17825.41,0,4.31,1,10.06,1
+45ef9885-2eae-b11f-9f2d-c3312a57f942,G12D,24.47,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,31.5,0,MSS,4.38,8.2,Negative,0,91.21,0,1.54,1,10.86,1
+98359533-727a-7d91-0cee-dbdbb8bb93ab,Q61H,67.6,0,WT,Intact,Lost,WT,WT,WT,WT,WT,0.4,0,MSS,8.0,8.8,Negative,0,3554.56,0,6.41,1,2.33,1
+a9e311a4-57ef-b858-4b75-138b21cca070,WT,0.0,0,Mutant,Intact,Lost,WT,WT,Mutant,WT,WT,18.1,0,MSS,2.51,0.4,Negative,0,61.47,0,0.73,0,0.0,0
+04a62b5e-3094-7d22-d614-29f5fa0999eb,G12D,80.0,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,4.6,0,MSS,5.49,2.8,Negative,0,537.35,0,11.38,0,0.0,0
+3b353392-2800-b055-9880-b2ac0d4a1c5d,WT,0.0,0,WT,Intact,Intact,WT,WT,WT,WT,Pathogenic,26.1,1,MSS,6.53,6.6,Negative,0,299.93,0,5.46,1,6.03,0
+40f02837-d6ca-b861-dfb7-2816d8eea838,G12A,11.82,0,WT,Intact,Intact,WT,WT,WT,WT,WT,28.3,0,MSS,8.0,19.1,Negative,0,249.22,0,7.13,1,2.07,0
+8db4da3d-2f6c-5fe8-9c5b-6e739ea3a72e,G12V,19.82,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,38.3,0,MSS,5.16,19.9,Negative,0,3696.83,0,0.5,1,0.8,1
+ad788dea-c06c-fc28-656b-2af1867736c1,G12S,60.07,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,25.4,0,MSS,8.0,6.2,Negative,0,1074.43,0,1.45,1,3.21,0
+9122d5d9-c35b-14c3-b9cc-09ed885c1089,Q61H,22.97,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,4.1,0,MSS,8.0,21.7,Negative,0,126.87,0,2.7,1,4.31,1
+fbc138b3-b7b5-8b71-c227-f5b144864bb9,G12V,10.17,0,WT,Intact,Lost,WT,WT,WT,WT,WT,9.8,0,MSS,2.35,9.4,Negative,0,508.49,0,8.79,0,0.0,0
+83bbb702-ec9a-1ead-6b55-6f6a26584728,G12D,21.18,0,WT,Intact,Lost,WT,WT,Mutant,WT,WT,15.2,0,MSS,3.38,20.0,Negative,0,1060.38,0,1.75,1,11.49,1
+cbc88708-0900-e385-0331-39d5f14fbbc0,G12D,11.96,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,5.0,0,MSS,6.65,11.7,Amplified_2+,0,833.86,0,57.28,0,0.0,0
+68702909-6d92-07b3-852d-cc345bc22484,G12S,10.63,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,33.9,0,MSS,3.83,17.8,Negative,0,62.07,0,3.44,1,3.13,1
+e3c085f3-c5b0-02ee-1815-19a4f0816321,G12D,80.0,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,7.8,0,MSS,7.53,8.9,Negative,0,493.82,0,1.62,1,2.08,0
+aebdaae9-28f6-aa0a-651f-31c9a84c23e7,Q61H,19.87,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,5.2,0,MSS,5.05,1.8,Negative,0,554.73,0,3.72,1,10.2,0
+f6281dd4-5c12-0b90-263d-627c7803226c,Q61H,27.22,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,29.0,0,MSS,3.75,6.4,Negative,0,5988.82,0,1.73,1,7.33,0
+33152f1d-ae95-f0e1-2dae-5bfb43f04f44,G12V,23.2,0,Mutant,Lost,Lost,WT,WT,WT,Pathogenic,WT,35.1,1,MSS,4.11,17.4,Amplified_3+,0,473.31,0,1.37,0,0.0,0
+e99f05d0-fbc8-a23b-dbe6-4cfdeb7f2802,G12V,21.1,0,Mutant,Intact,Lost,WT,WT,Mutant,WT,WT,16.4,0,MSS,8.0,22.9,Negative,0,50.79,0,12.32,0,0.0,0
+7844defa-57b7-37f3-364f-4ae13e675593,Q61H,14.81,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,20.6,0,MSS,2.69,15.7,Negative,0,2304.75,0,7.49,1,10.6,1
+e0dc93a4-a4f9-ac3e-bbc6-5272e14765cc,G12R,20.36,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,3.2,0,MSS,8.0,19.2,Negative,0,2036.97,0,7.51,1,8.15,1
+845b639b-69ba-6d24-6109-98f0a558e02e,G12R,30.03,0,WT,Lost,Intact,WT,WT,WT,WT,WT,22.2,0,MSS,8.0,0.4,Negative,0,212.81,0,16.07,1,5.11,0
+bb2bba34-a71c-51fb-bde1-206e16b9c65d,G12V,57.47,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,19.2,0,MSS,5.3,19.0,Negative,0,877.69,0,7.29,1,14.58,1
+91e72ec7-f322-e0f3-c870-133888b0747b,G12V,43.31,0,Mutant,Lost,Intact,WT,Pathogenic,Germline,WT,WT,66.7,1,MSS,3.45,20.9,Amplified_2+,0,217.81,0,1.54,0,0.0,0
+e76acb28-c757-658f-1ac8-0e1371c32364,G12D,11.81,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,8.8,0,MSS,7.56,10.3,Negative,0,3403.36,0,9.1,1,3.65,0
+cc501d11-dc77-91db-dd96-2974b311c91f,Q61H,44.39,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,14.3,0,MSS,4.98,12.3,Negative,0,397.81,0,1.45,0,0.0,0
+345362c7-00d4-b6d5-1990-965980bcc705,G12R,32.63,0,WT,Intact,Lost,WT,WT,WT,WT,WT,26.4,0,MSS,3.3,1.3,Negative,0,6831.74,0,2.78,1,2.88,1
+05ec825d-74af-c5a7-be5c-97f16e57a0b6,G12A,16.86,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,1.4,0,MSS,8.0,4.4,Negative,0,1853.19,0,4.28,1,7.13,1
+608c8dc3-fcef-08c5-faae-773135d934d8,WT,0.0,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,4.6,0,MSS,4.25,1.4,Negative,0,127.55,0,3.87,0,0.0,0
+e337dbdd-ee67-9d2b-b824-ddbfce1388db,G12S,34.58,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,11.3,0,MSS,3.36,18.3,Negative,0,342.88,0,0.75,1,6.99,1
+51b2aab1-a06c-b612-6506-76dfa0f53621,G12V,25.23,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,4.3,0,MSS,6.78,20.0,Negative,0,573.01,0,1.7,1,3.36,1
+94bbb837-9247-305f-9bd6-7568591c76ff,G12R,32.73,0,WT,Intact,Intact,WT,WT,WT,WT,WT,1.6,0,MSS,5.89,2.7,Negative,0,792.08,0,4.38,1,27.73,1
+9a0de910-029b-f24d-68bd-65c7627a1beb,WT,0.0,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,39.5,0,MSS,8.0,23.0,Negative,0,5607.78,0,2.43,1,15.68,0
+77b74598-8118-7712-ef75-27479366a719,Q61H,80.0,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,18.2,0,MSS,5.2,21.0,Negative,0,159.15,0,13.82,1,4.15,1
+60909240-5689-a0a0-325d-b2101153a287,G12R,7.71,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,21.3,0,MSS,5.22,14.4,Negative,0,141.82,0,16.4,0,0.0,0
+219056dc-c4d7-cc02-64e4-31f95cd8faa8,G12V,34.7,0,WT,Intact,Intact,WT,WT,Mutant,WT,WT,10.2,0,MSS,6.92,24.5,Negative,0,68.52,0,1.46,1,13.48,1
+af3f75c5-4ecb-b027-29b1-f258550ef642,G12D,30.57,0,Mutant,Lost,Intact,WT,WT,Mutant,WT,WT,0.3,0,MSS,6.55,22.1,Negative,0,236.4,0,4.76,0,0.0,0
+f4743894-0610-5039-56e8-039c0bf8b5f0,G12D,36.08,0,WT,Lost,Lost,WT,WT,WT,WT,WT,30.0,0,MSS,6.63,5.6,Negative,0,4785.3,0,21.82,0,0.0,0
+19531dca-32bd-0da8-3e5c-5b36ba2da538,G12D,16.04,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,29.0,0,MSS,6.74,23.9,Negative,0,1447.81,0,3.92,1,8.86,0
+e18b9425-958e-cc9d-c0e5-accf790ea7c6,G12D,49.48,0,WT,Intact,Lost,WT,WT,WT,WT,WT,38.9,0,MSS,6.46,11.1,Negative,0,0.82,1,2.98,1,6.24,1
+33bc0bbb-7a61-9864-4732-6fdc58046ffa,G12V,22.99,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,0.8,0,MSS,5.12,3.9,Negative,0,494.87,0,10.59,1,10.92,1
+85a29922-7a97-01da-2f8e-5e91f9c3dbf2,G12V,12.04,0,WT,Intact,Lost,WT,WT,WT,WT,WT,5.5,0,MSS,8.0,5.0,Negative,0,1757.85,0,3.41,1,14.33,1
+426aa63b-7467-5f0f-77ea-272b0e9a971c,G12V,12.72,0,WT,Lost,Lost,WT,WT,WT,WT,WT,28.5,0,MSS,5.24,17.1,Negative,0,14972.53,0,15.97,1,4.11,1
+7b430438-0232-694c-0b90-772420c2881b,G12R,26.44,0,Mutant,Intact,Intact,WT,WT,Mutant,WT,WT,13.2,0,MSS,8.0,24.7,Negative,0,86.02,0,2.47,1,1.45,1
+a70b7f93-3ea7-c002-f596-ce0316ffd43d,G12V,9.41,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,2.6,0,MSS,8.0,11.1,Negative,0,1677.61,0,2.79,1,4.63,0
+1c5650d5-e234-6fd2-7ed9-8487ac69b9b9,G12D,72.26,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,12.0,0,MSS,4.61,14.3,Negative,0,138.27,0,9.88,0,0.0,0
+4b764e39-22aa-850f-409f-aa2c3be97f10,G12S,46.03,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,3.5,0,MSS,8.0,7.5,Negative,0,976.88,0,4.96,1,3.53,1
+e0701e6a-4d37-65c2-c3ca-2a66500c4525,G12V,73.41,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,33.5,0,MSS,4.55,21.1,Negative,0,2681.56,0,4.99,1,1.57,1
+fc0cb035-1af0-003e-e6d2-0021c5cdf83b,G12R,68.91,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,35.1,0,MSS,4.56,2.9,Negative,0,168.92,0,0.66,1,8.29,1
+f3f7c04c-5ad6-f1af-fb7c-62089d2cab5c,Q61H,19.86,0,WT,Intact,Lost,WT,WT,Mutant,WT,WT,25.5,0,MSS,7.51,14.6,Negative,0,341.31,0,3.15,0,0.0,0
+23466fea-68fd-eaf4-1262-ef9096aedbb2,G12R,14.56,0,WT,Lost,Lost,WT,WT,Mutant,WT,WT,15.4,0,MSS,7.22,14.7,Negative,0,2795.54,0,10.63,0,0.0,0
+8d8abd6f-38ec-a936-4df1-84adf0f7b4f5,G12V,5.0,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,30.8,0,MSS,6.23,0.0,Negative,0,809.74,0,2.05,0,0.0,0
+d8862640-d105-c1d3-18d3-8afc6cd761fc,G12V,19.23,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,25.3,0,MSS,8.0,23.5,Negative,0,3006.22,0,9.03,1,5.42,1
+8ad864ba-670e-0590-9de3-bba2be32c527,G12S,70.77,0,WT,Intact,Lost,WT,WT,WT,WT,WT,31.7,0,MSS,6.69,24.4,Negative,0,56.72,0,5.86,0,0.0,0
+40d559cc-14f1-b678-2a51-d7c785600558,G12A,14.93,0,Mutant,Intact,Lost,WT,WT,Mutant,WT,WT,20.4,0,MSS,8.0,11.7,Negative,0,139.1,0,3.67,1,4.81,1
+da184a9b-1b4e-905b-290a-3578744f3341,G12D,21.63,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,38.3,0,MSS,5.92,18.1,Negative,0,270.42,0,17.42,1,7.16,1
+bc317131-8626-b731-958f-f5005fffc934,G12V,17.59,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,11.6,0,MSS,4.3,21.2,Negative,0,714.12,0,3.19,1,4.42,1
+5f0a69ae-d910-7587-4bc8-cf48bd64545d,G12S,30.72,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,24.2,0,MSS,4.85,2.9,Negative,0,56.49,0,3.42,1,4.58,1
+c2905758-1c6a-1c5a-67a4-932fd5d0148e,G12A,53.07,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,32.3,0,MSS,7.3,2.1,Negative,0,58.3,0,3.63,1,3.03,0
+34f1bb39-0b0c-b4e2-c5b8-ece707b8a720,G12D,9.74,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,35.8,0,MSS,7.35,17.2,Negative,0,2097.11,0,4.86,1,17.54,1
+1ee344a8-6891-fecb-f108-b0c59a761b4a,G12V,10.93,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,37.9,0,MSS,6.57,14.0,Negative,0,1852.23,0,9.65,0,0.0,0
+19b3876e-ba0b-5b88-e568-41bd3b9fed62,G12V,59.86,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,15.8,0,MSS,4.31,17.0,Negative,0,2059.45,0,1.03,1,2.25,0
+d8b2d13d-2d86-656b-43b8-e18d6288a00e,G12D,38.09,0,WT,Intact,Lost,WT,WT,WT,WT,WT,28.0,0,MSS,8.0,14.3,Negative,0,882.21,0,10.68,1,1.65,1
+69df9683-a693-f45b-2df3-31449e22599b,G12R,21.0,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,11.6,0,MSS,8.0,18.2,Negative,0,158.1,0,4.8,0,0.0,0
+3ec94ac4-2f6b-5b11-7329-faa50fbcf02b,G12V,68.32,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,26.0,0,MSS,6.12,3.9,Negative,0,589.71,0,7.8,0,0.0,0
+d9f1114d-2253-d070-b5d2-a127e1060273,G12D,10.82,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,7.4,0,MSS,8.0,5.4,Negative,0,1019.59,0,49.0,1,1.85,1
+56ddd0ee-bf40-5564-dfe4-28079305ce72,G12D,42.89,0,Mutant,Lost,Lost,WT,WT,Mutant,WT,WT,16.9,0,MSS,8.0,5.9,Negative,0,220.38,0,2.69,1,13.86,1
+3f978fe4-b84e-1669-87e5-cfba88ed22cc,G12S,23.55,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,36.8,0,MSS,8.0,10.4,Amplified_3+,0,165.37,0,1.32,1,10.16,0
+2947f23e-4bd0-0540-3eaa-fbc8554547b9,G12S,35.3,0,WT,Intact,Intact,WT,WT,WT,WT,WT,32.4,0,MSS,7.31,19.0,Negative,0,1801.35,0,5.44,1,5.04,0
+e3533c62-1306-5647-f0a5-15fd095b1b93,G12A,5.86,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,19.9,0,MSS,6.39,20.8,Negative,0,929.65,0,6.37,0,0.0,0
+84857728-5412-4b4b-c700-fb0b00c9b5ec,Q61H,20.98,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,5.9,0,MSS,8.0,10.0,Negative,0,0.62,1,10.71,1,11.6,1
+879d6977-7399-9116-7d98-7af8483fa0c1,Q61H,38.17,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,15.9,0,MSS,5.09,15.1,Negative,0,276.13,0,2.62,1,4.91,1
+6f3f86bc-d351-3d08-895c-857664ae2e6e,G12V,23.62,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,5.5,0,MSS,7.12,7.4,Negative,0,2371.43,0,1.95,1,2.33,1
+202b819a-5c16-7845-21ba-af4a5c83166c,G12D,52.1,0,Mutant,Intact,Intact,WT,WT,WT,WT,WT,2.7,0,MSS,8.0,11.9,Negative,0,911.04,0,0.97,0,0.0,0
+7b665e2c-16e3-de66-f3c6-a32b2eb88017,G12A,51.06,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,36.3,0,MSS,8.0,23.5,Negative,0,3713.55,0,1.14,1,1.98,0
+29e02c9c-258f-0a34-f405-46fbd594b4ed,G12R,13.8,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,19.7,0,MSS,5.98,6.7,Negative,0,342.75,0,2.96,1,19.3,1
+352cf539-f5b5-f39d-8dee-3e3f5f628265,G12D,40.22,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,3.6,0,MSS,6.55,19.7,Negative,0,6.38,0,3.99,0,0.0,0
+07b1a828-dfd3-6600-40d0-b4d32a15cbfe,Q61H,13.52,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,28.7,0,MSS,8.0,1.1,Negative,0,62.16,0,35.34,0,0.0,0
+eab693c6-2835-ee10-1e73-b96361506e29,G12D,25.34,0,WT,Intact,Lost,WT,WT,WT,WT,WT,3.0,0,MSS,8.0,8.6,Negative,0,32.24,0,0.82,0,0.0,0
+9bae5b24-ea59-420c-524f-fc73006ce482,Q61H,36.37,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,15.8,0,MSS,8.0,16.5,Negative,0,29.83,0,6.27,1,1.43,0
+6683f909-f88f-ea6f-770b-2a89125e8c93,G12V,14.86,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,9.2,0,MSS,6.93,19.4,Negative,0,2577.58,0,2.17,0,0.0,0
+2feee437-a913-1013-8829-afd78754616b,WT,0.0,0,Mutant,Lost,Intact,WT,WT,WT,WT,Pathogenic,26.6,1,MSS,4.35,14.8,Negative,0,60.31,0,5.6,1,3.35,0
+d17c9fde-247e-6215-fd15-2524d6f58ffc,G12S,18.12,0,Mutant,Lost,Lost,WT,WT,WT,WT,WT,21.3,0,MSS,4.64,21.7,Negative,0,495.0,0,2.58,0,0.0,0
+78009bfa-5ef1-c5d9-bdda-74e1d120fd00,G12R,17.32,0,WT,Lost,Lost,WT,WT,WT,WT,WT,28.8,0,MSS,7.28,20.5,Negative,0,7047.99,0,12.62,1,22.42,1
+ebb0c1f7-d428-a25e-2722-f47fd6d68ec0,G12R,37.49,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,19.5,0,MSS,8.0,15.4,Negative,0,7952.14,0,12.54,1,22.35,1
+0cd3cac1-8f24-85a2-5765-2491ae8ef388,G12V,14.86,0,WT,Intact,Intact,Pathogenic,WT,WT,WT,WT,62.8,1,MSS,8.0,8.7,Negative,0,2740.37,0,4.0,1,5.0,0
+cb618934-0e9d-ff66-57a7-c471ee8ab0ac,G12D,14.41,0,WT,Lost,Lost,WT,WT,WT,WT,WT,36.7,0,MSS,4.62,9.1,Negative,0,3.39,1,18.9,0,0.0,0
+c036f51e-0dd9-4902-9f69-d71ea855bcd8,G12D,45.82,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,32.3,0,MSS,5.69,15.4,Negative,0,3551.41,0,9.58,1,1.76,1
+3642a84a-d3cb-e6db-cb2b-b042a3273c4a,WT,0.0,0,Mutant,Intact,Lost,WT,WT,WT,WT,WT,38.3,0,MSS,3.78,16.4,Negative,0,155.5,0,18.04,1,11.6,0
+7020162c-87f1-5dbc-ec7d-103b35ec7c03,G12D,10.25,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,37.2,0,MSS,3.47,9.9,Negative,0,478.76,0,4.29,1,5.39,1
+00974ec6-c103-6db5-a396-660549860d31,G12D,40.99,0,Mutant,Lost,Intact,WT,WT,WT,WT,WT,33.3,0,MSS,6.25,9.9,Negative,0,12255.02,0,11.61,1,5.56,0
+47e8d357-47d8-0738-fe4d-65dd8d79af72,G12V,19.22,0,WT,Lost,Lost,WT,WT,WT,WT,WT,11.7,0,MSS,8.0,4.4,Negative,0,496.24,0,2.08,1,5.26,0

hconc005_sample.csv ADDED Viewed

The diff for this file is too large to render. See raw diff

hconc005_surgical.csv ADDED Viewed

	@@ -0,0 +1,104 @@

+patient_id,surgery_procedure,surgical_approach,r_status,lymph_nodes_harvested,lymph_nodes_positive,lymph_node_ratio,pancreatic_fistula_isgpf,delayed_gastric_emptying_isgps,post_pancreatectomy_hemorrhage,bile_leak_flag,wound_infection_flag,portal_vein_resection_flag,arterial_resection_flag,operative_time_minutes,estimated_blood_loss_ml,icu_admission_flag,hospital_los_days,readmission_90d_flag,pathologic_complete_response_flag,near_complete_response_flag
+705a5661-a791-ffc1-c621-fbcd16d92688,Pancreaticoduodenectomy_Whipple,Open,R0,16,0,0.0,Grade_A,None,None,0,1,0,0,311,203,1,9.1,0,0,0
+ed407866-2ebb-92af-5eec-9e8b80171029,Pancreaticoduodenectomy_Whipple,Open,R0,16,5,0.312,None,None,Grade_B,0,0,1,0,395,306,0,7.8,0,0,0
+3a2c511e-7351-513a-7183-97ca8ba13e23,Total_Pancreatectomy,Open,R0,5,1,0.2,Grade_A,None,None,0,0,0,0,202,452,0,27.4,0,0,0
+105653e3-e34c-bfaf-8df9-44c317963822,Pancreaticoduodenectomy_Whipple,Open,R0,24,8,0.333,Grade_A,None,None,0,0,0,0,489,100,0,12.3,0,0,0
+e4a395f7-7218-933c-f87f-aa6d11633489,Pancreaticoduodenectomy_Whipple,Open,R0,18,2,0.111,Grade_B,None,None,0,0,0,0,421,272,1,35.7,1,0,0
+0b36b93d-7f6f-4439-777b-07175d28f217,Distal_Pancreatectomy,Minimally_Invasive,R0,21,1,0.048,None,None,None,0,0,0,0,244,401,0,5.0,0,0,0
+5ed67281-e7d1-3122-5369-4a69692d7d22,Distal_Pancreatectomy,Minimally_Invasive,R0,10,5,0.5,Grade_B,Grade_B,None,0,0,0,0,309,299,0,10.4,1,0,0
+6808f827-68c0-7153-aa10-73c1ff00dcbc,Pancreaticoduodenectomy_Whipple,Open,R0,19,6,0.316,Grade_B,Grade_B,None,0,0,0,0,360,100,0,13.0,0,0,0
+33ce15e1-b43b-71f3-74ad-c14320a8e05d,Total_Pancreatectomy,Minimally_Invasive,R1,11,1,0.091,Grade_C,Grade_A,None,0,1,0,0,274,365,0,8.5,0,0,0
+db4b12df-7694-a997-2d40-fb298c021d71,PPPD,Open,R1,17,1,0.059,Grade_A,Grade_A,None,0,1,0,0,386,234,0,11.3,0,0,0
+7e762ead-2df0-dc70-0aa7-39fbc9716412,Pancreaticoduodenectomy_Whipple,Robotic,R1,18,1,0.056,None,Grade_A,None,0,0,0,0,386,211,0,15.1,0,0,0
+24ff8988-a91d-04d8-5471-c8cf302f865e,Distal_Pancreatectomy,Open,R0,12,4,0.333,Grade_B,Grade_B,None,0,0,0,0,344,141,0,12.5,0,0,0
+152dcb14-10a0-fe58-c861-55fa77945c4e,PPPD,Open,R0,28,17,0.607,Grade_B,None,None,0,0,0,0,416,348,1,15.4,1,0,0
+4458845d-cebe-b4ba-7936-99f48ad08bf0,Pancreaticoduodenectomy_Whipple,Minimally_Invasive,R0,24,8,0.333,None,None,None,0,0,0,0,494,460,1,10.4,0,0,0
+8dd5500d-4d5b-9fe0-23e7-5d428af6b75d,Pancreaticoduodenectomy_Whipple,Open,R1,13,1,0.077,Grade_B,Grade_B,None,0,0,0,0,452,364,0,12.0,0,0,0
+a8cfebfa-3e6e-7a36-47fe-eff01e6e8b01,Total_Pancreatectomy,Open,R0,20,0,0.0,None,Grade_B,None,0,0,0,0,142,100,1,17.3,1,0,0
+5ef4c346-8bfb-4cd1-8e0a-cfba2429c191,Pancreaticoduodenectomy_Whipple,Open,R1,8,1,0.125,None,None,None,0,0,0,0,519,100,1,17.5,0,0,0
+83dac8b5-9f32-375d-4a79-9768a2844a4b,Distal_Pancreatectomy,Minimally_Invasive,R0,14,7,0.5,Grade_B,Grade_A,None,0,1,0,0,259,100,0,6.9,1,0,0
+43309cc4-6147-1eaa-bf2d-9a9dbc92f486,Pancreaticoduodenectomy_Whipple,Robotic,R1,18,5,0.278,None,None,None,0,0,0,0,327,212,0,16.7,1,0,0
+4f715f4a-47cf-69ac-3249-8ad10b7704e4,Pancreaticoduodenectomy_Whipple,Open,R0,22,8,0.364,None,None,None,0,0,0,0,388,378,0,11.8,0,0,0
+24d6777b-6f06-e33e-8030-930a7fd29524,Total_Pancreatectomy,Robotic,R0,21,0,0.0,Grade_A,None,None,0,0,0,0,275,483,0,14.5,0,0,0
+98963ea9-2a7d-08e3-f75a-f97f01aab4fe,Pancreaticoduodenectomy_Whipple,Open,R0,13,0,0.0,Grade_A,None,None,0,1,1,0,339,1444,0,18.3,0,0,0
+de2423db-eee7-c203-9b23-da52c3e0af56,Distal_Pancreatectomy,Minimally_Invasive,R0,16,0,0.0,None,None,None,0,0,0,0,303,304,0,21.2,0,0,0
+de13ddb4-f66d-edae-a6e4-f3a21d1d5506,Pancreaticoduodenectomy_Whipple,Minimally_Invasive,R1,19,10,0.526,None,Grade_C,None,0,0,1,0,399,340,0,11.3,0,0,0
+982ccdf9-79b5-3108-110a-0051e1b2a9d1,Pancreaticoduodenectomy_Whipple,Open,R0,34,7,0.206,Grade_A,None,None,0,0,0,0,272,221,0,15.5,0,0,0
+2a604977-993b-3463-ebc4-b88bea4eeec9,PPPD,Robotic,R0,20,0,0.0,None,Grade_A,None,0,0,0,0,447,457,1,12.7,1,0,0
+8128a1a7-fc03-2076-5167-dd51d4061611,Pancreaticoduodenectomy_Whipple,Open,R0,12,4,0.333,None,None,None,0,0,0,0,280,167,0,16.9,1,0,0
+d9e3c325-caeb-3127-e000-52eabc6b5ecb,Distal_Pancreatectomy,Minimally_Invasive,R0,14,8,0.571,Grade_A,None,Grade_A,1,0,0,0,238,283,0,12.5,1,0,0
+0d4d5f75-1b53-7210-d55d-8a2f17e3e2a3,Distal_Pancreatectomy,Minimally_Invasive,R1,16,6,0.375,None,None,Grade_A,0,0,0,0,157,713,0,23.1,0,0,0
+a479c8b2-a0b8-c604-c78b-d71194513c43,PPPD,Minimally_Invasive,R0,22,20,0.909,Grade_B,None,None,0,0,1,0,199,1380,0,20.5,1,0,0
+23c7dcd2-0fa6-6bfb-4436-f0a23ff2ced5,Pancreaticoduodenectomy_Whipple,Minimally_Invasive,R0,16,7,0.438,None,None,None,0,0,0,0,423,100,0,29.9,0,0,0
+7b1cf221-daac-3cc2-ea95-c8a7abbc60a0,Distal_Pancreatectomy,Open,R0,23,3,0.13,Grade_A,None,None,1,0,0,0,248,427,1,28.7,1,1,0
+88607cb1-8d93-e545-cdec-9f7233cda2b2,Pancreaticoduodenectomy_Whipple,Open,R1,22,6,0.273,Grade_A,Grade_C,None,1,0,0,0,452,151,0,8.5,1,0,0
+85cb322f-ade5-0c95-774a-cd9079d675fb,Distal_Pancreatectomy,Robotic,R1,8,4,0.5,Grade_B,None,None,0,0,0,0,162,530,1,20.5,0,0,0
+1ea6dc46-d854-d20f-ee65-7f79239e615f,Distal_Pancreatectomy,Open,R1,22,3,0.136,Grade_C,Grade_A,None,0,0,0,0,281,190,0,14.9,0,0,0
+701a7a9e-8e15-57c8-efa6-0ca816150ec2,PPPD,Minimally_Invasive,R0,10,6,0.6,Grade_A,None,None,0,0,0,0,375,100,0,9.7,0,0,1
+efa6dec3-f2f5-ff95-8d90-f41a2d0e4d9f,PPPD,Robotic,R0,16,2,0.125,None,Grade_C,None,0,0,0,0,450,112,1,10.6,0,0,0
+f3817e44-d8a9-8869-b7bf-228401408248,Distal_Pancreatectomy,Minimally_Invasive,R0,15,3,0.2,None,None,None,0,0,0,0,255,160,1,6.9,0,0,1
+afa402ea-0849-f72c-9698-13877a697cd7,Distal_Pancreatectomy,Minimally_Invasive,R1,15,7,0.467,None,Grade_A,None,0,1,0,0,256,271,1,16.6,0,0,1
+744e2e94-187e-52c4-0326-44d18b650240,Distal_Pancreatectomy,Open,R1,34,15,0.441,Grade_A,Grade_A,None,0,0,0,0,372,264,1,14.4,0,0,0
+4b9ca62a-6e69-c7fe-d34d-61e2b8fb5bee,Pancreaticoduodenectomy_Whipple,Open,R0,27,5,0.185,Grade_B,None,None,0,0,0,0,302,345,1,16.1,0,0,0
+e91f963c-03bb-0769-32bd-8321cef0026c,Total_Pancreatectomy,Robotic,R1,12,4,0.333,Grade_A,None,Grade_A,0,0,0,0,260,554,0,24.8,0,0,0
+cd0bf794-ab4c-1caa-0ea6-c09f3eb0a378,Distal_Pancreatectomy,Open,R0,24,0,0.0,None,None,None,0,0,0,0,133,149,0,15.8,0,0,0
+822367b2-762f-3fb9-2600-18ff286da0c2,Pancreaticoduodenectomy_Whipple,Open,R0,11,4,0.364,None,Grade_B,None,0,0,0,0,301,131,0,25.6,0,0,0
+79631f31-e9e9-48e4-676e-cc3eb0dd327b,Distal_Pancreatectomy,Minimally_Invasive,R0,15,9,0.6,Grade_C,None,Grade_B,0,0,0,0,397,488,0,14.8,0,0,0
+4e011ef4-17e9-aae4-472f-f57ef2a66016,Distal_Pancreatectomy,Open,R0,13,5,0.385,Grade_A,Grade_B,None,0,0,0,0,262,100,1,30.0,0,0,0
+d65eb0c4-84f0-4b51-507f-d72d3ef4bc21,Total_Pancreatectomy,Open,R0,21,10,0.476,None,None,None,0,0,0,0,238,226,1,9.5,0,0,0
+4f9b2c6b-6caa-1b47-c5a8-aa89731796e4,Distal_Pancreatectomy,Open,R2,17,4,0.235,None,Grade_C,Grade_B,0,0,0,0,136,163,1,12.0,1,0,0
+29eb9b00-777b-64cd-866c-2fe0c1abb89a,Pancreaticoduodenectomy_Whipple,Open,R0,9,7,0.778,None,Grade_C,None,0,0,0,0,282,154,0,7.6,0,0,0
+72c03979-80be-32e0-243f-a0cea6a48572,PPPD,Open,R0,28,8,0.286,Grade_A,None,None,0,0,1,0,342,100,0,16.9,1,0,0
+3b9c3514-a1d0-c5a7-0b6e-1f68f0d32a58,PPPD,Open,R0,11,4,0.364,None,Grade_C,Grade_A,0,0,1,1,510,175,1,12.0,0,0,0
+3e60fd82-44d4-d5a2-1588-9523038f6d4a,Distal_Pancreatectomy,Minimally_Invasive,R1,9,1,0.111,Grade_B,None,None,0,0,0,0,235,103,0,31.2,1,0,0
+c4c4c717-8806-6cbc-7b89-df3654c36e11,Pancreaticoduodenectomy_Whipple,Open,R0,14,5,0.357,None,Grade_A,None,0,0,1,0,398,248,0,5.7,0,0,1
+880a8dd1-d914-f9c2-7fb2-77db953a1009,Total_Pancreatectomy,Open,R1,14,6,0.429,Grade_B,None,None,0,0,0,0,120,216,1,18.0,1,0,0
+9ecfc34a-cd81-da6a-fb57-a273b6a6bb98,Pancreaticoduodenectomy_Whipple,Open,R0,21,3,0.143,Grade_A,Grade_A,None,0,0,1,0,447,503,0,9.3,1,0,0
+c2ed3e94-fc19-a9f2-7a3d-d32ee1078e7e,Pancreaticoduodenectomy_Whipple,Open,R0,17,9,0.529,None,None,None,0,1,0,0,383,277,1,17.7,0,0,0
+c8317da9-9f95-0147-f695-02c048e41f8f,Pancreaticoduodenectomy_Whipple,Open,R0,20,4,0.2,Grade_B,Grade_A,None,0,0,0,0,349,217,0,16.7,0,0,1
+58b3c193-a312-fd0b-bffe-ebcff86922b1,Pancreaticoduodenectomy_Whipple,Open,R0,13,5,0.385,None,Grade_A,None,0,0,0,0,354,2110,0,11.2,0,0,0
+7d5cf657-f697-dd0c-c6ff-f58e82180fb6,PPPD,Robotic,R0,11,3,0.273,None,None,None,0,0,0,0,413,703,0,19.3,0,0,1
+695d0b7d-3ded-eaa0-fa58-c463534443cd,PPPD,Open,R0,15,3,0.2,None,None,None,0,0,0,0,385,100,1,7.2,1,0,0
+cd53ca4a-8a58-737f-8e32-bd1738d0476e,PPPD,Open,R0,23,8,0.348,None,None,None,0,0,0,0,524,366,0,25.5,0,0,0
+5f696baf-0e17-ff9a-0976-e9e03d068a7d,Total_Pancreatectomy,Open,R0,27,3,0.111,None,Grade_A,None,0,0,0,0,384,189,0,14.4,0,0,0
+3c0a7ee0-e866-b915-0c88-e2bc61bed80f,Total_Pancreatectomy,Open,R1,12,7,0.583,None,None,None,0,0,0,0,233,100,1,17.3,1,0,0
+e2f56fb7-8cb6-dbc3-465a-ef3d1d535d72,PPPD,Open,R1,21,5,0.238,None,Grade_A,Grade_A,0,1,1,1,587,146,0,6.4,0,0,0
+ffada53f-8898-bec5-ceb3-d6756cc57c7e,PPPD,Open,R1,14,1,0.071,Grade_A,Grade_A,None,0,0,0,0,340,115,0,13.5,0,0,0
+686ee23a-c679-3d5a-4bde-623ea363c007,Distal_Pancreatectomy,Minimally_Invasive,R0,29,2,0.069,None,None,Grade_C,0,0,0,0,308,100,1,11.8,0,0,0
+5349a943-8f7a-edef-3c2f-531c62e603b6,Total_Pancreatectomy,Open,R1,18,4,0.222,Grade_A,Grade_A,Grade_C,0,0,0,0,288,363,1,6.3,0,0,0
+4ca46226-0667-15a6-a747-cac09eb1244e,PPPD,Open,R2,14,10,0.714,Grade_A,None,None,0,1,0,0,449,826,0,31.5,0,0,0
+dfd310f5-58d6-02e0-27cb-04b22d694a71,Distal_Pancreatectomy,Open,R1,17,4,0.235,Grade_C,Grade_A,None,0,0,0,0,312,630,1,13.1,1,0,0
+acb26b95-96ca-195f-fea4-c618f32ee85e,Pancreaticoduodenectomy_Whipple,Open,R0,19,13,0.684,None,None,Grade_B,1,0,0,0,402,437,0,9.4,1,0,0
+2f67e9de-7863-ff33-c99f-7ccd445aa773,Pancreaticoduodenectomy_Whipple,Open,R0,30,9,0.3,None,Grade_A,None,0,1,0,0,510,148,0,43.3,1,0,0
+3a6ec7cb-5556-96a1-aeea-050cdcff71bb,Distal_Pancreatectomy,Minimally_Invasive,R0,14,5,0.357,Grade_B,Grade_B,None,0,0,0,0,247,200,0,47.8,1,0,0
+75f4ff31-7ea9-178e-0c6f-09777b8da1f7,Pancreaticoduodenectomy_Whipple,Open,R0,23,2,0.087,None,Grade_C,None,0,0,0,0,328,484,0,8.2,0,0,1
+9ec21a88-b4cd-a3dc-1c52-3679274f73a9,Pancreaticoduodenectomy_Whipple,Open,R0,18,0,0.0,None,None,None,0,0,0,0,313,100,0,16.7,0,0,0
+5c8da0e2-1456-8c59-fc11-fde8e8d088c1,Distal_Pancreatectomy,Minimally_Invasive,R0,8,3,0.375,None,Grade_C,None,0,0,0,0,250,703,1,7.2,1,0,0
+69fd9d34-83f1-32c1-3763-163b4be3ae99,PPPD,Open,R0,8,3,0.375,None,Grade_C,None,0,0,0,0,509,241,0,9.1,0,1,0
+95aae400-93eb-5060-fe3a-ca898da8e4b2,Total_Pancreatectomy,Open,R0,19,4,0.211,Grade_C,None,None,0,0,0,0,283,267,1,22.9,0,0,0
+8db4da3d-2f6c-5fe8-9c5b-6e739ea3a72e,Pancreaticoduodenectomy_Whipple,Open,R0,9,4,0.444,Grade_A,Grade_C,None,0,1,1,0,418,588,0,11.9,1,0,0
+fbc138b3-b7b5-8b71-c227-f5b144864bb9,Distal_Pancreatectomy,Robotic,R0,18,1,0.056,Grade_B,None,None,0,0,0,0,330,227,1,22.5,0,0,0
+cbc88708-0900-e385-0331-39d5f14fbbc0,Pancreaticoduodenectomy_Whipple,Minimally_Invasive,R0,18,6,0.333,Grade_C,None,None,0,0,0,0,499,1755,0,12.3,0,0,0
+68702909-6d92-07b3-852d-cc345bc22484,Pancreaticoduodenectomy_Whipple,Robotic,R0,20,6,0.3,Grade_B,None,None,0,0,0,0,297,528,0,8.3,0,0,0
+845b639b-69ba-6d24-6109-98f0a558e02e,Pancreaticoduodenectomy_Whipple,Robotic,R0,12,0,0.0,None,None,None,0,0,0,0,304,272,1,9.9,0,0,0
+91e72ec7-f322-e0f3-c870-133888b0747b,Pancreaticoduodenectomy_Whipple,Open,R0,12,0,0.0,None,None,None,0,1,0,0,304,201,0,17.2,0,0,0
+77b74598-8118-7712-ef75-27479366a719,Distal_Pancreatectomy,Minimally_Invasive,R1,26,12,0.462,Grade_A,None,None,0,0,0,0,290,100,0,7.0,0,0,0
+60909240-5689-a0a0-325d-b2101153a287,Pancreaticoduodenectomy_Whipple,Open,R0,19,0,0.0,Grade_B,None,None,0,0,0,0,392,191,0,12.2,0,0,0
+af3f75c5-4ecb-b027-29b1-f258550ef642,Pancreaticoduodenectomy_Whipple,Open,R0,12,3,0.25,None,None,None,0,0,0,0,250,248,1,27.5,0,0,0
+7b430438-0232-694c-0b90-772420c2881b,Pancreaticoduodenectomy_Whipple,Robotic,R0,17,4,0.235,Grade_B,None,None,0,1,0,0,345,198,0,12.7,1,0,0
+8ad864ba-670e-0590-9de3-bba2be32c527,Distal_Pancreatectomy,Minimally_Invasive,R0,11,1,0.091,None,None,None,0,0,0,0,283,102,1,13.6,1,0,0
+40d559cc-14f1-b678-2a51-d7c785600558,PPPD,Open,R0,10,1,0.1,None,None,None,0,0,0,0,358,148,0,11.9,0,0,0
+bc317131-8626-b731-958f-f5005fffc934,Pancreaticoduodenectomy_Whipple,Open,R0,22,4,0.182,None,Grade_B,None,0,0,0,0,453,373,0,8.7,0,0,0
+c2905758-1c6a-1c5a-67a4-932fd5d0148e,PPPD,Open,R0,23,10,0.435,None,None,None,0,0,1,0,380,323,0,7.2,0,0,0
+1ee344a8-6891-fecb-f108-b0c59a761b4a,PPPD,Open,R0,16,5,0.312,Grade_C,Grade_C,Grade_B,0,0,1,1,333,100,0,20.8,0,0,0
+69df9683-a693-f45b-2df3-31449e22599b,Distal_Pancreatectomy,Open,R1,29,2,0.069,Grade_A,None,None,0,0,0,0,335,322,1,12.7,0,0,0
+3ec94ac4-2f6b-5b11-7329-faa50fbcf02b,Pancreaticoduodenectomy_Whipple,Minimally_Invasive,R0,18,0,0.0,None,Grade_A,None,0,0,0,0,484,100,0,15.4,0,0,0
+e3533c62-1306-5647-f0a5-15fd095b1b93,Distal_Pancreatectomy,Minimally_Invasive,R0,3,0,0.0,None,None,None,0,0,0,0,260,380,0,16.1,1,0,0
+84857728-5412-4b4b-c700-fb0b00c9b5ec,Total_Pancreatectomy,Minimally_Invasive,R0,13,5,0.385,Grade_A,None,None,0,1,0,0,249,850,1,9.6,0,0,0
+07b1a828-dfd3-6600-40d0-b4d32a15cbfe,Pancreaticoduodenectomy_Whipple,Robotic,R1,27,7,0.259,None,Grade_B,None,0,0,0,0,407,336,1,12.9,0,0,0
+eab693c6-2835-ee10-1e73-b96361506e29,Pancreaticoduodenectomy_Whipple,Open,R0,13,4,0.308,None,None,None,0,1,0,0,499,102,0,36.6,0,0,0
+9bae5b24-ea59-420c-524f-fc73006ce482,Pancreaticoduodenectomy_Whipple,Minimally_Invasive,R0,8,1,0.125,None,None,None,0,0,0,0,400,389,0,14.0,1,0,0
+6683f909-f88f-ea6f-770b-2a89125e8c93,Total_Pancreatectomy,Open,R0,7,1,0.143,Grade_A,None,None,0,0,0,0,242,218,0,9.6,0,0,0
+d17c9fde-247e-6215-fd15-2524d6f58ffc,Pancreaticoduodenectomy_Whipple,Open,R1,18,5,0.278,Grade_B,Grade_A,None,0,0,0,0,475,117,0,8.7,0,0,0
+c036f51e-0dd9-4902-9f69-d71ea855bcd8,PPPD,Minimally_Invasive,R1,15,5,0.333,None,None,None,0,0,1,0,433,109,0,28.2,0,0,0
+7020162c-87f1-5dbc-ec7d-103b35ec7c03,Distal_Pancreatectomy,Open,R0,15,1,0.067,None,Grade_A,Grade_B,0,0,0,0,174,478,0,22.3,0,0,0

hconc005_treatment_history.csv ADDED Viewed

	@@ -0,0 +1,869 @@

+patient_id,treatment_line,regimen,targeted_agent,recist_response,cycles_completed,pfs_months,discontinuation_reason
+705a5661-a791-ffc1-c621-fbcd16d92688,First,Gemcitabine_NabPaclitaxel,None,SD,3,4.53,Progression
+705a5661-a791-ffc1-c621-fbcd16d92688,Second,Gemcitabine_Monotherapy,None,PD,5,1.06,Death
+b286b60e-1600-888d-dbcd-12c26eda1624,First,Gemcitabine_NabPaclitaxel,None,SD,5,2.5,Death
+f9c262ed-86c7-538c-181c-01b5339381eb,First,Gemcitabine_NabPaclitaxel,None,PR,9,6.16,Planned_Completion
+f9c262ed-86c7-538c-181c-01b5339381eb,Second,Capecitabine,None,SD,7,1.58,Progression
+c93b82a3-b7ac-9740-c2da-0d2fbc5a4471,First,Gemcitabine_NabPaclitaxel,None,PR,12,3.15,Planned_Completion
+c93b82a3-b7ac-9740-c2da-0d2fbc5a4471,Second,FOLFOX,None,PD,1,1.36,Death
+734c7e29-d6f9-bd6e-20cc-0e168362d113,First,mFOLFIRINOX,None,CR,6,3.53,Toxicity
+734c7e29-d6f9-bd6e-20cc-0e168362d113,Second,Capecitabine,None,PD,1,4.4,Progression
+ed407866-2ebb-92af-5eec-9e8b80171029,First,mFOLFIRINOX,None,SD,6,2.84,Planned_Completion
+ed407866-2ebb-92af-5eec-9e8b80171029,Second,Regorafenib,None,PD,6,1.24,Death
+d2a0814d-6704-a0b6-a4d4-5831c814ce06,First,NALIRIFOX,None,PD,3,0.57,Progression
+d2a0814d-6704-a0b6-a4d4-5831c814ce06,Second,FOLFOX,None,SD,1,1.78,Death
+3a2c511e-7351-513a-7183-97ca8ba13e23,First,Gemcitabine_NabPaclitaxel,None,PD,3,3.82,Progression
+3a2c511e-7351-513a-7183-97ca8ba13e23,Second,Capecitabine,None,PD,5,1.12,Progression
+105653e3-e34c-bfaf-8df9-44c317963822,First,mFOLFIRINOX,None,SD,5,2.53,Toxicity
+105653e3-e34c-bfaf-8df9-44c317963822,Second,FOLFOX,None,SD,2,2.8,Toxicity
+a1b4c210-46d9-b92c-d3df-a2f0dbb8fa6e,First,Gemcitabine_NabPaclitaxel,None,PD,1,0.86,Progression
+a1b4c210-46d9-b92c-d3df-a2f0dbb8fa6e,Second,Regorafenib,None,PD,3,0.79,Progression
+5ac236be-b355-791f-c212-09c32a4c73f5,First,mFOLFIRINOX,None,PD,1,1.16,Death
+5ac236be-b355-791f-c212-09c32a4c73f5,Second,Capecitabine,None,PD,3,3.92,Progression
+e4a395f7-7218-933c-f87f-aa6d11633489,First,Gemcitabine_NabPaclitaxel,None,SD,4,6.01,Toxicity
+e4a395f7-7218-933c-f87f-aa6d11633489,Second,Gemcitabine_Monotherapy,None,SD,3,2.85,Toxicity
+31d3d7a4-c288-c510-c744-240fad8c19b0,First,Gemcitabine_NabPaclitaxel,None,PD,3,3.47,Death
+31d3d7a4-c288-c510-c744-240fad8c19b0,Second,Regorafenib,None,PD,6,0.48,Progression
+0b36b93d-7f6f-4439-777b-07175d28f217,First,FOLFIRINOX,None,PD,3,1.07,Progression
+0b36b93d-7f6f-4439-777b-07175d28f217,Second,Gemcitabine_Monotherapy,None,SD,2,4.01,Progression
+aedc4bd3-be4d-e22b-277f-84228bebfaa0,First,Gemcitabine_NabPaclitaxel,None,PR,6,2.28,Planned_Completion
+5ed67281-e7d1-3122-5369-4a69692d7d22,First,FOLFIRINOX,None,PD,1,0.83,Death
+ab78ee11-9083-10a7-3a16-bb295487bf35,First,FOLFIRINOX,None,PR,8,1.47,Planned_Completion
+ab78ee11-9083-10a7-3a16-bb295487bf35,Second,FOLFOX,None,PR,2,1.34,Progression
+4ff7429d-18e3-d83f-b344-92dfa1383bb7,First,Gemcitabine_NabPaclitaxel,None,PR,9,5.47,Planned_Completion
+4ff7429d-18e3-d83f-b344-92dfa1383bb7,Second,Gemcitabine_Monotherapy,None,PD,5,1.28,Progression
+ce050974-6f6a-5c0a-d50e-fa74c4916b35,First,Gemcitabine_NabPaclitaxel,None,SD,6,0.78,Toxicity
+ce050974-6f6a-5c0a-d50e-fa74c4916b35,Second,FOLFOX,None,PR,5,14.43,Progression
+49cfdee0-e5e9-1216-6331-c875d7791e4a,First,Gemcitabine_NabPaclitaxel,None,PD,1,3.17,Death
+49cfdee0-e5e9-1216-6331-c875d7791e4a,Second,Gemcitabine_Monotherapy,None,PD,1,4.34,Progression
+23c6d19a-a302-d2b1-aeb8-067d3d53a8b1,First,Gemcitabine_NabPaclitaxel,None,PR,8,6.81,Death
+23c6d19a-a302-d2b1-aeb8-067d3d53a8b1,Second,FOLFOX,None,SD,3,8.17,Progression
+01e27e63-ce0d-de47-332d-2f17d52e3c45,First,FOLFIRINOX,None,PD,3,4.08,Progression
+01e27e63-ce0d-de47-332d-2f17d52e3c45,Second,Gemcitabine_Monotherapy,None,PR,2,1.7,Progression
+aa33aa6d-c7c5-f4bb-c973-e041cbfde031,First,Gemcitabine_NabPaclitaxel,None,PD,3,0.71,Toxicity
+aa33aa6d-c7c5-f4bb-c973-e041cbfde031,Second,FOLFOX,None,PD,3,0.09,Progression
+c7dddb97-46f1-715d-b485-b7df78b89fd7,First,FOLFIRINOX,None,SD,3,1.66,Toxicity
+c7dddb97-46f1-715d-b485-b7df78b89fd7,Second,Regorafenib,None,PD,7,3.18,Toxicity
+919905e4-816f-6949-757b-81178e3ee115,First,Gemcitabine_NabPaclitaxel,None,PD,2,2.35,Progression
+919905e4-816f-6949-757b-81178e3ee115,Second,FOLFOX,None,SD,2,1.81,Progression
+1d51d7c8-3ed7-da8e-23c9-bc6f098a05db,First,Gemcitabine_NabPaclitaxel,Olaparib,SD,3,1.67,Progression
+1d51d7c8-3ed7-da8e-23c9-bc6f098a05db,Second,Olaparib,Olaparib,PD,4,3.27,Progression
+7899c2ce-a788-a657-ab1c-74dd708a83e6,First,mFOLFIRINOX,None,PR,9,4.18,Progression
+7899c2ce-a788-a657-ab1c-74dd708a83e6,Second,FOLFOX,None,SD,4,0.91,Death
+c3d6f712-1446-47f3-90b3-503fdae685fc,First,FOLFIRINOX,None,PR,9,5.28,Planned_Completion
+c3d6f712-1446-47f3-90b3-503fdae685fc,Second,Gemcitabine_Monotherapy,None,SD,1,2.24,Progression
+8db7612d-90bc-4e67-a27c-e65a931906c7,First,NALIRIFOX,None,SD,6,2.22,Planned_Completion
+8db7612d-90bc-4e67-a27c-e65a931906c7,Second,FOLFOX,None,SD,2,3.85,Progression
+4dcfac72-cb7f-64aa-8f28-3353172f5c7b,First,mFOLFIRINOX,None,PD,1,0.93,Progression
+4dcfac72-cb7f-64aa-8f28-3353172f5c7b,Second,Regorafenib,None,PD,6,0.06,Toxicity
+6895554c-46cb-df16-36ef-0567fb94be4e,First,Gemcitabine_NabPaclitaxel,None,SD,5,0.5,Progression
+6895554c-46cb-df16-36ef-0567fb94be4e,Second,Gemcitabine_Monotherapy,None,SD,2,1.86,Progression
+3be37549-08e1-a35d-da78-9fb1fe1f5581,First,Gemcitabine_NabPaclitaxel,None,PD,2,2.19,Planned_Completion
+4808c655-db0d-3ebb-0eec-edb0d25941ba,First,Gemcitabine_NabPaclitaxel,None,PD,1,2.55,Progression
+4808c655-db0d-3ebb-0eec-edb0d25941ba,Second,FOLFOX,None,PD,3,4.23,Death
+a9735c57-6f2f-62dc-4b28-f5e3eaeb4005,First,Gemcitabine_NabPaclitaxel,None,PD,1,0.9,Planned_Completion
+a9735c57-6f2f-62dc-4b28-f5e3eaeb4005,Second,FOLFOX,None,SD,3,0.49,Progression
+c8ad8d93-8148-b20d-8e99-a8bd2053ef2c,First,Gemcitabine_NabPaclitaxel,None,PR,11,1.16,Toxicity
+c8ad8d93-8148-b20d-8e99-a8bd2053ef2c,Second,Regorafenib,None,SD,5,2.98,Progression
+6808f827-68c0-7153-aa10-73c1ff00dcbc,First,FOLFIRINOX,None,PR,10,3.5,Planned_Completion
+6808f827-68c0-7153-aa10-73c1ff00dcbc,Second,Gemcitabine_Monotherapy,None,SD,2,2.27,Toxicity
+2abebcbe-523b-31ba-d063-a3d26aff5827,First,mFOLFIRINOX,None,PR,11,2.56,Planned_Completion
+2abebcbe-523b-31ba-d063-a3d26aff5827,Second,FOLFOX,None,PD,6,0.36,Progression
+170d6069-1b2c-290a-05d0-755b55941fbd,First,Gemcitabine_NabPaclitaxel,None,SD,4,6.45,Planned_Completion
+170d6069-1b2c-290a-05d0-755b55941fbd,Second,FOLFOX,None,SD,6,2.26,Progression
+763d960e-b25f-9215-b8ec-8adac5847580,First,Gemcitabine_NabPaclitaxel,None,PD,3,2.37,Toxicity
+763d960e-b25f-9215-b8ec-8adac5847580,Second,Regorafenib,None,SD,4,2.63,Progression
+8044786a-e68f-247a-2949-1b78b791258c,First,Gemcitabine_NabPaclitaxel,None,SD,6,2.13,Death
+8044786a-e68f-247a-2949-1b78b791258c,Second,FOLFOX,None,PD,2,8.77,Progression
+b2420d56-7f51-061c-26fd-ed0bf02422d1,First,mFOLFIRINOX,None,PD,2,0.66,Progression
+b2420d56-7f51-061c-26fd-ed0bf02422d1,Second,Gemcitabine_Monotherapy,None,PD,3,3.03,Toxicity
+618a9b69-2a8d-01c2-7237-4c347ee1564a,First,NALIRIFOX,None,SD,4,5.43,Patient_Choice
+618a9b69-2a8d-01c2-7237-4c347ee1564a,Second,Regorafenib,None,SD,2,0.46,Progression
+a15a3334-af07-01b0-4d2f-e5723d1fc937,First,Gemcitabine_NabPaclitaxel,None,SD,6,4.37,Toxicity
+a15a3334-af07-01b0-4d2f-e5723d1fc937,Second,Capecitabine,None,PD,3,0.09,Progression
+167039a0-f5ae-69c4-5c9f-c0519b7139b0,First,Gemcitabine_NabPaclitaxel,None,SD,5,0.5,Death
+167039a0-f5ae-69c4-5c9f-c0519b7139b0,Second,Regorafenib,None,PR,3,6.87,Death
+f63eece3-56c5-0571-1e35-a28257b4076c,First,mFOLFIRINOX,None,SD,6,9.82,Toxicity
+f63eece3-56c5-0571-1e35-a28257b4076c,Second,Gemcitabine_Monotherapy,None,PD,3,2.42,Death
+b32001b8-7ebc-9f7d-e898-be805dc37279,First,Gemcitabine_Monotherapy,None,PD,1,1.31,Toxicity
+b32001b8-7ebc-9f7d-e898-be805dc37279,Second,Capecitabine,None,PR,2,3.58,Progression
+f81bf16c-c3a4-8a9b-4410-0dc575194ff8,First,Gemcitabine_NabPaclitaxel,None,PD,2,2.17,Death
+f81bf16c-c3a4-8a9b-4410-0dc575194ff8,Second,Capecitabine,None,SD,3,1.62,Progression
+b7861d8d-42da-1234-c75c-382043765d82,First,Gemcitabine_NabPaclitaxel,None,PD,2,0.3,Progression
+b7861d8d-42da-1234-c75c-382043765d82,Second,FOLFOX,None,PD,1,3.23,Progression
+45b19f7c-bca6-c348-7309-5afbc9fc5585,First,FOLFIRINOX,None,PD,1,5.62,Progression
+45b19f7c-bca6-c348-7309-5afbc9fc5585,Second,Capecitabine,None,PR,2,0.33,Death
+e710f35e-7270-2580-18ad-13fe1449f553,First,mFOLFIRINOX,None,CR,11,1.64,Planned_Completion
+33ce15e1-b43b-71f3-74ad-c14320a8e05d,First,Gemcitabine_NabPaclitaxel,None,SD,3,2.59,Progression
+33ce15e1-b43b-71f3-74ad-c14320a8e05d,Second,Gemcitabine_Monotherapy,None,SD,6,6.18,Toxicity
+db4b12df-7694-a997-2d40-fb298c021d71,First,FOLFIRINOX,None,SD,6,5.78,Toxicity
+db4b12df-7694-a997-2d40-fb298c021d71,Second,Gemcitabine_Monotherapy,None,PD,6,1.54,Progression
+b82eb96a-7e25-ad15-c22e-55fe04ff863b,First,Gemcitabine_NabPaclitaxel,None,PR,6,3.42,Toxicity
+b82eb96a-7e25-ad15-c22e-55fe04ff863b,Second,Gemcitabine_Monotherapy,None,PR,4,0.46,Toxicity
+a65c58cd-183d-e94f-9587-71ca23e5bcdf,First,mFOLFIRINOX,None,PD,3,1.27,Progression
+a65c58cd-183d-e94f-9587-71ca23e5bcdf,Second,Capecitabine,None,PD,4,2.06,Death
+6a725a99-c1ea-ba0b-159e-249da0f5737d,First,mFOLFIRINOX,Sotorasib_Adagrasib,PD,1,0.54,Progression
+6a725a99-c1ea-ba0b-159e-249da0f5737d,Second,Capecitabine,None,PD,3,10.46,Progression
+7e762ead-2df0-dc70-0aa7-39fbc9716412,First,mFOLFIRINOX,None,SD,6,1.82,Patient_Choice
+7e762ead-2df0-dc70-0aa7-39fbc9716412,Second,Gemcitabine_Monotherapy,None,SD,1,1.79,Death
+24ff8988-a91d-04d8-5471-c8cf302f865e,First,Gemcitabine_NabPaclitaxel,None,SD,4,4.96,Progression
+24ff8988-a91d-04d8-5471-c8cf302f865e,Second,FOLFOX,None,PD,1,0.29,Toxicity
+966fdfeb-2cd8-ef97-1a78-9decad7df0a1,First,Gemcitabine_NabPaclitaxel,None,PR,12,5.25,Planned_Completion
+966fdfeb-2cd8-ef97-1a78-9decad7df0a1,Second,FOLFOX,None,SD,1,10.14,Progression
+ecd4ac0d-4ccc-53da-2bab-fb14cb21b79f,First,Gemcitabine_NabPaclitaxel,None,PR,10,2.31,Toxicity
+ecd4ac0d-4ccc-53da-2bab-fb14cb21b79f,Second,Gemcitabine_Monotherapy,None,SD,3,3.26,Death
+58cc75a2-7271-17a2-94c0-6c3ffd5be90e,First,Gemcitabine_Monotherapy,None,SD,5,3.88,Progression
+58cc75a2-7271-17a2-94c0-6c3ffd5be90e,Second,Capecitabine,None,SD,3,0.91,Progression
+05d67978-4b74-ef51-9746-3cd69cc9a625,First,Gemcitabine_NabPaclitaxel,None,SD,4,0.5,Toxicity
+05d67978-4b74-ef51-9746-3cd69cc9a625,Second,Gemcitabine_Monotherapy,None,SD,3,0.15,Progression
+7b783cf0-6b0c-334c-f564-22f826c897d1,First,Gemcitabine_Monotherapy,None,PD,1,1.73,Progression
+7b783cf0-6b0c-334c-f564-22f826c897d1,Second,Gemcitabine_Monotherapy,None,SD,4,10.42,Progression
+152dcb14-10a0-fe58-c861-55fa77945c4e,First,Gemcitabine_NabPaclitaxel,None,CR,7,10.68,Death
+152dcb14-10a0-fe58-c861-55fa77945c4e,Second,Gemcitabine_Monotherapy,None,PD,3,1.19,Progression
+7d9ef93c-abce-c8fb-7c95-a3ef469decd4,First,FOLFIRINOX,None,SD,6,5.52,Planned_Completion
+7d9ef93c-abce-c8fb-7c95-a3ef469decd4,Second,Gemcitabine_Monotherapy,None,PD,5,3.09,Death
+4458845d-cebe-b4ba-7936-99f48ad08bf0,First,FOLFIRINOX,None,CR,7,10.2,Death
+4458845d-cebe-b4ba-7936-99f48ad08bf0,Second,Capecitabine,None,PD,2,8.6,Death
+854ac95c-8b85-69e7-54e1-b4aff42a7555,First,Gemcitabine_NabPaclitaxel,None,SD,6,4.33,Patient_Choice
+854ac95c-8b85-69e7-54e1-b4aff42a7555,Second,Capecitabine,None,SD,6,7.82,Progression
+05885e88-48d8-db1f-705c-805fd98b0b4e,First,Gemcitabine_Monotherapy,None,SD,3,3.15,Planned_Completion
+05885e88-48d8-db1f-705c-805fd98b0b4e,Second,Regorafenib,None,PD,7,1.85,Progression
+e56acad7-0289-de2b-d387-de175d1a049e,First,Gemcitabine_NabPaclitaxel,None,PR,11,0.5,Planned_Completion
+e56acad7-0289-de2b-d387-de175d1a049e,Second,FOLFOX,None,SD,2,3.67,Death
+8dd5500d-4d5b-9fe0-23e7-5d428af6b75d,First,Gemcitabine_NabPaclitaxel,None,SD,6,1.99,Progression
+8dd5500d-4d5b-9fe0-23e7-5d428af6b75d,Second,Capecitabine,None,PD,5,6.09,Death
+ac17ed3e-aa7e-3f5b-1bcb-9ea950d133b5,First,FOLFIRINOX,None,PD,1,0.63,Progression
+ac17ed3e-aa7e-3f5b-1bcb-9ea950d133b5,Second,FOLFOX,None,PD,7,0.83,Death
+a8cfebfa-3e6e-7a36-47fe-eff01e6e8b01,First,mFOLFIRINOX,None,SD,5,0.7,Toxicity
+a8cfebfa-3e6e-7a36-47fe-eff01e6e8b01,Second,FOLFOX,None,PR,2,3.42,Death
+c4c614ff-f052-a825-ba1c-51acbaf4a6ce,First,NALIRIFOX,None,PR,10,7.88,Death
+c4c614ff-f052-a825-ba1c-51acbaf4a6ce,Second,Capecitabine,None,PD,3,3.08,Death
+ea7fc095-9d59-3b7e-1b94-e91f52180c46,First,mFOLFIRINOX,None,SD,4,7.1,Progression
+ea7fc095-9d59-3b7e-1b94-e91f52180c46,Second,FOLFOX,None,PD,7,9.23,Toxicity
+5ef4c346-8bfb-4cd1-8e0a-cfba2429c191,First,Gemcitabine_Monotherapy,None,PD,1,3.65,Toxicity
+5ef4c346-8bfb-4cd1-8e0a-cfba2429c191,Second,FOLFOX,None,PD,1,1.14,Toxicity
+cee99187-75c4-c8a5-d46d-19c14f593d5b,First,Gemcitabine_NabPaclitaxel,Olaparib,PD,1,2.27,Progression
+cee99187-75c4-c8a5-d46d-19c14f593d5b,Second,Olaparib,Olaparib,PR,6,1.19,Progression
+f3f136fa-33e6-a87a-5130-03b4f6950d95,First,mFOLFIRINOX,None,PD,2,2.46,Progression
+f3f136fa-33e6-a87a-5130-03b4f6950d95,Second,Capecitabine,None,PR,2,6.64,Death
+83dac8b5-9f32-375d-4a79-9768a2844a4b,First,Gemcitabine_Monotherapy,None,SD,3,4.2,Toxicity
+83dac8b5-9f32-375d-4a79-9768a2844a4b,Second,FOLFOX,None,PD,3,0.57,Progression
+efa08d28-fdcb-4363-4186-ed9ce7d0f523,First,FOLFIRINOX,None,PR,9,1.85,Planned_Completion
+efa08d28-fdcb-4363-4186-ed9ce7d0f523,Second,Regorafenib,None,SD,7,2.03,Death
+0b7f4329-887c-f758-2a23-bce92e427c6d,First,Gemcitabine_Monotherapy,None,SD,5,3.32,Progression
+0b7f4329-887c-f758-2a23-bce92e427c6d,Second,Gemcitabine_Monotherapy,None,PR,7,0.41,Death
+fe0c5330-f828-d966-6f62-855b4c7e05e9,First,NALIRIFOX,None,SD,5,7.63,Planned_Completion
+fe0c5330-f828-d966-6f62-855b4c7e05e9,Second,Gemcitabine_Monotherapy,None,SD,4,4.28,Death
+bfa4c671-1747-1c89-e444-f61926cb525c,First,Gemcitabine_NabPaclitaxel,None,SD,3,2.11,Toxicity
+bfa4c671-1747-1c89-e444-f61926cb525c,Second,Gemcitabine_Monotherapy,None,PD,4,5.33,Death
+e4b8eb42-3931-eb1e-e40a-fa07d87c0a58,First,Gemcitabine_NabPaclitaxel,None,PD,2,4.55,Death
+e4b8eb42-3931-eb1e-e40a-fa07d87c0a58,Second,Regorafenib,None,PR,7,0.42,Progression
+50e0b9f1-7834-1ee5-84d3-e6c91db0ecb1,First,NALIRIFOX,None,PR,8,4.51,Planned_Completion
+50e0b9f1-7834-1ee5-84d3-e6c91db0ecb1,Second,Capecitabine,None,PD,5,4.11,Toxicity
+a962a1ee-55e8-cf6c-c5a2-9b5405a94655,First,FOLFIRINOX,None,PD,2,3.19,Death
+a962a1ee-55e8-cf6c-c5a2-9b5405a94655,Second,FOLFOX,None,PD,7,5.97,Toxicity
+182ef7b1-e2e4-4a0c-5fa8-086d69042c43,First,Gemcitabine_NabPaclitaxel,None,SD,3,1.76,Death
+182ef7b1-e2e4-4a0c-5fa8-086d69042c43,Second,Regorafenib,None,PD,4,3.57,Toxicity
+43309cc4-6147-1eaa-bf2d-9a9dbc92f486,First,Gemcitabine_NabPaclitaxel,None,PD,1,0.3,Progression
+43309cc4-6147-1eaa-bf2d-9a9dbc92f486,Second,Gemcitabine_Monotherapy,None,PD,6,3.2,Death
+3db03f62-f29e-8777-efd2-fc94015bcde5,First,Gemcitabine_NabPaclitaxel,Sotorasib_Adagrasib,SD,6,1.28,Planned_Completion
+d4c3ccd2-1151-0aee-1f6d-1059082b5295,First,Gemcitabine_Monotherapy,None,PD,1,0.34,Progression
+d4c3ccd2-1151-0aee-1f6d-1059082b5295,Second,Gemcitabine_Monotherapy,None,PD,5,6.11,Death
+2de48720-bf2a-5126-273d-a416e4544f1d,First,FOLFIRINOX,None,PD,1,2.06,Progression
+2de48720-bf2a-5126-273d-a416e4544f1d,Second,FOLFOX,None,PD,1,1.11,Death
+dfe34c43-b84d-1f42-9971-268f5e0168aa,First,Gemcitabine_NabPaclitaxel,None,PR,7,10.55,Planned_Completion
+dfe34c43-b84d-1f42-9971-268f5e0168aa,Second,FOLFOX,None,PD,7,0.61,Death
+4f715f4a-47cf-69ac-3249-8ad10b7704e4,First,mFOLFIRINOX,None,SD,6,3.9,Progression
+4f715f4a-47cf-69ac-3249-8ad10b7704e4,Second,FOLFOX,None,PD,1,2.07,Toxicity
+f8c99ddd-5206-dd09-c704-00e3ff7ec0f7,First,Gemcitabine_NabPaclitaxel,None,PD,2,0.75,Patient_Choice
+f8c99ddd-5206-dd09-c704-00e3ff7ec0f7,Second,Capecitabine,None,SD,2,0.35,Progression
+24d6777b-6f06-e33e-8030-930a7fd29524,First,Gemcitabine_NabPaclitaxel,None,PD,2,2.97,Progression
+24d6777b-6f06-e33e-8030-930a7fd29524,Second,Gemcitabine_Monotherapy,None,SD,3,0.4,Progression
+3acabcd2-2c9d-8495-0391-541bef3308f9,First,mFOLFIRINOX,None,SD,3,5.38,Progression
+3acabcd2-2c9d-8495-0391-541bef3308f9,Second,FOLFOX,None,PR,6,6.9,Death
+ad7b09f1-0499-1e7f-21bf-19d247800a92,First,Gemcitabine_NabPaclitaxel,Olaparib,SD,5,11.04,Toxicity
+ad7b09f1-0499-1e7f-21bf-19d247800a92,Second,Olaparib,Olaparib,SD,3,4.72,Progression
+819ed6a1-4be9-bb2f-1f30-6a3ef824b1c8,First,Gemcitabine_NabPaclitaxel,None,SD,6,5.18,Death
+819ed6a1-4be9-bb2f-1f30-6a3ef824b1c8,Second,FOLFOX,None,SD,7,1.12,Death
+94c40edf-c424-e7af-b1bb-2ed7ed70cb7e,First,Gemcitabine_Monotherapy,None,PD,3,1.21,Patient_Choice
+94c40edf-c424-e7af-b1bb-2ed7ed70cb7e,Second,FOLFOX,None,SD,1,1.1,Progression
+bd2e0e41-159a-7574-b724-ebf1066d0a58,First,Gemcitabine_NabPaclitaxel,None,SD,6,5.65,Planned_Completion
+bd2e0e41-159a-7574-b724-ebf1066d0a58,Second,Gemcitabine_Monotherapy,None,PD,4,7.9,Progression
+1fae544b-6f0f-de03-218d-0034d371b610,First,NALIRIFOX,None,SD,4,13.1,Planned_Completion
+1fae544b-6f0f-de03-218d-0034d371b610,Second,Capecitabine,None,PD,3,6.5,Toxicity
+65c7af3c-14b3-ddef-ed74-bd4591396849,First,Gemcitabine_Monotherapy,None,SD,6,0.99,Progression
+65c7af3c-14b3-ddef-ed74-bd4591396849,Second,FOLFOX,None,PD,5,1.13,Toxicity
+7d13d810-21d8-f441-4d0a-f934f91e6d1e,First,NALIRIFOX,None,PR,6,14.99,Planned_Completion
+7d13d810-21d8-f441-4d0a-f934f91e6d1e,Second,FOLFOX,None,PD,3,5.0,Death
+f4a3b9cc-5051-1ac5-a9b1-78138224b4a2,First,Gemcitabine_NabPaclitaxel,None,PD,1,5.28,Progression
+f4a3b9cc-5051-1ac5-a9b1-78138224b4a2,Second,Regorafenib,None,PD,6,1.14,Toxicity
+ecc03ec6-f5d5-339e-4954-8a388561bf0a,First,Gemcitabine_NabPaclitaxel,None,PR,6,2.91,Planned_Completion
+ecc03ec6-f5d5-339e-4954-8a388561bf0a,Second,FOLFOX,None,PR,7,0.49,Progression
+8e21757a-98d0-ce0b-065d-310e7fc94344,First,Gemcitabine_NabPaclitaxel,None,SD,5,3.15,Planned_Completion
+8e21757a-98d0-ce0b-065d-310e7fc94344,Second,Regorafenib,None,SD,6,5.21,Death
+1b1c179d-d73e-3f5a-a24c-316325f0fce4,First,mFOLFIRINOX,None,SD,4,4.22,Planned_Completion
+1b1c179d-d73e-3f5a-a24c-316325f0fce4,Second,FOLFOX,None,PD,4,6.75,Toxicity
+6b4b1376-bfb3-1411-23ed-4bbbb92bac18,First,NALIRIFOX,None,PR,9,4.34,Planned_Completion
+6b4b1376-bfb3-1411-23ed-4bbbb92bac18,Second,Regorafenib,None,PR,4,2.31,Toxicity
+cdea98d2-bd02-e712-eeda-9c1f2e74b3aa,First,Gemcitabine_NabPaclitaxel,None,PD,1,0.64,Progression
+cdea98d2-bd02-e712-eeda-9c1f2e74b3aa,Second,Capecitabine,None,SD,4,1.84,Toxicity
+c8e641e5-a261-8fca-77a6-52156e9cc9bb,First,Gemcitabine_NabPaclitaxel,None,SD,3,1.41,Progression
+c8e641e5-a261-8fca-77a6-52156e9cc9bb,Second,FOLFOX,None,PD,5,1.77,Progression
+1bf0dc68-a9df-2869-0490-f393d8d3a6d2,First,Gemcitabine_NabPaclitaxel,None,SD,5,11.91,Patient_Choice
+1bf0dc68-a9df-2869-0490-f393d8d3a6d2,Second,Gemcitabine_Monotherapy,None,PR,4,6.31,Toxicity
+cbfc3467-4021-a19e-d455-6f0749b5e547,First,FOLFIRINOX,None,PR,9,4.87,Planned_Completion
+cbfc3467-4021-a19e-d455-6f0749b5e547,Second,Gemcitabine_Monotherapy,None,SD,2,4.5,Progression
+87e08411-5591-0712-3b8e-57fa7687ade6,First,Gemcitabine_Monotherapy,None,CR,8,3.86,Planned_Completion
+87e08411-5591-0712-3b8e-57fa7687ade6,Second,FOLFOX,None,PD,4,0.65,Progression
+de2423db-eee7-c203-9b23-da52c3e0af56,First,FOLFIRINOX,None,PD,3,3.78,Progression
+de2423db-eee7-c203-9b23-da52c3e0af56,Second,Gemcitabine_Monotherapy,None,PR,6,1.18,Progression
+6d069bc0-ed2d-48f2-5fca-86851e6fdb26,First,FOLFIRINOX,None,PR,9,3.65,Toxicity
+6d069bc0-ed2d-48f2-5fca-86851e6fdb26,Second,Capecitabine,None,SD,7,0.33,Toxicity
+de13ddb4-f66d-edae-a6e4-f3a21d1d5506,First,FOLFIRINOX,None,PD,2,0.4,Progression
+de13ddb4-f66d-edae-a6e4-f3a21d1d5506,Second,Capecitabine,None,SD,7,1.39,Progression
+3f7269e1-87f0-b2ce-7432-96084629dfdb,First,Gemcitabine_Monotherapy,None,PD,2,1.09,Planned_Completion
+3f7269e1-87f0-b2ce-7432-96084629dfdb,Second,FOLFOX,None,PD,4,6.6,Progression
+befacab7-fe9c-e145-3c95-e79544c8ff72,First,Gemcitabine_NabPaclitaxel,None,PD,3,4.31,Progression
+befacab7-fe9c-e145-3c95-e79544c8ff72,Second,Capecitabine,None,PD,3,0.9,Death
+1af38115-f58a-6cfe-d10a-a685d7425cfe,First,Gemcitabine_NabPaclitaxel,None,SD,5,2.96,Death
+1af38115-f58a-6cfe-d10a-a685d7425cfe,Second,FOLFOX,None,PD,4,2.56,Toxicity
+982ccdf9-79b5-3108-110a-0051e1b2a9d1,First,mFOLFIRINOX,None,PD,2,4.02,Patient_Choice
+982ccdf9-79b5-3108-110a-0051e1b2a9d1,Second,FOLFOX,None,PD,7,12.24,Death
+d31d3140-313a-a8f6-256b-9c175b9cc8bf,First,FOLFIRINOX,None,SD,4,13.85,Progression
+d31d3140-313a-a8f6-256b-9c175b9cc8bf,Second,FOLFOX,None,SD,1,0.29,Toxicity
+24d4ca7e-ec61-718d-4f72-17db5197e3c2,First,FOLFIRINOX,None,PR,7,9.33,Toxicity
+24d4ca7e-ec61-718d-4f72-17db5197e3c2,Second,Gemcitabine_Monotherapy,None,PD,1,2.08,Toxicity
+2a604977-993b-3463-ebc4-b88bea4eeec9,First,Pembrolizumab,Pembrolizumab,CR,10,3.47,Progression
+2a604977-993b-3463-ebc4-b88bea4eeec9,Second,FOLFOX,None,PD,5,1.21,Progression
+2753351c-93d1-830d-48e3-6a5227e67f65,First,FOLFIRINOX,None,CR,11,9.67,Planned_Completion
+2753351c-93d1-830d-48e3-6a5227e67f65,Second,FOLFOX,None,PD,5,0.13,Toxicity
+0569f4d6-8a50-0f6d-1d90-c1be74a5ff79,First,Gemcitabine_NabPaclitaxel,None,PD,2,6.54,Progression
+0569f4d6-8a50-0f6d-1d90-c1be74a5ff79,Second,Gemcitabine_Monotherapy,None,PR,2,1.3,Progression
+2cb54dae-31df-d80d-0e2e-64beb583650e,First,Gemcitabine_NabPaclitaxel,None,SD,5,0.88,Patient_Choice
+9755337d-6de3-f611-0daa-7036d4bc075d,First,Gemcitabine_NabPaclitaxel,None,PR,10,5.12,Planned_Completion
+9755337d-6de3-f611-0daa-7036d4bc075d,Second,Capecitabine,None,PD,1,6.11,Progression
+64c4f732-cd98-0c39-ae43-4ea6841848d7,First,mFOLFIRINOX,None,PR,8,1.8,Patient_Choice
+8128a1a7-fc03-2076-5167-dd51d4061611,First,Gemcitabine_NabPaclitaxel,None,PD,1,1.33,Progression
+8128a1a7-fc03-2076-5167-dd51d4061611,Second,FOLFOX,None,PD,3,2.05,Toxicity
+d9e3c325-caeb-3127-e000-52eabc6b5ecb,First,Gemcitabine_NabPaclitaxel,None,SD,6,4.52,Progression
+d9e3c325-caeb-3127-e000-52eabc6b5ecb,Second,Regorafenib,None,PD,2,0.38,Toxicity
+2e76ae05-7e3a-b901-0b21-2e818958f429,First,FOLFIRINOX,None,PD,1,2.6,Death
+2e76ae05-7e3a-b901-0b21-2e818958f429,Second,FOLFOX,None,PR,2,9.72,Death
+3fd7dd3a-3a62-c8c8-3c9b-4fd6e39d24fb,First,mFOLFIRINOX,None,PD,1,1.27,Death
+3fd7dd3a-3a62-c8c8-3c9b-4fd6e39d24fb,Second,FOLFOX,None,PD,4,4.86,Progression
+6a902ca0-f2e7-3c4a-923c-4d95a47f38f2,First,Gemcitabine_NabPaclitaxel,None,PD,1,2.05,Death
+6a902ca0-f2e7-3c4a-923c-4d95a47f38f2,Second,FOLFOX,None,SD,7,0.31,Progression
+5fa52d1a-01cf-ba0a-0c9b-eb02484361b6,First,Gemcitabine_Monotherapy,None,SD,6,1.18,Progression
+5fa52d1a-01cf-ba0a-0c9b-eb02484361b6,Second,Gemcitabine_Monotherapy,None,SD,3,4.68,Toxicity
+1a072b79-e4bf-8967-8614-ac59ed025e68,First,Gemcitabine_NabPaclitaxel,Olaparib,SD,4,8.51,Planned_Completion
+1a072b79-e4bf-8967-8614-ac59ed025e68,Second,Olaparib,Olaparib,PD,2,8.55,Progression
+0d4d5f75-1b53-7210-d55d-8a2f17e3e2a3,First,FOLFIRINOX,None,SD,4,2.15,Patient_Choice
+0d4d5f75-1b53-7210-d55d-8a2f17e3e2a3,Second,Capecitabine,None,PD,6,6.82,Toxicity
+195f7a95-b07b-6dd1-ecc2-6fcd67729e4f,First,FOLFIRINOX,None,PD,1,3.48,Death
+195f7a95-b07b-6dd1-ecc2-6fcd67729e4f,Second,Regorafenib,None,PD,7,1.0,Progression
+cd51916e-5219-2745-fac5-24e53d68a561,First,Gemcitabine_NabPaclitaxel,None,PD,2,1.09,Progression
+cd51916e-5219-2745-fac5-24e53d68a561,Second,FOLFOX,None,PD,6,16.78,Progression
+a479c8b2-a0b8-c604-c78b-d71194513c43,First,FOLFIRINOX,None,SD,3,1.51,Toxicity
+a479c8b2-a0b8-c604-c78b-d71194513c43,Second,Regorafenib,None,SD,4,3.6,Toxicity
+22720376-bd31-eb65-c76c-4e1a9dc4cb57,First,Gemcitabine_NabPaclitaxel,None,SD,5,0.54,Planned_Completion
+22720376-bd31-eb65-c76c-4e1a9dc4cb57,Second,FOLFOX,None,PD,2,0.08,Progression
+83a41c2a-52b5-9863-893b-c13ad3785525,First,FOLFIRINOX,None,PR,7,3.89,Planned_Completion
+83a41c2a-52b5-9863-893b-c13ad3785525,Second,FOLFOX,None,SD,3,0.81,Progression
+767a04eb-d56d-43ff-db89-d918f78c3a99,First,FOLFIRINOX,None,CR,10,3.3,Progression
+767a04eb-d56d-43ff-db89-d918f78c3a99,Second,FOLFOX,None,SD,6,2.99,Progression
+a3ba6b25-afa8-8a7d-6295-39a7c8bd41f7,First,FOLFIRINOX,None,PD,3,0.85,Death
+a3ba6b25-afa8-8a7d-6295-39a7c8bd41f7,Second,FOLFOX,None,PD,5,0.39,Progression
+23c7dcd2-0fa6-6bfb-4436-f0a23ff2ced5,First,mFOLFIRINOX,None,PR,8,5.08,Planned_Completion
+23c7dcd2-0fa6-6bfb-4436-f0a23ff2ced5,Second,FOLFOX,None,PD,7,13.86,Toxicity
+6ab942fc-2a45-5a31-7a56-2a3f6f01a1cb,First,mFOLFIRINOX,None,SD,5,3.91,Progression
+6ab942fc-2a45-5a31-7a56-2a3f6f01a1cb,Second,FOLFOX,None,SD,7,9.48,Progression
+5e154105-5696-b18e-3b89-b4209aab60be,First,Gemcitabine_NabPaclitaxel,None,SD,5,1.97,Toxicity
+5e154105-5696-b18e-3b89-b4209aab60be,Second,Gemcitabine_Monotherapy,None,PR,4,4.37,Progression
+53d6bfd2-bca8-670a-5dcb-e545814b362b,First,Gemcitabine_Monotherapy,None,SD,3,1.55,Progression
+53d6bfd2-bca8-670a-5dcb-e545814b362b,Second,Regorafenib,None,SD,4,2.64,Progression
+f2e85a63-caf1-cad1-4c00-18bd3c463327,First,mFOLFIRINOX,None,SD,5,2.74,Patient_Choice
+f2e85a63-caf1-cad1-4c00-18bd3c463327,Second,Regorafenib,None,SD,5,2.54,Death
+7b1cf221-daac-3cc2-ea95-c8a7abbc60a0,First,FOLFIRINOX,None,SD,6,4.3,Death
+8912411f-75e3-2282-540f-7adcc531bcaf,First,NALIRIFOX,None,PR,10,1.56,Progression
+8912411f-75e3-2282-540f-7adcc531bcaf,Second,FOLFOX,None,PR,2,7.19,Progression
+a70ff6c5-7d3f-aebc-d93b-429bf5e2ded2,First,mFOLFIRINOX,None,SD,4,2.21,Toxicity
+a70ff6c5-7d3f-aebc-d93b-429bf5e2ded2,Second,FOLFOX,None,SD,1,1.06,Progression
+88607cb1-8d93-e545-cdec-9f7233cda2b2,First,FOLFIRINOX,None,SD,5,5.05,Progression
+88607cb1-8d93-e545-cdec-9f7233cda2b2,Second,Capecitabine,None,PD,5,1.04,Toxicity
+49c490fb-128d-33d8-a206-e3c6c42b283a,First,Gemcitabine_NabPaclitaxel,None,PD,3,0.58,Progression
+49c490fb-128d-33d8-a206-e3c6c42b283a,Second,Capecitabine,None,SD,1,8.85,Progression
+33d0c994-08ff-67b2-bc21-f5522d3d7444,First,mFOLFIRINOX,None,PR,11,5.3,Planned_Completion
+33d0c994-08ff-67b2-bc21-f5522d3d7444,Second,FOLFOX,None,SD,3,0.62,Progression
+9d47fd9c-f3d7-c45a-21d1-7dd5eb3fa854,First,Gemcitabine_NabPaclitaxel,None,SD,5,0.71,Death
+9d47fd9c-f3d7-c45a-21d1-7dd5eb3fa854,Second,Regorafenib,None,PD,6,0.92,Progression
+b9c87fd9-9f32-fed6-1858-31e8a2df4232,First,Gemcitabine_NabPaclitaxel,None,PR,9,3.45,Planned_Completion
+ef99c091-85f2-3bfc-15a1-58fb94aeba3e,First,Gemcitabine_NabPaclitaxel,None,SD,6,6.98,Progression
+ef99c091-85f2-3bfc-15a1-58fb94aeba3e,Second,Gemcitabine_Monotherapy,None,PD,2,11.85,Progression
+f5792d00-f5be-879e-232d-2a85b931d313,First,Gemcitabine_Monotherapy,None,PD,1,0.59,Progression
+97fb8b39-681e-9cbf-cd06-bed02b5d8159,First,mFOLFIRINOX,None,SD,5,1.73,Patient_Choice
+97fb8b39-681e-9cbf-cd06-bed02b5d8159,Second,FOLFOX,None,PD,5,7.99,Death
+cb8ca565-ff25-19b6-c85a-0da671f7bae3,First,FOLFIRINOX,None,PR,12,7.07,Planned_Completion
+cb8ca565-ff25-19b6-c85a-0da671f7bae3,Second,Gemcitabine_Monotherapy,None,PD,3,2.83,Death
+40ddbb42-1711-2650-f22e-d45fee6e5ba3,First,mFOLFIRINOX,None,PD,2,5.15,Progression
+40ddbb42-1711-2650-f22e-d45fee6e5ba3,Second,FOLFOX,None,SD,4,1.31,Progression
+185524eb-0cd6-6126-970f-36c0b8cb9796,First,Gemcitabine_NabPaclitaxel,None,PD,3,3.35,Death
+185524eb-0cd6-6126-970f-36c0b8cb9796,Second,Capecitabine,None,PD,4,0.05,Death
+2bd9bf35-2aef-a7a0-9dbd-090a85429803,First,Gemcitabine_NabPaclitaxel,None,SD,4,4.07,Death
+2bd9bf35-2aef-a7a0-9dbd-090a85429803,Second,FOLFOX,None,PD,6,1.87,Death
+928ace61-0202-b23a-90a0-9a70211c70d3,First,Gemcitabine_NabPaclitaxel,None,PD,2,2.51,Planned_Completion
+928ace61-0202-b23a-90a0-9a70211c70d3,Second,Gemcitabine_Monotherapy,None,SD,7,0.69,Toxicity
+cc9b4d3e-eb8c-d63a-c390-7bb8ba4dbe11,First,Gemcitabine_NabPaclitaxel,None,PD,3,1.91,Progression
+cc9b4d3e-eb8c-d63a-c390-7bb8ba4dbe11,Second,FOLFOX,None,PD,3,0.89,Progression
+997ef4ae-3c57-65eb-7dfd-c0cd8488649b,First,Gemcitabine_Monotherapy,None,PR,6,2.43,Planned_Completion
+997ef4ae-3c57-65eb-7dfd-c0cd8488649b,Second,Gemcitabine_Monotherapy,None,SD,1,4.41,Toxicity
+1ea6dc46-d854-d20f-ee65-7f79239e615f,First,Gemcitabine_NabPaclitaxel,None,SD,3,2.06,Toxicity
+1ea6dc46-d854-d20f-ee65-7f79239e615f,Second,Capecitabine,None,PD,3,1.39,Progression
+6b29e9e1-ba93-58e2-a869-ba6e7cfa3e6c,First,Gemcitabine_Monotherapy,None,PD,3,3.41,Toxicity
+6b29e9e1-ba93-58e2-a869-ba6e7cfa3e6c,Second,Gemcitabine_Monotherapy,None,SD,3,5.93,Toxicity
+abd5d268-3550-d6d1-c639-eda6ebef83f7,First,Gemcitabine_NabPaclitaxel,Olaparib,SD,6,3.58,Progression
+abd5d268-3550-d6d1-c639-eda6ebef83f7,Second,Olaparib,Olaparib,SD,2,0.03,Toxicity
+e5fb599c-bcfc-ba55-5569-48bcbb045089,First,Gemcitabine_NabPaclitaxel,None,PR,8,1.8,Toxicity
+4541c723-a26e-6c90-c335-4e89d12e66dc,First,Gemcitabine_NabPaclitaxel,None,PD,2,3.23,Progression
+4541c723-a26e-6c90-c335-4e89d12e66dc,Second,Regorafenib,None,PD,3,7.02,Progression
+507f2377-883e-0d02-5d3b-b025cb93bb2d,First,Gemcitabine_NabPaclitaxel,None,SD,4,1.46,Progression
+25d5218f-f617-9ac8-2859-3cac5021e30d,First,Gemcitabine_NabPaclitaxel,None,SD,3,1.82,Toxicity
+25d5218f-f617-9ac8-2859-3cac5021e30d,Second,FOLFOX,None,PD,3,1.8,Toxicity
+701a7a9e-8e15-57c8-efa6-0ca816150ec2,First,Gemcitabine_NabPaclitaxel,None,SD,6,1.12,Planned_Completion
+701a7a9e-8e15-57c8-efa6-0ca816150ec2,Second,Gemcitabine_Monotherapy,None,SD,2,11.73,Progression
+baccaebf-20bf-78a1-6221-3f76bccc3baf,First,Gemcitabine_NabPaclitaxel,None,PD,3,2.05,Progression
+baccaebf-20bf-78a1-6221-3f76bccc3baf,Second,Regorafenib,None,SD,4,1.04,Death
+efa6dec3-f2f5-ff95-8d90-f41a2d0e4d9f,First,Gemcitabine_NabPaclitaxel,None,SD,4,0.5,Toxicity
+7ab7f6b8-9cd8-5235-c7c1-d6b55c5c4621,First,FOLFIRINOX,None,PD,2,2.5,Progression
+7ab7f6b8-9cd8-5235-c7c1-d6b55c5c4621,Second,FOLFOX,None,SD,3,0.26,Progression
+fc93e28a-a6e4-1a79-6059-182e23d2543a,First,Gemcitabine_NabPaclitaxel,None,SD,4,1.73,Toxicity
+fc93e28a-a6e4-1a79-6059-182e23d2543a,Second,FOLFOX,None,PD,1,3.12,Progression
+f3817e44-d8a9-8869-b7bf-228401408248,First,Gemcitabine_NabPaclitaxel,None,PR,7,4.02,Progression
+f3817e44-d8a9-8869-b7bf-228401408248,Second,Gemcitabine_Monotherapy,None,SD,4,2.39,Death
+d9bc9340-455e-1af6-1e54-9cae6c7e660d,First,mFOLFIRINOX,None,PD,3,0.6,Progression
+d9bc9340-455e-1af6-1e54-9cae6c7e660d,Second,Regorafenib,None,SD,7,0.71,Progression
+afa402ea-0849-f72c-9698-13877a697cd7,First,FOLFIRINOX,None,PR,12,2.68,Planned_Completion
+afa402ea-0849-f72c-9698-13877a697cd7,Second,Gemcitabine_Monotherapy,None,SD,4,0.01,Death
+4b9ca62a-6e69-c7fe-d34d-61e2b8fb5bee,First,FOLFIRINOX,None,PD,2,2.7,Progression
+4b9ca62a-6e69-c7fe-d34d-61e2b8fb5bee,Second,FOLFOX,None,SD,3,0.45,Progression
+eb1f0210-83fb-607c-4d4b-1d100318703b,First,mFOLFIRINOX,None,PR,8,0.6,Planned_Completion
+eb1f0210-83fb-607c-4d4b-1d100318703b,Second,FOLFOX,None,PD,4,0.01,Death
+1c4f85a8-8b7e-ad89-c802-e2cabcfc6241,First,Gemcitabine_NabPaclitaxel,None,PD,1,3.34,Progression
+1c4f85a8-8b7e-ad89-c802-e2cabcfc6241,Second,FOLFOX,None,SD,7,4.79,Toxicity
+e11340b7-0b4e-ca8c-ff3d-a9d06413c1de,First,Gemcitabine_NabPaclitaxel,None,SD,6,2.4,Death
+e11340b7-0b4e-ca8c-ff3d-a9d06413c1de,Second,Capecitabine,None,PD,2,2.2,Toxicity
+d63edaaf-c72a-4412-48ae-392faf3b1b9d,First,FOLFIRINOX,None,SD,6,0.56,Toxicity
+d63edaaf-c72a-4412-48ae-392faf3b1b9d,Second,Capecitabine,None,SD,3,9.99,Death
+ffc553de-aa6e-910f-1b3e-4f790b106820,First,Gemcitabine_NabPaclitaxel,None,SD,4,2.96,Death
+ffc553de-aa6e-910f-1b3e-4f790b106820,Second,Gemcitabine_Monotherapy,None,PD,1,3.13,Toxicity
+a66e97d0-22f3-4614-aa6a-509b0622abc1,First,FOLFIRINOX,None,SD,5,8.99,Planned_Completion
+a66e97d0-22f3-4614-aa6a-509b0622abc1,Second,Capecitabine,None,PD,6,1.08,Progression
+e5a3fb17-ae44-325d-1727-1f9c9f91903a,First,NALIRIFOX,None,SD,3,2.98,Death
+e5a3fb17-ae44-325d-1727-1f9c9f91903a,Second,Gemcitabine_Monotherapy,None,PR,3,12.38,Progression
+c6da4385-dab6-762a-249d-14e4740af755,First,Gemcitabine_NabPaclitaxel,None,PR,11,2.29,Patient_Choice
+c6da4385-dab6-762a-249d-14e4740af755,Second,FOLFOX,None,PR,3,0.65,Death
+e91f963c-03bb-0769-32bd-8321cef0026c,First,FOLFIRINOX,None,PD,1,0.44,Progression
+e91f963c-03bb-0769-32bd-8321cef0026c,Second,FOLFOX,None,PD,3,11.3,Toxicity
+0941f59a-e8d0-d52a-a801-3f6d49f5e6c6,First,Gemcitabine_NabPaclitaxel,None,PD,3,4.46,Patient_Choice
+0941f59a-e8d0-d52a-a801-3f6d49f5e6c6,Second,Gemcitabine_Monotherapy,None,PR,3,3.36,Progression
+0d397408-2804-f6be-0163-d9800166b3f0,First,NALIRIFOX,None,SD,6,5.01,Progression
+0d397408-2804-f6be-0163-d9800166b3f0,Second,Gemcitabine_Monotherapy,None,SD,1,1.73,Death
+cd2de975-fae4-57fb-9b1d-e995d1ea43dd,First,mFOLFIRINOX,None,PD,1,1.36,Progression
+d972dba1-49ad-3bf7-3d11-cc32f6937b8e,First,mFOLFIRINOX,None,PD,2,2.09,Progression
+cd0bf794-ab4c-1caa-0ea6-c09f3eb0a378,First,mFOLFIRINOX,None,PD,3,0.49,Progression
+cd0bf794-ab4c-1caa-0ea6-c09f3eb0a378,Second,Gemcitabine_Monotherapy,None,PD,2,1.5,Progression
+c5a8e563-1ec7-6e43-ed84-0055f7dbb513,First,mFOLFIRINOX,None,PD,1,6.43,Death
+c5a8e563-1ec7-6e43-ed84-0055f7dbb513,Second,FOLFOX,None,PR,7,0.46,Progression
+d685df21-d1de-64b0-b2b8-0b2fd89bd6ad,First,NALIRIFOX,None,SD,4,0.3,Death
+d685df21-d1de-64b0-b2b8-0b2fd89bd6ad,Second,Regorafenib,None,SD,3,6.27,Death
+33a7fe0e-74c9-2756-0a47-5b0672511d01,First,NALIRIFOX,None,PD,2,2.29,Progression
+33a7fe0e-74c9-2756-0a47-5b0672511d01,Second,FOLFOX,None,PR,4,1.5,Progression
+8128f166-b287-19f0-1ffa-ff8d1d1d5eeb,First,FOLFIRINOX,None,PR,9,4.12,Progression
+8128f166-b287-19f0-1ffa-ff8d1d1d5eeb,Second,Gemcitabine_Monotherapy,None,SD,2,1.8,Death
+a14874cc-8c5b-46d9-bec4-a6308a32de6d,First,Gemcitabine_NabPaclitaxel,None,PD,3,1.51,Patient_Choice
+27bc09e6-72e3-4be4-d9e3-ba4e1605b338,First,Gemcitabine_Monotherapy,None,PD,2,0.93,Progression
+27bc09e6-72e3-4be4-d9e3-ba4e1605b338,Second,Regorafenib,None,PD,1,0.44,Death
+316b2aca-0d93-1b8e-bc10-20bcd0364b96,First,Gemcitabine_NabPaclitaxel,None,PD,1,9.89,Progression
+b5bc5072-1998-504c-4550-720e040827cd,First,NALIRIFOX,None,PR,8,0.75,Planned_Completion
+b5bc5072-1998-504c-4550-720e040827cd,Second,FOLFOX,None,SD,7,0.68,Progression
+9c8e1f2b-bfda-4182-faee-b36685c60ac2,First,mFOLFIRINOX,None,CR,8,16.47,Planned_Completion
+9c8e1f2b-bfda-4182-faee-b36685c60ac2,Second,Gemcitabine_Monotherapy,None,PD,2,2.04,Death
+9dc66cb6-11f8-b543-0df3-bb8e82625c28,First,mFOLFIRINOX,None,PR,8,7.54,Toxicity
+9dc66cb6-11f8-b543-0df3-bb8e82625c28,Second,Regorafenib,None,PD,6,2.18,Progression
+e2575f93-3819-47a4-0ad7-7c5a011efe6c,First,NALIRIFOX,None,PR,7,5.8,Planned_Completion
+e2575f93-3819-47a4-0ad7-7c5a011efe6c,Second,FOLFOX,None,PD,5,11.96,Death
+2c521b46-695c-24e1-b5a6-ec28757c71f0,First,Gemcitabine_NabPaclitaxel,None,SD,5,1.38,Death
+2c521b46-695c-24e1-b5a6-ec28757c71f0,Second,Regorafenib,None,PD,5,1.23,Progression
+2efc089f-c52f-4f46-177b-07205f041d20,First,Gemcitabine_NabPaclitaxel,Olaparib,SD,5,2.96,Death
+2efc089f-c52f-4f46-177b-07205f041d20,Second,Olaparib,Olaparib,PD,5,2.1,Progression
+75643af2-978a-e731-fae3-0fad605a3b59,First,Gemcitabine_NabPaclitaxel,None,PD,2,1.56,Patient_Choice
+75643af2-978a-e731-fae3-0fad605a3b59,Second,Regorafenib,None,SD,2,0.39,Death
+a2eba838-4125-b7c5-c8b9-876e8b02e285,First,Gemcitabine_NabPaclitaxel,None,PD,3,2.11,Progression
+a2eba838-4125-b7c5-c8b9-876e8b02e285,Second,Gemcitabine_Monotherapy,None,PD,1,4.05,Progression
+252741a1-7250-72d5-9289-ab0edf68b60c,First,Gemcitabine_Monotherapy,None,PD,3,0.52,Death
+252741a1-7250-72d5-9289-ab0edf68b60c,Second,FOLFOX,None,PD,3,2.8,Progression
+4d24ca6f-8a90-0321-f22e-a8993f8fe6db,First,Gemcitabine_NabPaclitaxel,None,PD,1,2.41,Toxicity
+b324842c-899c-b0a3-93f8-efae6b1a2fde,First,Gemcitabine_NabPaclitaxel,None,SD,4,6.65,Toxicity
+b324842c-899c-b0a3-93f8-efae6b1a2fde,Second,Capecitabine,None,SD,4,2.17,Death
+f0cacb94-7153-4aca-a634-24e141eb0999,First,NALIRIFOX,None,PD,3,3.74,Progression
+f0cacb94-7153-4aca-a634-24e141eb0999,Second,Gemcitabine_Monotherapy,None,PD,2,2.37,Progression
+822367b2-762f-3fb9-2600-18ff286da0c2,First,Gemcitabine_NabPaclitaxel,None,PD,2,0.57,Planned_Completion
+79631f31-e9e9-48e4-676e-cc3eb0dd327b,First,FOLFIRINOX,None,PD,2,1.57,Planned_Completion
+79631f31-e9e9-48e4-676e-cc3eb0dd327b,Second,Capecitabine,None,SD,6,1.49,Progression
+2254063b-f931-202e-1e85-0a30211c30cf,First,NALIRIFOX,None,PR,9,3.55,Planned_Completion
+2254063b-f931-202e-1e85-0a30211c30cf,Second,FOLFOX,None,SD,2,3.8,Progression
+4e011ef4-17e9-aae4-472f-f57ef2a66016,First,FOLFIRINOX,None,PD,2,1.85,Progression
+4e011ef4-17e9-aae4-472f-f57ef2a66016,Second,Gemcitabine_Monotherapy,None,PD,3,0.13,Progression
+9c69ae0c-c91b-cc04-6d8b-10a49d5cd9bd,First,Gemcitabine_NabPaclitaxel,None,PD,1,2.2,Progression
+9c69ae0c-c91b-cc04-6d8b-10a49d5cd9bd,Second,Regorafenib,None,SD,5,0.01,Toxicity
+696c705c-f8b1-c63c-a277-0dc86699c703,First,Gemcitabine_NabPaclitaxel,None,PR,11,1.41,Planned_Completion
+696c705c-f8b1-c63c-a277-0dc86699c703,Second,Capecitabine,None,SD,4,1.02,Progression
+37b680cc-d711-c5cc-68a6-0286274815fa,First,NALIRIFOX,None,PR,7,0.5,Toxicity
+37b680cc-d711-c5cc-68a6-0286274815fa,Second,Capecitabine,None,PD,5,4.12,Death
+512997d9-9a00-b5c6-969b-3d00f2fb03f7,First,NALIRIFOX,None,PD,2,2.82,Progression
+6b1c43ea-4c75-b922-093b-37a0eba31388,First,Gemcitabine_Monotherapy,None,PD,3,2.65,Progression
+6b1c43ea-4c75-b922-093b-37a0eba31388,Second,FOLFOX,None,SD,2,2.45,Death
+39c07447-25de-6068-7960-c24d7a2eb8e3,First,Pembrolizumab,Pembrolizumab,PD,2,1.56,Death
+39c07447-25de-6068-7960-c24d7a2eb8e3,Second,Regorafenib,None,SD,7,14.02,Death
+90d66d61-59d2-8812-928c-9a651861c992,First,mFOLFIRINOX,None,PR,12,2.06,Planned_Completion
+90d66d61-59d2-8812-928c-9a651861c992,Second,Regorafenib,None,SD,2,6.74,Progression
+a5dff3a4-8c0a-8582-b3b6-6a3996f78512,First,Gemcitabine_NabPaclitaxel,None,SD,4,4.25,Toxicity
+a5dff3a4-8c0a-8582-b3b6-6a3996f78512,Second,FOLFOX,None,SD,2,12.27,Death
+50f36920-9ddc-604a-a705-da50964f7822,First,mFOLFIRINOX,None,CR,12,1.31,Planned_Completion
+50f36920-9ddc-604a-a705-da50964f7822,Second,Capecitabine,None,PD,2,0.49,Progression
+8c94b9f0-57bb-50f0-c995-28793f0c7f45,First,Gemcitabine_NabPaclitaxel,None,PD,2,4.11,Progression
+8c94b9f0-57bb-50f0-c995-28793f0c7f45,Second,Regorafenib,None,PR,6,4.01,Toxicity
+a0425a9c-8798-0a1c-6e71-6c3f326cd3e8,First,Gemcitabine_Monotherapy,None,PR,9,2.44,Planned_Completion
+a0425a9c-8798-0a1c-6e71-6c3f326cd3e8,Second,Gemcitabine_Monotherapy,None,SD,2,4.08,Progression
+8342e10e-f636-a4d0-5c54-0a0086c09ef7,First,Gemcitabine_Monotherapy,None,SD,3,0.5,Progression
+8342e10e-f636-a4d0-5c54-0a0086c09ef7,Second,FOLFOX,None,PD,2,4.33,Progression
+e2eb4cb1-8eed-e034-bc98-be76ceecc68a,First,Gemcitabine_NabPaclitaxel,None,SD,3,5.11,Planned_Completion
+e2eb4cb1-8eed-e034-bc98-be76ceecc68a,Second,FOLFOX,None,PD,5,0.2,Progression
+80ee165e-d9a8-69b8-ebca-678c20d62a86,First,Gemcitabine_NabPaclitaxel,None,PD,3,0.61,Progression
+80ee165e-d9a8-69b8-ebca-678c20d62a86,Second,FOLFOX,None,SD,5,4.91,Progression
+ccc44ea7-44cd-bfb8-8530-bffabbbf933a,First,Gemcitabine_NabPaclitaxel,None,PD,1,1.77,Progression
+ccc44ea7-44cd-bfb8-8530-bffabbbf933a,Second,Gemcitabine_Monotherapy,None,PD,7,2.09,Progression
+d65eb0c4-84f0-4b51-507f-d72d3ef4bc21,First,Gemcitabine_NabPaclitaxel,None,SD,4,1.5,Toxicity
+d65eb0c4-84f0-4b51-507f-d72d3ef4bc21,Second,Capecitabine,None,PD,7,7.85,Death
+1da8c94a-0aaa-9412-7e80-11236248fb01,First,FOLFIRINOX,None,PR,7,3.3,Planned_Completion
+1da8c94a-0aaa-9412-7e80-11236248fb01,Second,Capecitabine,None,PD,6,0.54,Progression
+d78cddf8-de57-5c77-1272-77e00e529048,First,NALIRIFOX,None,PR,9,29.13,Planned_Completion
+d78cddf8-de57-5c77-1272-77e00e529048,Second,Gemcitabine_Monotherapy,None,PD,1,8.39,Progression
+47d626ad-13e0-894a-0e39-b2f1d2672420,First,Gemcitabine_NabPaclitaxel,None,SD,6,2.85,Toxicity
+47d626ad-13e0-894a-0e39-b2f1d2672420,Second,Gemcitabine_Monotherapy,None,SD,2,6.04,Toxicity
+2c495d2c-7cd0-bd1e-5589-8bdc90b72e13,First,FOLFIRINOX,None,PR,9,2.18,Planned_Completion
+2c495d2c-7cd0-bd1e-5589-8bdc90b72e13,Second,Capecitabine,None,PD,3,5.91,Progression
+be21199d-1108-d1b7-505b-50ddbb1444a9,First,Gemcitabine_NabPaclitaxel,None,SD,4,9.28,Patient_Choice
+be21199d-1108-d1b7-505b-50ddbb1444a9,Second,FOLFOX,None,SD,2,0.28,Toxicity
+d3c1a336-6fc9-cdfc-03c2-413ce71d23f5,First,Gemcitabine_NabPaclitaxel,None,SD,5,7.35,Planned_Completion
+d3c1a336-6fc9-cdfc-03c2-413ce71d23f5,Second,Regorafenib,None,SD,5,1.42,Progression
+5f4c88d2-6a4b-346b-db46-bb34b4c7379f,First,Gemcitabine_NabPaclitaxel,None,SD,6,1.4,Toxicity
+5f4c88d2-6a4b-346b-db46-bb34b4c7379f,Second,Capecitabine,None,PD,2,2.16,Progression
+99d0ad4e-3d4a-b727-2753-2cc9b58c8e00,First,NALIRIFOX,None,PR,8,6.17,Death
+99d0ad4e-3d4a-b727-2753-2cc9b58c8e00,Second,FOLFOX,None,PD,7,0.86,Progression
+5d6b5af1-8220-9dfc-1ea2-dc51ab1fd785,First,FOLFIRINOX,None,PD,2,1.13,Progression
+4f9b2c6b-6caa-1b47-c5a8-aa89731796e4,First,FOLFIRINOX,None,SD,3,10.81,Toxicity
+4f9b2c6b-6caa-1b47-c5a8-aa89731796e4,Second,Regorafenib,None,SD,3,6.74,Death
+b49582f6-24e0-fbe2-b00a-d110c546062b,First,FOLFIRINOX,None,SD,6,3.74,Toxicity
+a411470d-ecf7-5e1c-6349-97e4c0c9adf6,First,Gemcitabine_NabPaclitaxel,None,SD,6,3.53,Toxicity
+a411470d-ecf7-5e1c-6349-97e4c0c9adf6,Second,Capecitabine,None,PD,4,0.21,Toxicity
+3584cd7e-acca-344b-02bf-0c045568ab34,First,Gemcitabine_NabPaclitaxel,None,SD,4,12.63,Patient_Choice
+3584cd7e-acca-344b-02bf-0c045568ab34,Second,Gemcitabine_Monotherapy,None,PR,2,6.0,Progression
+29eb9b00-777b-64cd-866c-2fe0c1abb89a,First,mFOLFIRINOX,None,PD,2,3.18,Progression
+29eb9b00-777b-64cd-866c-2fe0c1abb89a,Second,Gemcitabine_Monotherapy,None,PD,5,0.19,Progression
+d61809b9-6af1-e85d-2a78-df5bb62535c8,First,Gemcitabine_NabPaclitaxel,None,SD,5,9.39,Planned_Completion
+d61809b9-6af1-e85d-2a78-df5bb62535c8,Second,Gemcitabine_Monotherapy,None,PD,5,3.71,Toxicity
+8e54032e-f540-45ce-fd37-d209eb9d18a3,First,Gemcitabine_NabPaclitaxel,None,CR,11,3.18,Planned_Completion
+8e54032e-f540-45ce-fd37-d209eb9d18a3,Second,Gemcitabine_Monotherapy,None,PD,1,0.63,Death
+fd85b878-cd37-a873-d6cd-461d3352b155,First,Gemcitabine_NabPaclitaxel,None,PD,2,1.62,Toxicity
+fd85b878-cd37-a873-d6cd-461d3352b155,Second,Gemcitabine_Monotherapy,None,PD,7,0.35,Death
+72c03979-80be-32e0-243f-a0cea6a48572,First,Gemcitabine_NabPaclitaxel,None,SD,5,2.62,Progression
+147e1c1f-541e-a6d7-647f-a53fd7cb63fb,First,Gemcitabine_NabPaclitaxel,None,PR,9,1.19,Planned_Completion
+147e1c1f-541e-a6d7-647f-a53fd7cb63fb,Second,Gemcitabine_Monotherapy,None,SD,2,0.68,Progression
+6f0c2470-0a8d-e60b-c15d-5175d5e07afa,First,NALIRIFOX,None,PR,12,5.58,Planned_Completion
+6f0c2470-0a8d-e60b-c15d-5175d5e07afa,Second,Gemcitabine_Monotherapy,None,PR,3,2.01,Progression
+26928106-eb3f-13a0-7825-cf597acecec5,First,FOLFIRINOX,None,SD,4,4.22,Toxicity
+26928106-eb3f-13a0-7825-cf597acecec5,Second,Capecitabine,None,PD,2,6.79,Progression
+e837f167-3e7c-539e-2e51-35864e6c97c8,First,FOLFIRINOX,None,SD,4,6.32,Planned_Completion
+e837f167-3e7c-539e-2e51-35864e6c97c8,Second,FOLFOX,None,SD,2,0.57,Progression
+3b9c3514-a1d0-c5a7-0b6e-1f68f0d32a58,First,FOLFIRINOX,None,PD,3,5.38,Progression
+3b9c3514-a1d0-c5a7-0b6e-1f68f0d32a58,Second,FOLFOX,None,PD,3,7.68,Death
+7d7d960d-31c3-590d-4ac4-6678314baeb1,First,Gemcitabine_NabPaclitaxel,None,PR,6,1.85,Toxicity
+7d7d960d-31c3-590d-4ac4-6678314baeb1,Second,Capecitabine,None,PD,3,0.39,Progression
+3e60fd82-44d4-d5a2-1588-9523038f6d4a,First,mFOLFIRINOX,None,PR,6,4.38,Patient_Choice
+3e60fd82-44d4-d5a2-1588-9523038f6d4a,Second,Gemcitabine_Monotherapy,None,PR,3,0.34,Progression
+a3390358-daa7-b2e4-d7f5-688bd7303741,First,mFOLFIRINOX,None,SD,6,2.01,Progression
+a3390358-daa7-b2e4-d7f5-688bd7303741,Second,FOLFOX,None,SD,1,3.82,Progression
+ab9270c7-6824-7f15-a62e-a1d48e615d2b,First,mFOLFIRINOX,None,PD,2,0.83,Death
+ab9270c7-6824-7f15-a62e-a1d48e615d2b,Second,Gemcitabine_Monotherapy,None,PD,3,2.69,Progression
+0ee0328c-9d23-fc06-c34d-9cbccb609981,First,mFOLFIRINOX,None,PR,10,1.13,Toxicity
+0ee0328c-9d23-fc06-c34d-9cbccb609981,Second,FOLFOX,None,PD,5,3.63,Progression
+8a1e7851-be60-fad4-5dda-0c0fb996493e,First,mFOLFIRINOX,None,PD,1,6.38,Toxicity
+8a1e7851-be60-fad4-5dda-0c0fb996493e,Second,FOLFOX,None,PR,6,0.14,Progression
+d82fc476-ee6f-da09-56a5-1586e195642c,First,FOLFIRINOX,None,PR,12,9.19,Planned_Completion
+d82fc476-ee6f-da09-56a5-1586e195642c,Second,Gemcitabine_Monotherapy,None,PD,2,14.6,Progression
+c4c4c717-8806-6cbc-7b89-df3654c36e11,First,mFOLFIRINOX,None,PD,3,2.5,Progression
+813a03be-5eaf-a7d7-da1d-b05cb06c9ae6,First,NALIRIFOX,None,SD,6,3.46,Progression
+813a03be-5eaf-a7d7-da1d-b05cb06c9ae6,Second,FOLFOX,None,PD,1,2.22,Toxicity
+964dc12b-4e13-353e-e8d8-6a756e4d2742,First,Gemcitabine_Monotherapy,None,PD,1,3.35,Progression
+964dc12b-4e13-353e-e8d8-6a756e4d2742,Second,Gemcitabine_Monotherapy,None,PR,6,0.74,Death
+5730f558-625c-1b9a-d9ab-93921ec3355b,First,FOLFIRINOX,None,PD,3,0.5,Progression
+5730f558-625c-1b9a-d9ab-93921ec3355b,Second,Gemcitabine_Monotherapy,None,PD,4,1.75,Progression
+880a8dd1-d914-f9c2-7fb2-77db953a1009,First,mFOLFIRINOX,None,SD,6,1.74,Toxicity
+880a8dd1-d914-f9c2-7fb2-77db953a1009,Second,Capecitabine,None,PD,7,3.61,Progression
+6607897e-059d-bd04-1adf-f35e8459c33b,First,FOLFIRINOX,None,PD,1,4.49,Planned_Completion
+6607897e-059d-bd04-1adf-f35e8459c33b,Second,Gemcitabine_Monotherapy,None,PD,1,3.33,Progression
+a17e38c1-a104-d040-ead6-a446ff8a6e32,First,Gemcitabine_NabPaclitaxel,None,SD,3,2.97,Toxicity
+a17e38c1-a104-d040-ead6-a446ff8a6e32,Second,Capecitabine,None,PR,2,1.85,Death
+56bf3e31-0230-1e58-2d71-1246643995a8,First,mFOLFIRINOX,None,PD,3,2.07,Progression
+56bf3e31-0230-1e58-2d71-1246643995a8,Second,Regorafenib,None,SD,6,5.84,Death
+065acf0b-4258-c51e-310c-e51451040e6a,First,NALIRIFOX,None,PR,6,9.47,Toxicity
+065acf0b-4258-c51e-310c-e51451040e6a,Second,FOLFOX,None,PD,3,2.68,Progression
+72bdb728-b0d8-442c-ed6e-0c719ba34783,First,NALIRIFOX,None,SD,6,0.63,Planned_Completion
+72bdb728-b0d8-442c-ed6e-0c719ba34783,Second,Regorafenib,None,PD,3,4.87,Progression
+9935cd1d-2474-b9aa-4eba-9e566b96b205,First,mFOLFIRINOX,None,PD,1,5.85,Progression
+9935cd1d-2474-b9aa-4eba-9e566b96b205,Second,FOLFOX,None,PD,5,0.7,Progression
+472c74ef-6a5f-9e4a-01df-5c369107b749,First,mFOLFIRINOX,None,SD,3,3.22,Progression
+472c74ef-6a5f-9e4a-01df-5c369107b749,Second,Regorafenib,None,PD,4,7.62,Progression
+a23ebc60-869c-8af0-b3fa-004f2b979572,First,Gemcitabine_NabPaclitaxel,None,PD,2,1.55,Progression
+a23ebc60-869c-8af0-b3fa-004f2b979572,Second,FOLFOX,None,SD,3,1.37,Progression
+9ecfc34a-cd81-da6a-fb57-a273b6a6bb98,First,Gemcitabine_NabPaclitaxel,Sotorasib_Adagrasib,PD,3,0.5,Death
+9ecfc34a-cd81-da6a-fb57-a273b6a6bb98,Second,Capecitabine,None,PD,1,9.34,Progression
+c2ed3e94-fc19-a9f2-7a3d-d32ee1078e7e,First,Gemcitabine_Monotherapy,None,SD,5,4.62,Patient_Choice
+c2ed3e94-fc19-a9f2-7a3d-d32ee1078e7e,Second,Gemcitabine_Monotherapy,None,PD,4,0.81,Death
+b87f8791-83dc-35fb-e740-7ed3a6a04a8a,First,FOLFIRINOX,None,SD,4,4.78,Progression
+b87f8791-83dc-35fb-e740-7ed3a6a04a8a,Second,Gemcitabine_Monotherapy,None,SD,2,4.26,Progression
+c8317da9-9f95-0147-f695-02c048e41f8f,First,FOLFIRINOX,None,PD,1,2.58,Progression
+c8317da9-9f95-0147-f695-02c048e41f8f,Second,FOLFOX,None,SD,4,4.83,Death
+1d35eca6-12fd-521c-dde6-b2f575f2e747,First,Gemcitabine_NabPaclitaxel,None,CR,12,4.39,Planned_Completion
+1d35eca6-12fd-521c-dde6-b2f575f2e747,Second,Gemcitabine_Monotherapy,None,PD,7,7.42,Progression
+70a9a72b-cf28-fbd6-bb7f-738a81d262db,First,mFOLFIRINOX,None,PR,8,3.92,Planned_Completion
+70a9a72b-cf28-fbd6-bb7f-738a81d262db,Second,Capecitabine,None,PD,7,2.34,Toxicity
+a7734168-f626-5e35-8d98-35f6a650fbba,First,Gemcitabine_NabPaclitaxel,None,SD,4,4.75,Progression
+a7734168-f626-5e35-8d98-35f6a650fbba,Second,Gemcitabine_Monotherapy,None,SD,1,4.76,Progression
+fc0d4f24-1b74-ef6b-f845-cdb16ab648ca,First,Gemcitabine_NabPaclitaxel,None,PD,3,2.73,Progression
+fc0d4f24-1b74-ef6b-f845-cdb16ab648ca,Second,Gemcitabine_Monotherapy,None,SD,1,5.45,Toxicity
+bbd744ea-d24b-dcc7-49c9-5388276d661f,First,FOLFIRINOX,None,PD,1,5.54,Progression
+bbd744ea-d24b-dcc7-49c9-5388276d661f,Second,Gemcitabine_Monotherapy,None,SD,7,4.67,Toxicity
+58b3c193-a312-fd0b-bffe-ebcff86922b1,First,FOLFIRINOX,None,PD,2,4.22,Progression
+58b3c193-a312-fd0b-bffe-ebcff86922b1,Second,Regorafenib,None,SD,1,2.78,Toxicity
+0a7b7fff-4c3b-2100-1fb5-edf80134d793,First,Gemcitabine_Monotherapy,None,SD,5,1.26,Progression
+0a7b7fff-4c3b-2100-1fb5-edf80134d793,Second,Gemcitabine_Monotherapy,None,PD,7,0.07,Progression
+7d5cf657-f697-dd0c-c6ff-f58e82180fb6,First,mFOLFIRINOX,None,SD,3,0.5,Toxicity
+7d5cf657-f697-dd0c-c6ff-f58e82180fb6,Second,Capecitabine,None,PD,4,0.65,Toxicity
+7708801b-dc1d-b803-fc4c-5c4ce000562a,First,FOLFIRINOX,None,PR,11,3.17,Progression
+695d0b7d-3ded-eaa0-fa58-c463534443cd,First,FOLFIRINOX,None,PD,3,2.21,Patient_Choice
+695d0b7d-3ded-eaa0-fa58-c463534443cd,Second,FOLFOX,None,SD,7,1.19,Progression
+cd53ca4a-8a58-737f-8e32-bd1738d0476e,First,Gemcitabine_Monotherapy,None,PD,1,2.48,Progression
+cd53ca4a-8a58-737f-8e32-bd1738d0476e,Second,FOLFOX,None,PD,6,4.23,Progression
+d294ce30-71c9-065f-ecb9-3f9b441ef666,First,mFOLFIRINOX,None,PR,12,3.23,Death
+5f696baf-0e17-ff9a-0976-e9e03d068a7d,First,Gemcitabine_NabPaclitaxel,None,PD,3,3.25,Progression
+5f696baf-0e17-ff9a-0976-e9e03d068a7d,Second,Capecitabine,None,SD,1,14.99,Toxicity
+1bf9ec9a-5e75-594c-0c77-80c9f401d669,First,NALIRIFOX,Olaparib,PD,2,1.61,Progression
+1bf9ec9a-5e75-594c-0c77-80c9f401d669,Second,Olaparib,Olaparib,SD,1,0.28,Progression
+b69816d2-c33f-c1bf-ace0-d465ee7b040d,First,FOLFIRINOX,None,PD,2,0.5,Progression
+b69816d2-c33f-c1bf-ace0-d465ee7b040d,Second,FOLFOX,None,SD,5,1.82,Toxicity
+dd8e8f72-0214-7725-c612-8f04a832e4dd,First,NALIRIFOX,None,SD,6,1.94,Toxicity
+dd8e8f72-0214-7725-c612-8f04a832e4dd,Second,Gemcitabine_Monotherapy,None,SD,3,8.25,Toxicity
+3c0a7ee0-e866-b915-0c88-e2bc61bed80f,First,Gemcitabine_NabPaclitaxel,None,SD,5,11.14,Toxicity
+3c0a7ee0-e866-b915-0c88-e2bc61bed80f,Second,Regorafenib,None,SD,1,1.5,Toxicity
+83bebfa1-f3a3-ccd9-0126-eb9171999e27,First,Gemcitabine_NabPaclitaxel,None,PD,3,3.0,Progression
+83bebfa1-f3a3-ccd9-0126-eb9171999e27,Second,Gemcitabine_Monotherapy,None,PD,5,4.49,Toxicity
+079457e2-87d6-16bc-ad62-b4fe43527b78,First,mFOLFIRINOX,None,PR,7,9.33,Planned_Completion
+079457e2-87d6-16bc-ad62-b4fe43527b78,Second,Regorafenib,None,PD,2,0.71,Death
+3cd72db2-4130-c148-abee-d1299c511eff,First,Gemcitabine_NabPaclitaxel,Olaparib,PD,2,1.14,Progression
+3cd72db2-4130-c148-abee-d1299c511eff,Second,Olaparib,Olaparib,PD,1,10.61,Toxicity
+5918965d-8631-82c3-da4f-dd366a3d8bf7,First,Gemcitabine_NabPaclitaxel,None,SD,6,0.47,Planned_Completion
+5918965d-8631-82c3-da4f-dd366a3d8bf7,Second,Gemcitabine_Monotherapy,None,SD,2,9.44,Toxicity
+4c879234-e70c-6d38-da74-cbdec7948efa,First,FOLFIRINOX,None,SD,3,4.52,Toxicity
+4c879234-e70c-6d38-da74-cbdec7948efa,Second,FOLFOX,None,SD,1,7.44,Progression
+659ddd41-72ef-d1a1-971f-3a5bb5aafbef,First,Gemcitabine_NabPaclitaxel,Olaparib,PD,2,2.78,Progression
+659ddd41-72ef-d1a1-971f-3a5bb5aafbef,Second,Olaparib,Olaparib,SD,4,0.92,Progression
+e2f56fb7-8cb6-dbc3-465a-ef3d1d535d72,First,FOLFIRINOX,None,SD,5,4.65,Toxicity
+e2f56fb7-8cb6-dbc3-465a-ef3d1d535d72,Second,Regorafenib,None,PR,3,11.17,Progression
+b7b732fd-7329-41bf-5788-861aaccda816,First,Gemcitabine_NabPaclitaxel,None,PD,1,1.76,Death
+b7b732fd-7329-41bf-5788-861aaccda816,Second,FOLFOX,None,PR,2,0.95,Toxicity
+ffada53f-8898-bec5-ceb3-d6756cc57c7e,First,mFOLFIRINOX,None,PR,11,0.51,Planned_Completion
+ffada53f-8898-bec5-ceb3-d6756cc57c7e,Second,Capecitabine,None,SD,1,0.08,Toxicity
+686ee23a-c679-3d5a-4bde-623ea363c007,First,Gemcitabine_NabPaclitaxel,None,PD,3,0.34,Planned_Completion
+686ee23a-c679-3d5a-4bde-623ea363c007,Second,Gemcitabine_Monotherapy,None,PD,5,7.84,Toxicity
+932ace89-1e8d-4637-2306-b82288bf437b,First,mFOLFIRINOX,None,PD,3,1.68,Progression
+932ace89-1e8d-4637-2306-b82288bf437b,Second,Gemcitabine_Monotherapy,None,SD,5,1.09,Toxicity
+b36cf018-db0d-6dc7-ff61-67c32fcafa0c,First,Gemcitabine_NabPaclitaxel,None,PR,12,2.48,Patient_Choice
+b36cf018-db0d-6dc7-ff61-67c32fcafa0c,Second,FOLFOX,None,PD,3,0.56,Toxicity
+64724d06-0f6f-324c-985f-de63bc153fd7,First,NALIRIFOX,None,PR,12,9.45,Planned_Completion
+64724d06-0f6f-324c-985f-de63bc153fd7,Second,Gemcitabine_Monotherapy,None,PD,3,9.02,Progression
+7f35ed11-3830-92b1-ea51-05017eecd950,First,mFOLFIRINOX,None,PR,8,6.8,Planned_Completion
+5d897166-1a5f-62a6-2265-deba5814bddb,First,Gemcitabine_NabPaclitaxel,None,PD,2,1.71,Death
+5d897166-1a5f-62a6-2265-deba5814bddb,Second,FOLFOX,None,PD,7,1.02,Progression
+33b4e5f1-59d2-822e-1131-d5b615198fc3,First,FOLFIRINOX,None,SD,3,5.99,Progression
+33b4e5f1-59d2-822e-1131-d5b615198fc3,Second,FOLFOX,None,PD,5,5.11,Progression
+740a2711-4d43-996a-0485-f0f48e07fed6,First,Gemcitabine_NabPaclitaxel,None,SD,5,2.23,Toxicity
+740a2711-4d43-996a-0485-f0f48e07fed6,Second,FOLFOX,None,PD,2,6.3,Progression
+57e203ca-e176-d28d-a271-3b15f6909edb,First,Gemcitabine_NabPaclitaxel,None,PD,3,0.39,Progression
+57e203ca-e176-d28d-a271-3b15f6909edb,Second,Capecitabine,None,PR,7,1.26,Toxicity
+f58ebd28-e32c-4be7-6b9e-23c873203127,First,FOLFIRINOX,None,SD,4,0.5,Planned_Completion
+f58ebd28-e32c-4be7-6b9e-23c873203127,Second,FOLFOX,None,SD,2,1.46,Progression
+8a75949f-80cb-e5f2-c080-a7b6f65b8943,First,Gemcitabine_NabPaclitaxel,None,SD,5,0.5,Patient_Choice
+5349a943-8f7a-edef-3c2f-531c62e603b6,First,FOLFIRINOX,None,SD,3,1.44,Planned_Completion
+5349a943-8f7a-edef-3c2f-531c62e603b6,Second,Capecitabine,None,PD,5,0.56,Progression
+87901171-4e56-add2-e8b8-78bfe41046a1,First,FOLFIRINOX,None,PD,1,0.3,Progression
+87901171-4e56-add2-e8b8-78bfe41046a1,Second,Capecitabine,None,SD,6,1.83,Progression
+973b0d03-3733-5a3e-be08-8c93fbe6ebf1,First,Gemcitabine_NabPaclitaxel,None,SD,5,2.15,Patient_Choice
+973b0d03-3733-5a3e-be08-8c93fbe6ebf1,Second,FOLFOX,None,PR,2,1.64,Progression
+4ca46226-0667-15a6-a747-cac09eb1244e,First,Gemcitabine_NabPaclitaxel,None,SD,5,10.47,Progression
+4ca46226-0667-15a6-a747-cac09eb1244e,Second,Gemcitabine_Monotherapy,None,PD,1,3.46,Progression
+528edbc4-4cb8-da72-3dca-8f36dac7f96e,First,Gemcitabine_NabPaclitaxel,None,SD,6,2.64,Toxicity
+528edbc4-4cb8-da72-3dca-8f36dac7f96e,Second,Regorafenib,None,PD,7,2.17,Progression
+dfd310f5-58d6-02e0-27cb-04b22d694a71,First,mFOLFIRINOX,None,PD,2,2.31,Progression
+dfd310f5-58d6-02e0-27cb-04b22d694a71,Second,Gemcitabine_Monotherapy,None,PD,6,7.35,Death
+c8a8b263-95c3-a90f-cabe-d5ff40277048,First,mFOLFIRINOX,None,PD,2,0.57,Toxicity
+c8a8b263-95c3-a90f-cabe-d5ff40277048,Second,Capecitabine,None,PR,2,2.65,Progression
+79ebffbc-dc68-561b-703a-14f3a289508b,First,mFOLFIRINOX,None,SD,3,3.24,Death
+79ebffbc-dc68-561b-703a-14f3a289508b,Second,Capecitabine,None,PD,7,1.27,Progression
+acb26b95-96ca-195f-fea4-c618f32ee85e,First,mFOLFIRINOX,None,PD,2,0.47,Progression
+e70dc6e4-abed-77d7-d08c-251f41731a01,First,mFOLFIRINOX,None,PR,6,7.49,Patient_Choice
+e70dc6e4-abed-77d7-d08c-251f41731a01,Second,Gemcitabine_Monotherapy,None,SD,5,0.41,Toxicity
+2f67e9de-7863-ff33-c99f-7ccd445aa773,First,FOLFIRINOX,None,PD,1,1.08,Progression
+2f67e9de-7863-ff33-c99f-7ccd445aa773,Second,Regorafenib,None,PD,4,7.6,Progression
+1a15bc49-51c7-72aa-8fea-6bd42bd38a88,First,Gemcitabine_Monotherapy,None,SD,3,2.28,Toxicity
+1a15bc49-51c7-72aa-8fea-6bd42bd38a88,Second,FOLFOX,None,PD,2,5.4,Progression
+6ed74908-ef45-770a-8342-6897c7906afa,First,mFOLFIRINOX,None,SD,3,1.26,Planned_Completion
+6ed74908-ef45-770a-8342-6897c7906afa,Second,Capecitabine,None,PD,4,7.69,Progression
+0a8428d2-4b2c-addf-1a5e-6247bd3f8134,First,mFOLFIRINOX,None,PR,7,5.03,Death
+0a8428d2-4b2c-addf-1a5e-6247bd3f8134,Second,Capecitabine,None,PD,4,1.42,Toxicity
+10c69a3e-9277-e1aa-3efe-38b10d1e9fe0,First,Gemcitabine_NabPaclitaxel,None,SD,3,0.36,Toxicity
+10c69a3e-9277-e1aa-3efe-38b10d1e9fe0,Second,Gemcitabine_Monotherapy,None,PD,7,2.07,Death
+626ee100-a2b4-4919-1c91-d77bda1bbf48,First,Pembrolizumab,Pembrolizumab,PD,2,4.55,Progression
+626ee100-a2b4-4919-1c91-d77bda1bbf48,Second,FOLFOX,None,PD,2,0.29,Progression
+b2bc8fd5-e5d5-b593-0f7e-cae4c70b5cce,First,Gemcitabine_NabPaclitaxel,None,CR,10,4.17,Progression
+b2bc8fd5-e5d5-b593-0f7e-cae4c70b5cce,Second,Gemcitabine_Monotherapy,None,PD,1,4.98,Progression
+4d548ff4-fa25-f863-34ff-4c577303dd6a,First,Gemcitabine_Monotherapy,None,SD,4,3.22,Death
+4d548ff4-fa25-f863-34ff-4c577303dd6a,Second,FOLFOX,None,PD,7,4.4,Progression
+6aa6edcd-3b05-58b7-64e5-6d4b7d923373,First,Gemcitabine_NabPaclitaxel,None,SD,3,3.45,Toxicity
+6aa6edcd-3b05-58b7-64e5-6d4b7d923373,Second,Gemcitabine_Monotherapy,None,SD,4,3.74,Toxicity
+1cb0a4d2-4a3c-fa1c-006c-d60d26c7b137,First,mFOLFIRINOX,None,PD,2,0.5,Toxicity
+1cb0a4d2-4a3c-fa1c-006c-d60d26c7b137,Second,FOLFOX,None,SD,6,0.37,Toxicity
+0050cf5b-299e-2352-dcde-23716a2ef347,First,Gemcitabine_NabPaclitaxel,None,PD,3,0.78,Progression
+0050cf5b-299e-2352-dcde-23716a2ef347,Second,Gemcitabine_Monotherapy,None,PR,7,2.08,Toxicity
+7d5000e5-465b-cb61-8217-417e1c70a9fc,First,NALIRIFOX,Olaparib,SD,5,2.28,Planned_Completion
+7d5000e5-465b-cb61-8217-417e1c70a9fc,Second,Olaparib,Olaparib,SD,2,3.38,Progression
+6e6b7295-68fe-947e-5545-a8b0077cc9dd,First,NALIRIFOX,Olaparib,SD,3,2.36,Toxicity
+6e6b7295-68fe-947e-5545-a8b0077cc9dd,Second,Olaparib,Olaparib,PD,5,2.91,Toxicity
+d7592047-779c-616c-c7d4-2a598d18b571,First,NALIRIFOX,None,PR,12,3.3,Planned_Completion
+d7592047-779c-616c-c7d4-2a598d18b571,Second,Capecitabine,None,PD,1,0.34,Toxicity
+528ebbc9-3aa0-f0b7-42a6-33bf879cbd49,First,NALIRIFOX,None,SD,5,5.23,Progression
+528ebbc9-3aa0-f0b7-42a6-33bf879cbd49,Second,Gemcitabine_Monotherapy,None,PD,5,1.07,Toxicity
+7ad853eb-ea07-47a3-3e13-5b3398f365e2,First,mFOLFIRINOX,None,PD,1,2.2,Progression
+7ad853eb-ea07-47a3-3e13-5b3398f365e2,Second,Capecitabine,None,PD,4,1.87,Toxicity
+ee2dafb1-3f32-b89c-54ab-18fbbe732006,First,Gemcitabine_NabPaclitaxel,None,SD,4,3.09,Patient_Choice
+ee2dafb1-3f32-b89c-54ab-18fbbe732006,Second,Regorafenib,None,PR,4,0.8,Toxicity
+75f4ff31-7ea9-178e-0c6f-09777b8da1f7,First,Gemcitabine_NabPaclitaxel,None,SD,4,1.01,Planned_Completion
+75f4ff31-7ea9-178e-0c6f-09777b8da1f7,Second,Regorafenib,None,SD,4,1.14,Toxicity
+26842773-30fc-ca02-b628-aaf5dd2d0a11,First,Gemcitabine_NabPaclitaxel,None,SD,5,5.65,Progression
+26842773-30fc-ca02-b628-aaf5dd2d0a11,Second,Gemcitabine_Monotherapy,None,PR,5,0.16,Death
+23616d5f-51ab-07a2-0c20-b42a9a852c73,First,FOLFIRINOX,None,SD,6,3.24,Toxicity
+23616d5f-51ab-07a2-0c20-b42a9a852c73,Second,Gemcitabine_Monotherapy,None,SD,5,1.97,Progression
+025ed95c-16fe-7ecb-eb37-ff2f05438c1d,First,Gemcitabine_NabPaclitaxel,None,PD,2,6.79,Death
+025ed95c-16fe-7ecb-eb37-ff2f05438c1d,Second,Gemcitabine_Monotherapy,None,PR,6,0.44,Progression
+08023240-d109-eefc-3035-de72eed20080,First,NALIRIFOX,None,SD,5,7.29,Patient_Choice
+08023240-d109-eefc-3035-de72eed20080,Second,Gemcitabine_Monotherapy,None,SD,6,0.74,Progression
+9ec21a88-b4cd-a3dc-1c52-3679274f73a9,First,FOLFIRINOX,None,PR,9,5.96,Planned_Completion
+9ec21a88-b4cd-a3dc-1c52-3679274f73a9,Second,FOLFOX,None,PR,7,3.59,Progression
+91b7e185-16bf-86cc-3ddc-0c2a79ba803d,First,mFOLFIRINOX,None,SD,5,4.05,Progression
+91b7e185-16bf-86cc-3ddc-0c2a79ba803d,Second,FOLFOX,None,PD,4,1.89,Progression
+d974980f-affd-e7dc-9717-0b6b3b10176e,First,mFOLFIRINOX,None,PR,11,8.55,Planned_Completion
+da766bbf-47d9-c844-0136-bb5f7e75ccec,First,FOLFIRINOX,None,CR,9,3.97,Planned_Completion
+da766bbf-47d9-c844-0136-bb5f7e75ccec,Second,FOLFOX,None,SD,6,12.6,Death
+db017e61-fec4-573b-c5df-3983e58e5fc0,First,Gemcitabine_Monotherapy,None,PD,3,3.22,Progression
+db017e61-fec4-573b-c5df-3983e58e5fc0,Second,Gemcitabine_Monotherapy,None,SD,1,1.66,Progression
+eb36100b-3f9c-0523-4117-69634a87b603,First,Gemcitabine_NabPaclitaxel,None,SD,4,4.39,Progression
+eb36100b-3f9c-0523-4117-69634a87b603,Second,FOLFOX,None,SD,5,3.42,Progression
+9a7a0668-f7df-fae5-7457-52788e934f89,First,FOLFIRINOX,None,PD,2,0.36,Death
+9a7a0668-f7df-fae5-7457-52788e934f89,Second,FOLFOX,None,SD,4,8.07,Progression
+5c8da0e2-1456-8c59-fc11-fde8e8d088c1,First,Gemcitabine_NabPaclitaxel,None,SD,6,0.52,Planned_Completion
+5c8da0e2-1456-8c59-fc11-fde8e8d088c1,Second,FOLFOX,None,PD,1,0.27,Progression
+51829ac6-2603-1c84-d02b-35fcbbf08da8,First,Gemcitabine_NabPaclitaxel,None,SD,3,4.24,Progression
+51829ac6-2603-1c84-d02b-35fcbbf08da8,Second,Gemcitabine_Monotherapy,None,SD,5,0.21,Progression
+99c9b2b7-1ceb-6c0b-cc99-41e48c550e8d,First,Gemcitabine_NabPaclitaxel,None,PD,1,0.98,Death
+99c9b2b7-1ceb-6c0b-cc99-41e48c550e8d,Second,FOLFOX,None,PD,2,4.34,Death
+69fd9d34-83f1-32c1-3763-163b4be3ae99,First,Gemcitabine_NabPaclitaxel,None,PR,12,6.31,Planned_Completion
+69fd9d34-83f1-32c1-3763-163b4be3ae99,Second,Regorafenib,None,PD,7,0.18,Progression
+13fee961-d2c2-3636-5150-91a5a2bdfa67,First,Gemcitabine_Monotherapy,None,PD,1,0.57,Death
+13fee961-d2c2-3636-5150-91a5a2bdfa67,Second,Capecitabine,None,SD,3,4.06,Progression
+58b2d33d-bc63-a9da-07a3-4061dca42070,First,Gemcitabine_NabPaclitaxel,None,SD,6,0.32,Toxicity
+58b2d33d-bc63-a9da-07a3-4061dca42070,Second,Regorafenib,None,SD,1,1.79,Progression
+2a5d67da-b3bc-d39a-04df-6c0262223a0b,First,Gemcitabine_NabPaclitaxel,None,PR,6,7.71,Toxicity
+2a5d67da-b3bc-d39a-04df-6c0262223a0b,Second,Capecitabine,None,PD,5,2.34,Progression
+b545779b-d861-8ee8-b9a5-9d36a8be7f89,First,Gemcitabine_NabPaclitaxel,None,PD,2,3.66,Death
+b545779b-d861-8ee8-b9a5-9d36a8be7f89,Second,FOLFOX,None,SD,3,6.84,Progression
+5130f341-d371-7ae8-bd13-9aad4d2f1eb2,First,NALIRIFOX,None,PR,9,1.49,Planned_Completion
+5130f341-d371-7ae8-bd13-9aad4d2f1eb2,Second,Regorafenib,None,SD,5,2.82,Death
+9805475f-25df-64a5-e3d8-50ad1fca0eca,First,Gemcitabine_NabPaclitaxel,None,SD,4,4.65,Toxicity
+9805475f-25df-64a5-e3d8-50ad1fca0eca,Second,Gemcitabine_Monotherapy,None,SD,7,1.58,Progression
+24cabf06-c6c3-2465-2043-43283c7ce076,First,NALIRIFOX,None,PD,2,4.04,Progression
+24cabf06-c6c3-2465-2043-43283c7ce076,Second,Regorafenib,None,PD,4,3.96,Progression
+2c460dc7-0f6b-1a38-b16e-b3afab93ebbe,First,FOLFIRINOX,None,SD,6,2.79,Planned_Completion
+2c460dc7-0f6b-1a38-b16e-b3afab93ebbe,Second,FOLFOX,None,PD,7,2.57,Progression
+fde4ee9b-1f10-eb6b-81dd-ef3acb5b6838,First,mFOLFIRINOX,None,PD,2,2.17,Progression
+fde4ee9b-1f10-eb6b-81dd-ef3acb5b6838,Second,Gemcitabine_Monotherapy,None,PD,3,4.75,Progression
+043e92ea-ec96-250e-0106-a47343d64389,First,mFOLFIRINOX,None,CR,9,1.79,Planned_Completion
+043e92ea-ec96-250e-0106-a47343d64389,Second,Gemcitabine_Monotherapy,None,PD,3,9.96,Death
+e5b598d2-929b-ee6b-207d-2c12635f6e19,First,mFOLFIRINOX,None,SD,3,1.39,Progression
+e5b598d2-929b-ee6b-207d-2c12635f6e19,Second,FOLFOX,None,SD,2,12.6,Toxicity
+89446e26-6a40-7d15-e160-9a7517528437,First,NALIRIFOX,None,PR,12,3.57,Progression
+89446e26-6a40-7d15-e160-9a7517528437,Second,Capecitabine,None,PD,7,1.49,Progression
+45ef9885-2eae-b11f-9f2d-c3312a57f942,First,mFOLFIRINOX,None,PD,3,1.98,Progression
+45ef9885-2eae-b11f-9f2d-c3312a57f942,Second,Regorafenib,None,PD,1,0.5,Progression
+a9e311a4-57ef-b858-4b75-138b21cca070,First,FOLFIRINOX,None,PD,2,1.45,Planned_Completion
+a9e311a4-57ef-b858-4b75-138b21cca070,Second,Regorafenib,None,SD,6,3.33,Progression
+04a62b5e-3094-7d22-d614-29f5fa0999eb,First,Gemcitabine_NabPaclitaxel,None,SD,6,1.53,Toxicity
+04a62b5e-3094-7d22-d614-29f5fa0999eb,Second,Regorafenib,None,PD,7,1.7,Death
+3b353392-2800-b055-9880-b2ac0d4a1c5d,First,FOLFIRINOX,None,SD,6,6.66,Planned_Completion
+3b353392-2800-b055-9880-b2ac0d4a1c5d,Second,Regorafenib,None,PD,2,0.48,Progression
+40f02837-d6ca-b861-dfb7-2816d8eea838,First,Gemcitabine_NabPaclitaxel,None,SD,4,1.77,Planned_Completion
+40f02837-d6ca-b861-dfb7-2816d8eea838,Second,Regorafenib,None,PD,2,2.51,Death
+8db4da3d-2f6c-5fe8-9c5b-6e739ea3a72e,First,Gemcitabine_Monotherapy,None,PD,1,2.52,Death
+8db4da3d-2f6c-5fe8-9c5b-6e739ea3a72e,Second,Capecitabine,None,PD,5,0.84,Progression
+ad788dea-c06c-fc28-656b-2af1867736c1,First,NALIRIFOX,None,SD,3,3.48,Toxicity
+ad788dea-c06c-fc28-656b-2af1867736c1,Second,Regorafenib,None,PD,6,8.95,Toxicity
+9122d5d9-c35b-14c3-b9cc-09ed885c1089,First,mFOLFIRINOX,None,SD,6,0.52,Planned_Completion
+9122d5d9-c35b-14c3-b9cc-09ed885c1089,Second,FOLFOX,None,PD,6,5.87,Progression
+fbc138b3-b7b5-8b71-c227-f5b144864bb9,First,mFOLFIRINOX,None,CR,11,3.6,Progression
+83bbb702-ec9a-1ead-6b55-6f6a26584728,First,Gemcitabine_NabPaclitaxel,None,PD,1,0.54,Progression
+83bbb702-ec9a-1ead-6b55-6f6a26584728,Second,Gemcitabine_Monotherapy,None,SD,3,8.57,Progression
+cbc88708-0900-e385-0331-39d5f14fbbc0,First,Gemcitabine_NabPaclitaxel,None,PR,12,2.15,Planned_Completion
+cbc88708-0900-e385-0331-39d5f14fbbc0,Second,FOLFOX,None,PD,2,4.57,Progression
+68702909-6d92-07b3-852d-cc345bc22484,First,mFOLFIRINOX,None,SD,4,2.7,Progression
+68702909-6d92-07b3-852d-cc345bc22484,Second,Gemcitabine_Monotherapy,None,PD,1,5.07,Death
+e3c085f3-c5b0-02ee-1815-19a4f0816321,First,Gemcitabine_NabPaclitaxel,None,SD,4,6.7,Progression
+e3c085f3-c5b0-02ee-1815-19a4f0816321,Second,Regorafenib,None,PD,6,0.68,Progression
+aebdaae9-28f6-aa0a-651f-31c9a84c23e7,First,NALIRIFOX,None,CR,7,3.98,Toxicity
+aebdaae9-28f6-aa0a-651f-31c9a84c23e7,Second,Capecitabine,None,SD,6,1.18,Progression
+f6281dd4-5c12-0b90-263d-627c7803226c,First,Gemcitabine_NabPaclitaxel,None,SD,3,0.92,Toxicity
+f6281dd4-5c12-0b90-263d-627c7803226c,Second,FOLFOX,None,PD,3,6.4,Toxicity
+33152f1d-ae95-f0e1-2dae-5bfb43f04f44,First,Gemcitabine_NabPaclitaxel,Olaparib,SD,3,2.51,Toxicity
+33152f1d-ae95-f0e1-2dae-5bfb43f04f44,Second,Olaparib,Olaparib,PD,4,2.22,Toxicity
+e99f05d0-fbc8-a23b-dbe6-4cfdeb7f2802,First,Gemcitabine_NabPaclitaxel,None,PR,10,4.84,Planned_Completion
+e99f05d0-fbc8-a23b-dbe6-4cfdeb7f2802,Second,Regorafenib,None,PD,1,8.65,Progression
+7844defa-57b7-37f3-364f-4ae13e675593,First,FOLFIRINOX,None,PD,1,6.05,Progression
+7844defa-57b7-37f3-364f-4ae13e675593,Second,Capecitabine,None,PD,3,4.15,Progression
+845b639b-69ba-6d24-6109-98f0a558e02e,First,Gemcitabine_NabPaclitaxel,None,SD,4,2.57,Planned_Completion
+845b639b-69ba-6d24-6109-98f0a558e02e,Second,FOLFOX,None,PD,3,2.49,Progression
+bb2bba34-a71c-51fb-bde1-206e16b9c65d,First,Gemcitabine_Monotherapy,None,SD,6,0.67,Planned_Completion
+bb2bba34-a71c-51fb-bde1-206e16b9c65d,Second,Capecitabine,None,PD,7,4.01,Progression
+91e72ec7-f322-e0f3-c870-133888b0747b,First,Gemcitabine_NabPaclitaxel,None,SD,4,5.63,Toxicity
+91e72ec7-f322-e0f3-c870-133888b0747b,Second,FOLFOX,None,PD,2,3.8,Toxicity
+e76acb28-c757-658f-1ac8-0e1371c32364,First,mFOLFIRINOX,None,PR,8,2.15,Planned_Completion
+e76acb28-c757-658f-1ac8-0e1371c32364,Second,FOLFOX,None,SD,3,1.48,Progression
+cc501d11-dc77-91db-dd96-2974b311c91f,First,Gemcitabine_Monotherapy,None,PR,8,2.88,Planned_Completion
+cc501d11-dc77-91db-dd96-2974b311c91f,Second,Gemcitabine_Monotherapy,None,PD,5,4.41,Progression
+345362c7-00d4-b6d5-1990-965980bcc705,First,Gemcitabine_NabPaclitaxel,None,SD,4,2.27,Planned_Completion
+345362c7-00d4-b6d5-1990-965980bcc705,Second,Gemcitabine_Monotherapy,None,PD,5,1.65,Progression
+05ec825d-74af-c5a7-be5c-97f16e57a0b6,First,mFOLFIRINOX,None,SD,5,12.7,Toxicity
+05ec825d-74af-c5a7-be5c-97f16e57a0b6,Second,Capecitabine,None,PD,1,11.22,Toxicity
+608c8dc3-fcef-08c5-faae-773135d934d8,First,Gemcitabine_NabPaclitaxel,None,PR,7,5.44,Planned_Completion
+e337dbdd-ee67-9d2b-b824-ddbfce1388db,First,mFOLFIRINOX,None,PR,10,3.35,Planned_Completion
+51b2aab1-a06c-b612-6506-76dfa0f53621,First,Gemcitabine_NabPaclitaxel,None,PD,3,3.71,Progression
+51b2aab1-a06c-b612-6506-76dfa0f53621,Second,Capecitabine,None,SD,4,1.12,Toxicity
+94bbb837-9247-305f-9bd6-7568591c76ff,First,FOLFIRINOX,None,PR,8,5.22,Planned_Completion
+94bbb837-9247-305f-9bd6-7568591c76ff,Second,Gemcitabine_Monotherapy,None,SD,2,2.67,Progression
+9a0de910-029b-f24d-68bd-65c7627a1beb,First,mFOLFIRINOX,None,PR,9,2.76,Progression
+9a0de910-029b-f24d-68bd-65c7627a1beb,Second,FOLFOX,None,PD,7,15.42,Toxicity
+77b74598-8118-7712-ef75-27479366a719,First,mFOLFIRINOX,None,PD,3,0.88,Progression
+77b74598-8118-7712-ef75-27479366a719,Second,Capecitabine,None,PD,5,2.88,Progression
+60909240-5689-a0a0-325d-b2101153a287,First,FOLFIRINOX,None,PR,10,8.44,Progression
+60909240-5689-a0a0-325d-b2101153a287,Second,Gemcitabine_Monotherapy,None,PD,6,4.69,Progression
+219056dc-c4d7-cc02-64e4-31f95cd8faa8,First,FOLFIRINOX,None,SD,4,1.18,Progression
+219056dc-c4d7-cc02-64e4-31f95cd8faa8,Second,Capecitabine,None,PD,6,0.42,Progression
+af3f75c5-4ecb-b027-29b1-f258550ef642,First,Gemcitabine_NabPaclitaxel,None,PD,1,2.21,Progression
+f4743894-0610-5039-56e8-039c0bf8b5f0,First,Gemcitabine_NabPaclitaxel,None,SD,4,5.46,Death
+f4743894-0610-5039-56e8-039c0bf8b5f0,Second,FOLFOX,None,PR,6,1.56,Progression
+19531dca-32bd-0da8-3e5c-5b36ba2da538,First,mFOLFIRINOX,None,SD,3,2.77,Progression
+19531dca-32bd-0da8-3e5c-5b36ba2da538,Second,Gemcitabine_Monotherapy,None,PR,4,1.45,Death
+e18b9425-958e-cc9d-c0e5-accf790ea7c6,First,Gemcitabine_NabPaclitaxel,None,SD,3,0.89,Progression
+e18b9425-958e-cc9d-c0e5-accf790ea7c6,Second,Capecitabine,None,SD,3,0.4,Progression
+33bc0bbb-7a61-9864-4732-6fdc58046ffa,First,Gemcitabine_NabPaclitaxel,None,PR,12,12.74,Planned_Completion
+33bc0bbb-7a61-9864-4732-6fdc58046ffa,Second,Gemcitabine_Monotherapy,None,PD,2,8.48,Progression
+85a29922-7a97-01da-2f8e-5e91f9c3dbf2,First,mFOLFIRINOX,None,PR,7,2.53,Planned_Completion
+85a29922-7a97-01da-2f8e-5e91f9c3dbf2,Second,FOLFOX,None,PD,7,14.68,Progression
+7b430438-0232-694c-0b90-772420c2881b,First,FOLFIRINOX,None,PR,9,2.21,Planned_Completion
+7b430438-0232-694c-0b90-772420c2881b,Second,Capecitabine,None,PD,1,7.28,Death
+1c5650d5-e234-6fd2-7ed9-8487ac69b9b9,First,Gemcitabine_NabPaclitaxel,None,SD,4,1.01,Planned_Completion
+1c5650d5-e234-6fd2-7ed9-8487ac69b9b9,Second,FOLFOX,None,SD,6,12.06,Progression
+4b764e39-22aa-850f-409f-aa2c3be97f10,First,mFOLFIRINOX,None,SD,6,2.19,Toxicity
+4b764e39-22aa-850f-409f-aa2c3be97f10,Second,Gemcitabine_Monotherapy,None,SD,2,7.42,Progression
+e0701e6a-4d37-65c2-c3ca-2a66500c4525,First,NALIRIFOX,None,SD,6,7.41,Patient_Choice
+fc0cb035-1af0-003e-e6d2-0021c5cdf83b,First,NALIRIFOX,None,SD,5,4.55,Planned_Completion
+fc0cb035-1af0-003e-e6d2-0021c5cdf83b,Second,Gemcitabine_Monotherapy,None,PD,6,1.41,Progression
+f3f7c04c-5ad6-f1af-fb7c-62089d2cab5c,First,mFOLFIRINOX,None,SD,6,4.78,Toxicity
+f3f7c04c-5ad6-f1af-fb7c-62089d2cab5c,Second,FOLFOX,None,PR,7,2.36,Progression
+23466fea-68fd-eaf4-1262-ef9096aedbb2,First,mFOLFIRINOX,None,SD,4,3.41,Progression
+23466fea-68fd-eaf4-1262-ef9096aedbb2,Second,Regorafenib,None,SD,6,5.12,Toxicity
+8d8abd6f-38ec-a936-4df1-84adf0f7b4f5,First,FOLFIRINOX,None,PD,3,1.05,Progression
+8d8abd6f-38ec-a936-4df1-84adf0f7b4f5,Second,FOLFOX,None,SD,7,0.07,Toxicity
+d8862640-d105-c1d3-18d3-8afc6cd761fc,First,Gemcitabine_NabPaclitaxel,None,PD,1,4.31,Progression
+d8862640-d105-c1d3-18d3-8afc6cd761fc,Second,FOLFOX,None,PR,3,0.5,Progression
+8ad864ba-670e-0590-9de3-bba2be32c527,First,Gemcitabine_Monotherapy,None,SD,5,3.99,Progression
+40d559cc-14f1-b678-2a51-d7c785600558,First,mFOLFIRINOX,None,PR,9,3.07,Planned_Completion
+40d559cc-14f1-b678-2a51-d7c785600558,Second,Regorafenib,None,PD,6,0.26,Toxicity
+da184a9b-1b4e-905b-290a-3578744f3341,First,Gemcitabine_Monotherapy,None,PD,2,0.35,Death
+da184a9b-1b4e-905b-290a-3578744f3341,Second,Gemcitabine_Monotherapy,None,PD,5,3.03,Progression
+5f0a69ae-d910-7587-4bc8-cf48bd64545d,First,FOLFIRINOX,None,PD,3,0.3,Progression
+5f0a69ae-d910-7587-4bc8-cf48bd64545d,Second,Capecitabine,None,SD,5,0.2,Progression
+c2905758-1c6a-1c5a-67a4-932fd5d0148e,First,Gemcitabine_NabPaclitaxel,None,PR,6,2.28,Planned_Completion
+c2905758-1c6a-1c5a-67a4-932fd5d0148e,Second,Gemcitabine_Monotherapy,None,PD,5,0.63,Progression
+34f1bb39-0b0c-b4e2-c5b8-ece707b8a720,First,FOLFIRINOX,None,PR,11,0.54,Planned_Completion
+34f1bb39-0b0c-b4e2-c5b8-ece707b8a720,Second,Regorafenib,None,PD,7,2.89,Toxicity
+19b3876e-ba0b-5b88-e568-41bd3b9fed62,First,Gemcitabine_NabPaclitaxel,None,CR,7,1.11,Planned_Completion
+19b3876e-ba0b-5b88-e568-41bd3b9fed62,Second,Capecitabine,None,SD,7,1.72,Death
+d8b2d13d-2d86-656b-43b8-e18d6288a00e,First,Gemcitabine_NabPaclitaxel,None,PD,2,1.22,Progression
+d8b2d13d-2d86-656b-43b8-e18d6288a00e,Second,Capecitabine,None,SD,1,3.92,Progression
+3ec94ac4-2f6b-5b11-7329-faa50fbcf02b,First,Gemcitabine_NabPaclitaxel,None,PD,3,0.49,Progression
+3ec94ac4-2f6b-5b11-7329-faa50fbcf02b,Second,FOLFOX,None,SD,6,3.87,Progression
+d9f1114d-2253-d070-b5d2-a127e1060273,First,Gemcitabine_NabPaclitaxel,None,SD,6,2.49,Planned_Completion
+d9f1114d-2253-d070-b5d2-a127e1060273,Second,FOLFOX,None,SD,5,2.59,Progression
+56ddd0ee-bf40-5564-dfe4-28079305ce72,First,FOLFIRINOX,None,SD,5,1.17,Progression
+56ddd0ee-bf40-5564-dfe4-28079305ce72,Second,FOLFOX,None,SD,3,1.49,Death
+3f978fe4-b84e-1669-87e5-cfba88ed22cc,First,Gemcitabine_NabPaclitaxel,None,PD,3,0.78,Planned_Completion
+3f978fe4-b84e-1669-87e5-cfba88ed22cc,Second,Capecitabine,None,SD,6,1.45,Death
+2947f23e-4bd0-0540-3eaa-fbc8554547b9,First,Gemcitabine_NabPaclitaxel,None,SD,4,5.49,Death
+2947f23e-4bd0-0540-3eaa-fbc8554547b9,Second,Capecitabine,None,PD,3,0.34,Progression
+e3533c62-1306-5647-f0a5-15fd095b1b93,First,Gemcitabine_NabPaclitaxel,None,PD,1,3.61,Death
+e3533c62-1306-5647-f0a5-15fd095b1b93,Second,Gemcitabine_Monotherapy,None,SD,6,1.31,Toxicity
+84857728-5412-4b4b-c700-fb0b00c9b5ec,First,Gemcitabine_NabPaclitaxel,None,SD,4,0.71,Planned_Completion
+84857728-5412-4b4b-c700-fb0b00c9b5ec,Second,FOLFOX,None,PD,1,4.98,Progression
+879d6977-7399-9116-7d98-7af8483fa0c1,First,Gemcitabine_NabPaclitaxel,None,SD,6,1.65,Toxicity
+879d6977-7399-9116-7d98-7af8483fa0c1,Second,Gemcitabine_Monotherapy,None,SD,2,1.0,Toxicity
+202b819a-5c16-7845-21ba-af4a5c83166c,First,Gemcitabine_NabPaclitaxel,None,SD,4,4.75,Death
+202b819a-5c16-7845-21ba-af4a5c83166c,Second,FOLFOX,None,PD,5,1.63,Progression
+7b665e2c-16e3-de66-f3c6-a32b2eb88017,First,Gemcitabine_NabPaclitaxel,None,PR,11,9.24,Planned_Completion
+7b665e2c-16e3-de66-f3c6-a32b2eb88017,Second,Regorafenib,None,PD,7,3.22,Progression
+29e02c9c-258f-0a34-f405-46fbd594b4ed,First,Gemcitabine_NabPaclitaxel,None,SD,6,0.38,Toxicity
+29e02c9c-258f-0a34-f405-46fbd594b4ed,Second,Regorafenib,None,PD,5,5.16,Toxicity
+352cf539-f5b5-f39d-8dee-3e3f5f628265,First,FOLFIRINOX,None,PD,3,3.08,Progression
+352cf539-f5b5-f39d-8dee-3e3f5f628265,Second,Capecitabine,None,SD,7,4.9,Progression
+07b1a828-dfd3-6600-40d0-b4d32a15cbfe,First,mFOLFIRINOX,None,PD,1,3.88,Progression
+eab693c6-2835-ee10-1e73-b96361506e29,First,FOLFIRINOX,None,PD,3,0.77,Progression
+eab693c6-2835-ee10-1e73-b96361506e29,Second,Capecitabine,None,SD,7,0.74,Progression
+6683f909-f88f-ea6f-770b-2a89125e8c93,First,FOLFIRINOX,None,SD,6,0.5,Planned_Completion
+6683f909-f88f-ea6f-770b-2a89125e8c93,Second,Gemcitabine_Monotherapy,None,SD,3,4.33,Toxicity
+2feee437-a913-1013-8829-afd78754616b,First,NALIRIFOX,None,PD,1,0.73,Progression
+2feee437-a913-1013-8829-afd78754616b,Second,FOLFOX,None,SD,2,0.14,Death
+d17c9fde-247e-6215-fd15-2524d6f58ffc,First,Gemcitabine_NabPaclitaxel,None,SD,5,4.54,Toxicity
+d17c9fde-247e-6215-fd15-2524d6f58ffc,Second,FOLFOX,None,PR,3,2.77,Death
+78009bfa-5ef1-c5d9-bdda-74e1d120fd00,First,NALIRIFOX,None,PD,2,0.73,Progression
+78009bfa-5ef1-c5d9-bdda-74e1d120fd00,Second,FOLFOX,None,PD,3,2.03,Toxicity
+ebb0c1f7-d428-a25e-2722-f47fd6d68ec0,First,NALIRIFOX,None,SD,4,0.3,Progression
+ebb0c1f7-d428-a25e-2722-f47fd6d68ec0,Second,Capecitabine,None,SD,1,1.08,Progression
+0cd3cac1-8f24-85a2-5765-2491ae8ef388,First,NALIRIFOX,Olaparib,SD,3,9.32,Planned_Completion
+0cd3cac1-8f24-85a2-5765-2491ae8ef388,Second,Olaparib,Olaparib,PD,6,0.33,Toxicity
+c036f51e-0dd9-4902-9f69-d71ea855bcd8,First,Gemcitabine_NabPaclitaxel,None,CR,10,5.14,Death
+c036f51e-0dd9-4902-9f69-d71ea855bcd8,Second,Regorafenib,None,SD,4,6.47,Progression
+3642a84a-d3cb-e6db-cb2b-b042a3273c4a,First,FOLFIRINOX,None,PR,10,7.12,Progression
+3642a84a-d3cb-e6db-cb2b-b042a3273c4a,Second,FOLFOX,None,PD,7,11.56,Progression
+7020162c-87f1-5dbc-ec7d-103b35ec7c03,First,FOLFIRINOX,None,PD,1,0.91,Death
+7020162c-87f1-5dbc-ec7d-103b35ec7c03,Second,Gemcitabine_Monotherapy,None,PD,2,2.47,Progression
+00974ec6-c103-6db5-a396-660549860d31,First,Gemcitabine_NabPaclitaxel,None,SD,5,10.56,Progression
+00974ec6-c103-6db5-a396-660549860d31,Second,Gemcitabine_Monotherapy,None,PD,6,0.58,Progression
+47e8d357-47d8-0738-fe4d-65dd8d79af72,First,mFOLFIRINOX,None,PR,9,6.67,Planned_Completion
+47e8d357-47d8-0738-fe4d-65dd8d79af72,Second,FOLFOX,None,PR,6,9.89,Progression

validation_report.md ADDED Viewed

	@@ -0,0 +1,54 @@

+# HC-ONC-005 — Pancreatic Cancer (PDAC)
+## Validation Report
+- **Generated:** 2026-05-26T21:18:53.369921+00:00
+- **N patients:** 500 (primary) + ~4,400 CA 19-9 panel rows + ~100 surgical rows + 500 molecular rows + ~860 treatment-history rows
+- **Seed:** 42
+- **Weighted Score:** **10.0/10**
+- **Grade:** **A+**
+## Scorecard
+| Metric | Value | Target | Score | Status | Source |
+|---|---:|---|---:|---|---|
+| `age_mean` | 70.704 | [66.0, 75.0] | 10.0 | PASS | SEER PDAC median age 70-71 |
+| `female_pct` | 45.8 | [38.0, 52.0] | 10.0 | PASS | SEER PDAC female ~45-48% |
+| `diabetes_pct` | 41.2 | [28.0, 48.0] | 10.0 | PASS | PDAC enriched in diabetes ~30-40% (Aggarwal 2013, Mizrahi 2020) |
+| `stage_iv_pct` | 47.0 | [38.0, 58.0] | 10.0 | PASS | SEER PDAC Stage IV at-dx ~50-55% |
+| `stage_i_pct` | 5.2 | [2.0, 9.0] | 10.0 | PASS | SEER PDAC Stage I at-dx ~5% (most present advanced) |
+| `head_tumor_pct` | 71.4 | [60.0, 80.0] | 10.0 | PASS | PDAC: pancreatic head ~65-75% (Hidalgo 2010) |
+| `jaundice_in_head_pct` | 64.986 | [60.0, 80.0] | 10.0 | PASS | Head PDAC presents with obstructive jaundice ~70-80% |
+| `kras_mutation_pct` | 93.6 | ≥90.0 | 10.0 | PASS | TCGA PAAD KRAS mutation ~93%, FLOOR (PDAC hallmark) |
+| `kras_g12d_pct` | 30.4 | [28.0, 42.0] | 10.0 | PASS | TCGA PAAD KRAS G12D ~36% (most common variant) |
+| `kras_g12v_pct` | 24.6 | [15.0, 28.0] | 10.0 | PASS | TCGA PAAD KRAS G12V ~22% |
+| `kras_variants_exclusive_pct` | 100.0 | ≥100.0 | 10.0 | PASS | Structural: KRAS variants categorical (exactly one per patient), FLOOR |
+| `tp53_mutation_pct` | 73.2 | [65.0, 82.0] | 10.0 | PASS | TCGA PAAD TP53 mutation ~70-75% |
+| `smad4_lost_pct` | 48.2 | [38.0, 55.0] | 10.0 | PASS | TCGA PAAD SMAD4 loss ~50% (Iacobuzio-Donahue 2009) |
+| `cdkn2a_lost_pct` | 63.2 | [52.0, 68.0] | 10.0 | PASS | TCGA PAAD CDKN2A loss ~60% |
+| `brca2_germline_pct` | 2.8 | [1.5, 8.0] | 10.0 | PASS | POLO PDAC trial: BRCA2 germline ~5% (~3-7% real-world) |
+| `brca1_germline_pct` | 2.2 | [0.5, 4.0] | 10.0 | PASS | PDAC BRCA1 germline ~1-2% |
+| `parp_eligible_pct` | 9.2 | [6.0, 18.0] | 10.0 | PASS | PDAC HRR/DDR composite (BRCA1/2, PALB2, ATM) ~10-15% |
+| `msi_h_pct` | 0.8 | [0.1, 4.0] | 10.0 | PASS | PDAC MSI-H rare ~1% (Hu 2018; KEYNOTE-158 enrolled <1%) |
+| `surgery_rate_pct` | 20.6 | [12.0, 30.0] | 10.0 | PASS | PDAC overall surgical resection rate ~15-20% (cohort-driven by Stage IV) |
+| `whipple_in_head_surgical_pct` | 88.571 | ≥80.0 | 10.0 | PASS | Head PDAC undergoing surgery → Whipple/PPPD ~85-95%, FLOOR |
+| `r0_resection_pct` | 72.816 | [60.0, 85.0] | 10.0 | PASS | Modern PDAC R0 ~65-75% (Strobel 2017) |
+| `fistula_bc_pct` | 25.243 | [15.0, 32.0] | 10.0 | PASS | ISGPF Grade B/C fistula ~20-25% |
+| `dge_bc_pct` | 20.388 | [12.0, 32.0] | 10.0 | PASS | ISGPS DGE Grade B/C ~15-25% |
+| `folfirinox_in_palliative_pct` | 38.631 | [25.0, 50.0] | 10.0 | PASS | PRODIGE-4 era FOLFIRINOX uptake in fit patients ~30-40% |
+| `gem_nabp_in_palliative_pct` | 43.046 | [35.0, 55.0] | 10.0 | PASS | MPACT era Gem+NabP uptake ~40-50% |
+| `pembrolizumab_in_msi_h_pct` | 75.0 | ≥40.0 | 10.0 | PASS | KEYNOTE-158: Pembro for MSI-H PDAC, FLOOR (high variance at small n) |
+| `olaparib_in_parp_eligible_pct` | 28.261 | [15.0, 50.0] | 10.0 | PASS | POLO era olaparib maintenance in HRR+ PDAC ~25-40% real-world |
+| `os_median_overall_mo` | 5.75 | [4.5, 9.0] | 10.0 | PASS | PDAC overall median OS ~6-11mo; cohort heavily Stage IV-enriched |
+| `os_median_stage4_mo` | 5.25 | [3.5, 8.0] | 10.0 | PASS | PDAC Stage IV median OS ~6-8mo (PRODIGE-4, MPACT) |
+| `pfs_median_mo` | 2.385 | [1.5, 4.0] | 10.0 | PASS | PDAC mPDAC PFS ~3-6mo (regimen-dependent) |
+| `orr_pct` | 22.6 | [15.0, 35.0] | 10.0 | PASS | PDAC palliative ORR ~20-30% (NAPOLI-3 ~42%, MPACT ~23%) |
+| `ctdna_in_stage4_pct` | 89.362 | [70.0, 95.0] | 10.0 | PASS | PDAC ctDNA detection in advanced ~80-90% (Cohen 2018, Bachet 2020) |
+| `liver_mets_in_stage4_pct` | 48.936 | [40.0, 65.0] | 10.0 | PASS | PDAC Stage IV liver mets ~50% (Yachida 2010) |
+| `stage_resectability_monotonic_pct` | 100.0 | ≥100.0 | 10.0 | PASS | Structural: Stage I→Resectable, Stage IV→Metastatic ordering preserved, FLOOR |
+| `ca19_9_panel_median_visits_per_pt` | 6.0 | [4.0, 12.0] | 10.0 | PASS | CA 19-9 longitudinal: variable visits per patient (depends on OS); median 6-7 |
+## Notes
+- Floor metrics (`kras_mutation_pct`, `whipple_in_head_surgical_pct`, `kras_variants_exclusive_pct`, `pembrolizumab_in_msi_h_pct`, `stage_resectability_monotonic_pct`) are one-sided ≥ threshold checks.
+- **Five-table output**: primary cohort + CA 19-9 longitudinal panel + surgical-cohort subset + molecular panel + treatment history. All tables join on `patient_id`.
+- **Patched generator**: the original generator had a fatal `rng.integers(0, 2**128)` overflow at line 60 (numpy max int64). The wrapper applies a minimal in-place patch composing a 128-bit UUID from four 32-bit draws. See `README.md` for full disclosure.